US Pat. No. 11,065,505

BICYCLE TRAINER AND METHOD OF ITS OPERATION

Tacx B.V., Wassenaar (NL...


1. A bicycle trainer comprising:a computer; and
an electronically variable brake configured to apply a braking resistance to rotatable pedals associated with a bicycle,
wherein the computer is coupled with the variable brake to control the braking resistance to simulate a surface condition of a road, wherein the braking resistance is controlled by utilizing a time variable setting with variations within a frequency band which depend on the simulated surface condition of the road.

US Pat. No. 11,065,504

VARIABLE-RESISTANCE EXERCISE MACHINE WITH WIRELESS COMMUNICATION FOR SMART DEVICE CONTROL AND INTERACTIVE SOFTWARE APPLICATIONS

BLUE GOJI LLC., Austin, ...


1. A variable-resistance exercise machine with communication for smart device control and interactive software applications, comprising:a network interface configured to communicate with a plurality of user devices via a network, and configured to receive input from a connected user device and configured to provide output to a connected user device, the input comprising at least a user interaction received via an interactive software application operating on a user device; and
a plurality of moving surfaces each configured to provide an independent degree of resistance to movement, and configured to detect movement, produce output based at least in part on detected movement, and provide the output to a user device.

US Pat. No. 11,065,503

HANDRAIL CONFIGURATION FOR A TREADMILL

Woodway USA, Inc., Wauke...


1. A console for a treadmill, the console comprising:a base having a first side and a second side;
a first lower push bar coupled to and extending substantially inward towards a longitudinal center portion of the treadmill and away from the first side of the base;
a second lower push bar coupled to and extending substantially inward towards the longitudinal center portion of the treadmill and away from the second side of the base;
a first section coupled to and extending at an angle substantially upwards and away from the first lower push bar;
a second section coupled to and extending at an angle substantially upwards and away from the second push bar;
an upper section coupled to the first and second sections; and
a protrusion provided on at least one of the first or second sections, the protrusion extending substantially upwards and above at least a portion of the upper section, and wherein the protrusion is configured to selectively engage with a hand of a user.

US Pat. No. 11,065,502

POSITION ADJUSTING DEVICE FOR EXERCISING APPARATUS

Johnson Health Tech Co., ...


1. A height adjustment mechanism for exercising apparatus, comprising:a first frame body defining an adjusting direction;
a second frame body telescopically mounted within one end of the first frame body and being movable in the adjusting direction;
a slidable block slidably mounted on the first frame body, the slidable block being movable in the adjusting direction between a first end and a second end of a limited range;
a pressing member being movable relative to the first frame body between a tightening position where the pressing member is operable to apply a pressing force to the second frame body in a direction substantially perpendicular to the adjusting direction, and a loosening position where the pressing force applied to the second frame body is released; and
at least one connecting arm connecting the pressing member to the slidable block;
wherein when the slidable block moves toward the first end of the limited range, the pressing member is pulled inward by the at least one connecting arm to the tightening position to clamp the second frame body; and wherein when the slidable block moves toward the second end of the limited range, the pressing member is released to move to the loosening position.

US Pat. No. 11,065,501

SINGLE-ARM WORKOUT BODY CONDITIONING MACHINE


16. A single-arm workout body conditioning machine, comprising:a horizontal base;
a user platform at an angle greater than zero to the horizontal base;
a single arm above the user platform;
an adjustable counterweight arrangement attached to the single arm;
a drive chain system having an adjustable weight fan;
a pull rod having a first end attached to the single arm and a second end attached to the drive chain system;
a recoiler attached to the single arm; and
an on-off function,
wherein the recoiler is configured to automatically return the single arm to a rest position of the single arm,
wherein the adjustable weight fan is configured to create resistance to upward movement of the arm, and
wherein the on-off function is configured to switch the single-arm workout body conditioning machine between a first configuration for plyometric exercise and a second configuration for isometric exercise.

US Pat. No. 11,065,500

ALL-IN-ONE EXERCISE MACHINE FOR DEVELOPING SPEED, AGILITY, AND STRENGTH


1. An exercise machine comprising:a main deck having a first section, having a first forward end and an opposing first rearward end and a second section, having a second forward end facing the first rearward end, the second section also having an opposing second rearward end;
a control console located on the first section of the main deck;
a treadmill located on the second section of the main deck, the treadmill having a front end and a back end, the treadmill having a continuous running belt thereon;
a pair of parallel rails that extend rearwardly from the first rearward end of the first section of the main deck so that the second section of the main deck longitudinally slides along the rails so as to be longitudinally adjustable with respect to the first section so that the distance between the treadmill and the control console is longitudinally variable during treadmill operation;
a resistance hub located on the second section of the main deck proximate the back end of the treadmill, the resistance hub having a spool, the spool having a winding force imparted thereon; and
a cable having first end and a second end such that the first end of the cable is attached to and partially wound about the spool so that placing a pulling force on the cable in order to unwind the cable from the spool works against the winding force imparted on the spool; a clip attached to the side of the main deck below the treadmill, the cable passing through the clip.

US Pat. No. 11,065,499

ADJUSTABLE DUMBBELL

FLORIEY INDUSTRIES INTERN...


1. An adjustable dumbbell assembly comprising:a receptacle including a first compartment and a second compartment,
a first dumbbell mechanism including a first weight member engaged in said first compartment of said receptacle, a second weight member engaged in said second compartment of said receptacle, and a handle bar engaged between said first weight member and said second weight member, said handle bar including a bore formed in said handle bar,
a first catch and a second catch slidably received and engaged in said bore of said handle bar and extendible out of said handle bar and respectively engageable with said first weight member and said second weight member, for detachably attaching said first weight member and said second weight member to said handle bar,
a first follower and a second follower slidably received and engaged in said receptacle, and
a wheel engaged with said first and said second followers for actuating said first and said second followers to move relative to said receptacle and for actuating said first and said second followers to move said first catch and said second catch to engage with said first weight member and said second weight member.

US Pat. No. 11,065,498

TUBULAR EXERCISE DEVICE

ViPR PRO, LLC, Solana Be...


1. A device for use in physical exercise, the device comprising:a substantially cylindrical tubular body centered around a longitudinal axis, the body having one or more flared ends and an exterior surface, wherein the flared ends of the body extend radially outward from the longitudinal axis, wherein the flared ends have raised edges such that a diameter at an outermost plane of the flared ends is larger than a diameter of the tubular body, wherein the body comprises:
a plurality of first apertures axially aligned on the exterior surface of the body and, wherein each first aperture is spanned by a first handle comprising an arc intersecting each aperture and centered around the longitudinal axis; and
a second aperture on the exterior surface of the body, wherein the second aperture is spanned by a second handle parallel to the longitudinal axis, wherein the second handle intersects the second aperture.

US Pat. No. 11,065,497

KETTLE-SHAPED PLASTIC STEEL DUMBBELL

OHFG TECHNOLOGIES (SHANGH...


1. A kettle-shaped plastic steel dumbbell, comprising:a kettle-shaped dumbbell piece (6);
a dumbbell shell (1) molded by injection at an exterior of the dumbbell piece (6);
a handle (2) being fixed on an exterior of the dumbbell shell (1); and
a corner sleeve (3) being placed at a joint of the dumbbell shell (1) and the handle (2), an exterior of a top part of the handle (2) being covered by an anti-slip sleeve (7) with corrugated drain slots (8).

US Pat. No. 11,065,496

HIGH-LOW PULLEY RACK SYSTEM FOR WEIGHT MACHINE

Specialty Fitness Systems...


1. A pulley rack for an exercise machine, the pulley rack comprising:a support frame;
an upright extending generally vertically within the support frame;
a counterweight having one or more counterweight pulleys, the counterweight moveable in a vertical direction relative to the support frame;
one or more guide pulleys mounted to the support frame;
a cable end assembly mounted to the upright; and
a pull cable having a fixed attachment end assembly and a pullable end freely passing through the cable end assembly;
wherein the pull cable is routed through the cable end assembly, the counterweight pulleys, and guide pulleys such that a force exerted on the pullable end raises the counterweight,
wherein the fixed attachment end assembly of the pull cable is connected to the cable end assembly adjacent to a first vertical side of the upright, and
wherein a section of the pull cable extends from the pullable end through the cable end assembly and downwardly to one of the guide pulleys mounted below the cable end assembly along a second vertical side of the upright.

US Pat. No. 11,065,495

SPRING ANCHOR BAR AND CARRIAGE STOP ASSEMBLY

BALANCED BODY, INC., Sac...


1. A reformer exercise apparatus comprising:a frame having a head end, a foot end and two spaced parallel side members;
a movable carriage mounted to the side members for movement between the head end and foot end of the frame;
one or more resilient biasing members each having one end fastened to the carriage; and
an anchor bar and carriage stop assembly fastened to the side members comprising:a pair of anchor bar support brackets each fastened to one of the side members adjacent the foot end of the frame, each bracket having a plurality of spaced apart upright curved slots therein;
an elongated anchor bar plate member having opposite ends adapted to be carried in a pair of the slots in the support brackets, the plate member having a central cutout forming a plurality of spaced apart anchor tabs each for receiving and holding a free end of one of the resilient biasing members, the plate member having a flat planar portion spanning between the ends merging with a first curved portion spanning between the ends, wherein the first curved portion is shaped complementary to the upright curved slots in the support brackets; and
one or more carriage stops projecting outward from the planar portion for engaging the carriage to maintain a predetermined minimum distance between the carriage and the anchor bar plate member when the plate member is positioned in different pairs of the slots in the support brackets.


US Pat. No. 11,065,494

EXERCISING DEVICE WITH REHABILITATION FUNCTION

High Spot Health Technolo...


1. An exercising device comprising:a main frame, a seat, a backrest, a swing unit, a magnetically controlled damper, and an electronic control panel;
wherein:
the main frame includes a front stand, a rear stand, a front support, a rear support, and an upright;
the seat is secured on the rear support of the main frame;
the backrest is secured on the upright of the main frame, and corresponds to the seat;
the swing unit is swingably mounted on the upright of the main frame;
the swing unit and the backrest are located at two opposite sides of the upright;
the swing unit includes two handlebars extending from the upright of the main frame to the seat respectively;
the magnetically controlled damper has a first end pivotally connected with the swing unit and a second end pivotally connected with the main frame;
the magnetically controlled damper includes a cylinder, a drive shaft, a transmission mechanism, a generating unit, a threaded sleeve, a threaded rod, and a driving belt;
the drive shaft is movable linearly in the cylinder;
the generating unit includes a rotation shaft, a rotor, a plurality of magnets, a coil module, and a belt wheel;
the threaded sleeve is connected with the drive shaft, and is moved linearly in concert with the drive shaft;
the threaded sleeve is screwed onto the threaded rod;
the transmission mechanism is connected with and driven by the threaded rod;
the driving belt is mounted between the transmission mechanism and the belt wheel;
the belt wheel is secured on the rotation shaft to rotate the rotation shaft;
the rotor is secured on and rotated by the rotation shaft;
the magnets are secured on and rotated in concert with the rotor;
the magnets surround the coil module; and
the electronic control panel is mounted on the main frame, and is electrically connected with the magnetically controlled damper.

US Pat. No. 11,065,493

PLYOMETRIC FITNESS PLATFORM WITH CONSTRAINED ADJUSTABILITY

PERFORM-X TRAINING SYSTEM...


1. A plyometric fitness system for facilitating constrained multi-directional movements of a user comprising:a training platform placed on or within a floor section upon which the user is able to stand and perform multi-directional exercise movements;
at least one track anchoring system fixated adjacent to said training platform, said at least one track anchoring system comprising a plurality of openings wherein said plurality of openings being arranged sequentially along said at least one track anchoring system;
at least one elastic cord that attaches on a proximal end to a body attachment strap configured to attach to a body part of said user, and at a distal end to said at least one track anchoring system;
at least one quick-release anchor that facilitates adjustable attachment at multiple points on said at least one track anchoring system to provide fixation of said distal end of said at least one elastic cord with respect to said training platform, thereby providing said constraint for said multi-directional exercise movements of the user, said at least one quick-release anchor comprising a fixator placeable within one of said plurality of openings in said at least one track anchoring system;
an exercise pattern design on said training platform that comprises a plurality of targets that are visible to the user during said multi-directional exercise movements, said plurality of targets that act as start-points or end-points for said body part of said user undertaking said movements; and
a pair of lateral platforms placed on opposing sides of said training platform, said pair of lateral platforms that provide a surface that is different in surface structure than said training platform.

US Pat. No. 11,065,490

METHOD FOR ADDITION OF FIRE SUPPRESSION ADDITIVE TO BASE FOAM SOLUTIONS

Tyco Fire Products LP, L...


1. A method of proportioning a finished foam, the method comprising:a) foaming a stream of a first foam solution to form a first finished foam, and delivering the first finished foam on a hazard;
b) selecting an amount of a fluorinated additive; and
c) adding the selected amount of the fluorinated additive to the stream of the first foam solution to form a first fluorinated finished foam.

US Pat. No. 11,065,489

FIRE PROTECTION SPRINKLER ASSEMBLIES AND INSTALLATIONS WITH ADJUSTABLE PUSH-TO-CONNECT FITTINGS

Tyco Fire Products LP, L...


1. A sprinkler assembly comprising:a fire protection sprinkler having a body defining an inlet and an outlet with a passageway extending between the inlet and the outlet along a longitudinal axis, a deflector supported by the body and spaced from the outlet, the body having an outer encasing surface surrounding at least a portion of the passageway having an axial length in the direction of the longitudinal axis to define a first contact zone;
an escutcheon having a receiver and a rim surrounding the fire protection sprinkler to define an aperture between the receiver and the sprinkler, the receiver having a surface defining a second contact zone; and
a push-to-connect fitting including:a tubular member with an end for connection to a pipe, the tubular member including an exterior surface and an inner surface, the inner surface defining an internal conduit that receives the body of the sprinkler;
a seal member and a retaining ring disposed within the internal conduit, the seal member forming a fluid tight seal about the first contact zone with the retaining ring engaged in a grip about the first contact zone to form an adjustable seal and grip about the outer encasing surface of the body of the sprinkler along the first contact zone; and
a releasing member that translates with respect to the tubular member to disengage the grip of the retaining ring about the first contact zone, the second contact zone of the escutcheon translating with respect to the tubular member to define an adjustable deflector-to-rim distance between the rim of the escutcheon and the deflector of the sprinkler.


US Pat. No. 11,065,488

REPOSITIONABLE CONSOLE

Oshkosh Corporation, Osh...


1. A vehicle comprising:a chassis;
a plurality of tractive assemblies coupled to the chassis;
a body assembly coupled to the chassis;
a turntable rotatably coupled to the chassis;
a platform coupled to the turntable and configured to support an operator;
a railing coupled to the platform;
a control console, comprising:a base section coupled to the turntable and spaced from the railing such that an access opening is defined between the railing and the base section, wherein the platform is at least selectively accessible by the operator through the access opening; and
a movable section that is movably coupled to the base section, the movable section including an operator interface configured to receive commands from the operator to control one or more systems of the vehicle,
wherein the movable section of the control console is selectively repositionable relative to the base section between a stowed position and an operating position, and wherein the operator interface is configured to be accessed by the operator when the operator is supported by the platform and the movable section is in the operating position; and

a step coupled to at least one of the turntable or the chassis, wherein the step is aligned with the access opening, and wherein the movable section of the control console extends across the access opening when in the operating position, thereby limiting operator accessibility through the access opening.

US Pat. No. 11,065,487

DRY SPRINKLER ASSEMBLIES

Tyco Fire Products LP, L...


1. A pendent dry sprinkler assembly comprising:an outer structure assembly having an inlet fitting defining an inlet end and an outlet frame defining a distal end, the outlet structure assembly having an internal passageway and an outlet defining a sprinkler axis, the outlet frame includes a pair of spaced apart arms disposed about the outlet to define a first plane that includes the sprinkler axis and define a second plane that includes and is perpendicular to the first plane such that one arm is disposed on each side of the second plane;
an inner structural assembly disposed within the internal passageway; and
a deflector that distributes a fluid delivered to the inlet fitting to protect a rack storage arrangement, the deflector having a central portion centered about the sprinkler axis and a plurality of tines each extending radially from the central portion to a terminal portion, the terminal portion of at least two tines of the plurality of tines being angled relative to the central portion such that the terminal portion is axially further away from the outlet frame than the central portion,
each tine having a base extending from the central portion, a body extending away from the base, the terminal portion extending from the body to a terminal edge, and a pair of lateral edges extending from the base to the terminal edge, the plurality of tines being circumferentially spaced about the central portion to defines a plurality of slots therebetween, the lateral edges of circumferentially adjacent tines converging to define an innermost portion of one of the plurality of slots, the innermost portion of each slot defining a radiused end having the shortest radial distance of the slot to the sprinkler axis of the radiused end, the pair of spaced apart arms aligned along the first plane, the sprinkler axis being disposed along the intersection of the first and second planes, the first and second plane dissecting the deflector into four quadrants about the sprinkler axis, the innermost portion of each slot in one of the four quadrants defining a different radial distance to the sprinkler axis than the other slots in the quadrant, the plurality of tines include a first pair of diametrically opposed T-shaped tines bisected by the first plane and a second pair of diametrically opposed T-shaped tines bisected by the second plane, the second pair of diametrically opposed T-shaped tines having a second width greater than a first width of a widest portion of the first pair of diametrically opposed T-shaped tines.

US Pat. No. 11,065,486

FIRE SUPPRESSANT DEVICE AND METHOD, INCLUDING EXPANSION AGENT

Federal Express Corporati...


1. A fire suppressant device, comprising:a housing defining a hollow cylinder;
a column disposed at least partially within the hollow cylinder, the column including a piercing end; and
an end cap having a cap portion and a base portion engaged with the cap portion, the end cap being threadingly connectable to the column opposite the piercing end,
wherein the column defines a chamber disposed between the end cap and the piercing end, and
wherein the column is configured to extend from the housing and pierce a container to deliver a fire extinguishing agent from the chamber to an inside space of the container.

US Pat. No. 11,065,485

FIXED SYSTEMS AND METHODS FOR EXTINGUISHING INDUSTRIAL TANK FIRES, WITH AND WITHOUT FIXED ROOF, INCLUDING AERATED FOAM PROJECTING NOZZLES AND CENTER DIRECTED NOZZLES

Tyco Fire Products LP, L...


1. An aerated foam fire fighting apparatus structured for attachment to a tank with a fixed roof, comprising:a first ambient air aeration chamber located upstream of, and in fluid communication with, a fire fighting nozzle, the first ambient air aeration chamber structured to produce aerated foam;
a tapered portion located downstream of, and in fluid communication with, the first ambient air aeration chamber, the tapered portion having a first end and a second end, the first end of the tapered portion being larger than the second end of the tapered portion, the second end being connected to a tip portion of the fire fighting nozzle;
at least one stream shaper located in the tip portion of the fire fighting nozzle, the at least one stream shaper having fins with a longitudinal dimension greater than a radial dimension, the fins terminating substantially flush with a discharge orifice; and
at least two discharge ports located in a fluid conduit between the first ambient air aeration chamber and tip portion of the fire fighting nozzle, each discharge port having a deflector portion located in the conduit proximate each discharge port.

US Pat. No. 11,065,484

PORTABLE FIRE PROTECTION SPRINKLER SYSTEM

Youssef G. Bakhos, Anahe...


1. A portable Tripod like fire protection sprinkler system that, when contrived, stands upright and perpendicular to the ground comprising:an adjustable tubular center beam having an inner tubular member and an outer tubular member arranged for vertical telescopic movement, wherein the inner tubular member has an 11 foot length, and the outer tubular member has a 6 foot length, wherein the inner tubular member includes a flame retardant source adapter at a base and an adjustable sprinkler head at a summit;
the adjustable tubular center beam including a pole lock to selectively retain a position of the inner tube relative to the outer tube, the central beam having a central beam height that can be adjusted between 6 feet and 18 feet due to the telescopic movement of the inner and outer tubular members of the adjustable tubular center beam;
an expandable and retractable rubber hose, connected to the flame retardant source adapter and configured to extend through the inside of the outer tubular member when the adjustable tubular member is extended, the expandable and retractable rubber hose supplying the sprinkler head with a flame retardant fluid;
a plurality of adjustable and foldable legs having an inner tubular member which is inserted into an outer tubular member arranged for telescopic movement, said foldable legs allowing for easy transport and increased stability of the device, wherein the inner tubular member has a length of 3 feet, the outer tubular member having a 5 foot length;
the plurality of adjustable and foldable legs including a leg lock to selectively retain a position of the inner tubular member relative to the outer tubular member, the plurality of adjustable foldable legs having a leg height that can be adjusted between 5 feet and 8 feet due to the telescopic movement of the inner and outer tubular members of the plurality of adjustable and foldable legs;
wherein the adjustable sprinkler head is adjustable by a 360 degree rotation and has a range up to 85 feet of coverage when the adjustable tubular center beam and the plurality of adjustable foldable legs are at a maximum extension.

US Pat. No. 11,065,483

SYSTEMS AND METHODS FOR FIRE CONTAINMENT


1. An apparatus for containing fires comprising:a fire containment pouch comprising an upper portion and a lower portion, wherein the fire containment pouch is a flame-resistant material;
the upper portion comprising a pouch section having a closed end and an open end, wherein at least a portion of the pouch section is coated with an intumescent material;
the lower portion comprising a cuff section having a top and a bottom, the cuff section being open on the top and the bottom thereof;
the open end of the pouch section of the upper portion and the top of the cuff section of the lower portion juxtaposed one against each other to define an outer containment portion of elongate length from the closed end of the pouch section to the bottom of the cuff section;
wherein the bottom of the cuff section is configured to be folded around the upper portion such that a surface of the cuff section covers at least a portion of the pouch section to thereby protect the intumescent material when not in use;
the fire containment pouch adaptable to be pulled inside out thereby transforming the outer containment portion to an inner containment portion;
a fastener secured to the bottom of the cuff section to seal an object within the inner containment portion after the fire containment pouch has been pulled inside out; and
wherein the intumescent material may be molded around the object after the fire containment pouch has been pulled inside out to enhance fire containment.

US Pat. No. 11,065,482

TIP RESISTANT SYSTEM WITH QUICK DISCONNECT

United States of America ...


1. A tip resistant system for use with a belay tether, the tip resistant system consisting of:a user tether having a first length and configured to be connectable between one of a waist harness and a hip harness and the belay tether, the user tether having a belay tether connector adjacent one end of the user tether, and a user connector adjacent an opposite end of the user tether; and
an auxiliary tether having a second length less than the first length of the user tether and configured to be removably fixed between equipment worn about an upper body portion of a user, and the user tether, wherein the worn equipment is one of a backpack and body armor, the auxiliary tether including:a user tether connector located adjacent a first end of the auxiliary tether, and
an auxiliary user connector located adjacent a second end of the auxiliary tether opposite the user tether connector,

wherein, during use of the tip resistant system by the user, the auxiliary tether operates to
prevent tipping and to maintain the user in a desired static attitude.

US Pat. No. 11,065,481

SAFETY HARNESS MOTION DETECTOR SYSTEMS AND METHODS FOR USE

US SAFETY TECHNOLOGIES LL...


1. A system for monitoring elevation of a worker at a job site, the system comprising:at least two reference devices, each reference device comprisinga power source,
a barometric pressure sensor, and
a communications transceiver for relaying reference barometric pressure measurements; first processing circuitry configured to
receive, from each of the at least two reference devices, at least one respective reference barometric pressure measurement, and
calculate, using i) the reference barometric pressure measurements of the at least two reference devices and ii) respective elevation information regarding a respective installation position of each of the at least two reference devices at the job site, an atmospheric pressure offset; and

second processing circuitry configured toapply the atmospheric pressure offset to a barometric pressure measurement obtained from barometric sensor data captured by a portable computing device carried or worn by the worker at the job site to determine a present elevation of the portable computing device, and
convert the present elevation to a corresponding floor of a structure at the job site.


US Pat. No. 11,065,480

PPE WITH ROTATING ASSEMBLY PROVIDING MULTIPLE FACE COVERS


1. A Personal Protective Equipment (PPE) device configured for different human users, said PPE device comprising:a rotating face cover assembly with a circular base, a height, a plurality of mask sides, and a mask top, each mask side of the plurality of mask sides having a surface, said assembly configured to fit over different user's heads and attach to a circular collar in at least one orientation;
wherein said plurality of mask sides are disposed between said circular base and said mask top; and each of said plurality of mask sides is connected to their neighboring mask sides of the plurality of mask sides, said circular base, and said mask top so as to form a continuous covering surrounding all sides and head top of different user's heads;
said circular base and said circular collar configured with an adjustable mechanism enabling different mask sides of the plurality of mask sides to be positioned in front of a face of said different users;
each said mask side of the plurality of mask sides configured with a microbial filter element, a transparent element, and mask side supporting elements configured to shape portions of said surface of each said mask side of the plurality of mask sides so that, when said rotating face cover assembly is worn by a user, said surface of each said mask side of the plurality of mask sides does not contact a nose, mouth, or eyes of at least one user;
wherein each mask side of the plurality of mask sides has different mask side supporting elements so that a first mask side of the plurality of mask sides maintains a first set of distances between said first mask side and said nose, mouth, or eyes of a first human user, and so that a second mask side of the plurality of mask sides that is different from the first mask side maintains a second set of distances that are different from the first set of distances between said second mask side and said nose, mouth, or eyes of a different human user;
said PPE device configured so that a first human user is able to adjust the first mask side in front of said first human user's face, and a different human user is able to adjust said second mask side in front of said different human user's face;
said circular collar attached to a zip-up body suit configured to fit over a body of said users, said zip-up body suit comprising microbial impermeable materials.

US Pat. No. 11,065,479

PORTABLE AIR POWERED RESPIRATOR


1. A portable air-powered respirator for personal use, the respirator for cleaning and disinfection of ambient air from substances causing infectious diseases in humans, the respirator comprising:A personal mask comprising a frame, a clear visor, and supporting strips, the frame positioned on an upper portion of a user's head supporting and carrying the visor;Said visor formed from a transparent material, said visor attached to the front of the frame and situated at a distance from the user's face allowing the user to put on glasses, the visor providing an unobstructed view while isolating the user's eyes, nose, mouth, and at least a part of the forehead;
Said supporting strips attached to the frame and positioned to support the respirator on the user's head;
A system for filtration located on the frame, said system purifying and delivering clean air for breathing, the system including replaceable suction filters, a battery-powered fan, an air hose delivering clean air to an under-mask space for breathing, and a suction compartment that houses said fan mounted on vibration damping spacers;
Vents for venting of exhaled air and excesses of supplied air pumped by the fan to ambient while maintaining pressure in the under-mask space higher than atmospheric pressure, said vents including at least of:one or plurality of venting filters, calibrated orifices, venting check valves, or combination of one or a plurality of filters, check valves and calibrated orifices;

An electrical system providing power to the fan, said electrical system situated on and around the frame, said electrical system comprising;A battery, an on/off switch, connectors, and wiring;

A soft cover insulating the under-mask space and protecting a portion of the user's head not covered by the mask from untreated air, the cover spreading from the top of the user's head down to the user's neck or shoulders with seals around the visor, the vents, the suction filters, and the neck or shoulders; and
A sealed port for devices and/or equipment required for work and/or for lifesaving measures, the sealed port located in the soft cover providing insulation of the devices and/or the equipment inside of the under-mask space from ambient, thus allowing safe usage of a stethoscope and other medical devices and/or equipment for medical personnel.


US Pat. No. 11,065,478

PORTABLE CONTAINMENT DEVICE


1. A portable containment device for isolating airborne particles, comprising:a pliable sleeve forming an expandable chamber, wherein the pliable sleeve comprises a sheet of flexible material, the pliable sleeve having a side wall, a first end, and a second end;
an opening formed at the first end sized to cover at least a human mouth without covering the eyes, nostrils, or nose; and
a filter arranged at the second end, the filter being operable to entrap airborne particles entering the opening formed at the first end;
wherein the chamber is configured to have an expanded configuration having a first longitudinal length between the opening and the filter when operating the portable containment device and a compressed configuration having a second longitudinal length between the opening and the filter for storing the portable containment device;
wherein the pliable sleeve is longitudinally expandable between the opening and the filter to keep the opening open while in the compressed configuration;
wherein the wherein the first longitudinal length is greater than the second longitudinal length;
wherein the device is disk-shaped in the compressed configuration and has a tubular shape in the expanded configuration; wherein the second end further comprises an end cap formed from the pliable sleeve, the end cap being configured to accommodate the filter, the filter being seated on the endcap, the end cap comprising a central opening configured to allow exhausted air to exit the filter; and wherein the pliable sleeve is wrapped around a ring to form the opening of the expandable chamber.

US Pat. No. 11,065,477

FALL-PROTECTION APPARATUS WITH BRAKING SYSTEM

3M Innovative Properties ...


1. A fall-protection apparatus, comprising:a main body comprising a friction-braking system comprising a pivotally movable braking cam and a braking sheave that define a space therebetween that can accommodate at least one rope;
the friction-braking system further comprising a handle, said handle includes a disconnectable connection to the braking cam so that when the handle is moved from a first, braking position to a second, non-braking position the braking cam is pivotally moved from a first, braking configuration to a second, non-braking configuration, and so that when the handle is moved to a third, disconnecting position the connection between the handle and the braking cam is disconnected;
wherein the disconnectable connection between the handle and the braking cam comprises:an elongate pin that is slidably seated within an elongate channel that is at least partially defined within the handle, the elongate pin being slidably movable between a forward position and a rearward position and being configured so that when the elongate pin is in the forward position the elongate pin is engaged with the braking cam and when the elongate pin is in the rearward position the elongate pin is disengaged from the braking cam;
a biasing member that biases the elongate pin forward towards the forward position; and
a cam plate that is attached to the main body of the apparatus and that comprises an actuating surface along which a transversely-protruding boss of the elongate pin can slidably move during movement of the handle between the first, second, and third positions,wherein the cam plate comprises a lobe portion that is configured so that as the handle is moved to its third, disconnecting position, slidable movement of the boss of the elongate pin along the actuating surface of the lobe portion of the cam plate causes the elongate pin to be urged into the rearward position.



US Pat. No. 11,065,476

MID-PLANE RANGE-PROBING TECHNIQUES FOR PARTICLE THERAPY

The Board of Regents of t...


1. A method for probing beam ranges for particle therapy, the method comprising:determining a configuration of each of one or more probing spots, where each of the one or more probing spots comprises a first dose of radiation delivered prior to performing the particle therapy, where the configuration of each of the one or more probing spots specifies a planned location along a mid-plane of a first interior region of a tumor volume where the first dose of radiation is to be delivered, where the first interior region of the tumor volume is different from a second interior region of the tumor volume proximate an exterior surface of the tumor volume, wherein the second interior region of the tumor volume surrounds the first interior region of the tumor volume, and where the planned location of each of the one or more probing spots is determined such that each of the one or more probing spots is delivered within the tumor volume despite occurrence of a beam shift due to internal body structures of a patient present in a delivery path of a radiation beam;
delivering, via the radiation beam, each of the one or more probing spots to the tumor volume in accordance with the configuration of each of the one or more probing spots;
capturing one or more images of the tumor volume, where the one or more images provide data representative of an actual delivery location of each of the one or more probing spots delivered by the radiation beam;
determining one or more beam shifts based on the one or more images, where each beam shift of the one or more beam shifts corresponds to one probing spot of the one or more probing spots, where each beam shift represents an impact of internal body structures present in the delivery path of the radiation beam on the planned location of the corresponding probing spot, where the internal body structures include bones and air pockets, where first beam shifts associated with a bone present in the delivery path indicate a bone-altered delivery location that is shallower than the planned location of the corresponding probing spot and second beam shifts associated with an air pocket present in the delivery path indicate an air-altered delivery location that is deeper than the planned location of the corresponding probing spot; and
configuring delivery locations for the particle therapy based on the one or more beam shifts determined based on the one or more captured images, where the first dose of radiation for each of the one or more probing spots is less than a second dose of radiation delivered during the particle therapy.

US Pat. No. 11,065,475

MULTI-CYCLE DOSIMETRY AND DOSE UNCERTAINTY ESTIMATION

Siemens Medical Solutions...


1. A system comprising:a nuclear imaging scanner to acquire a set of tomographic images of a patient volume associated with each of a plurality of timepoints of a first radiopharmaceutical therapy cycle;
a processing system to:for each of the plurality of timepoints, determine a systematic uncertainty for each of a plurality of regions within the patient volume based on the set of tomographic images associated with the timepoint;
for each of the plurality of timepoints, determine a quantitative statistical uncertainty based on the set of tomographic images associated with the timepoint; and
determine a dose and a dose uncertainty for each of the plurality of regions based on the set of tomographic images, the systematic uncertainty and the quantitative statistical uncertainty for each of the plurality of timepoints; and

a display to present a cumulative dose and cumulative dose uncertainty for each of the plurality of regions based on the dose and the dose uncertainty determined for each of the plurality of regions.

US Pat. No. 11,065,474

PATIENT ALIGNMENT METHOD AND SYSTEM USING LIGHT FIELD AND LIGHT REFLECTOR DURING RADIATION THERAPY

The Catholic University o...


1. A system to align an object using a light reflector, the system comprising:a user input unit which pre-sets a first region in which radiation is to be emitted to the object;
a display unit which displays information on the first region;
a radiation emitting unit which emits the radiation to the first region;
a light reflector which is formed to correspond to a shape of the first region is configured to be attached to the first region of the object;
a light emitting unit which emits light in the same direction as the radiation to the first region;
a camera which photographs a region of the light reflector which reflects light when the light reflector reflects light emitted by the light emitting unit; and
a control unit which controls the display unit to display the region of the light reflector which reflects light photographed by the camera, and determines whether the radiation is aligned to the first region of the object based on whether the region of the light reflector is included in the shape of the first region.

US Pat. No. 11,065,473

METHODS AND SYSTEMS FOR CHECKING ALIGNMENT OF COMPONENTS OF A RADIOTHERAPY SYSTEM

Elekta Limited, Crawley ...


1. A method of operating a radiotherapy system comprising a gantry rotatable around a treatment location, a radiotherapy beam generator located on the gantry, a radiotherapy imaging system located on the opposite side of the treatment location, and at least one component that is static with respect to the treatment location, wherein a beam path is defined between the radiotherapy beam generator and the radiotherapy imaging system so as to pass through the static component, the method comprising:obtaining a reference image using the radiotherapy imaging system with the gantry in a predetermined position so as to provide the beam generator, the imaging system and the static component in reference positions, the reference image including the static component;
rotating the gantry relative to the static component;
returning the gantry to the predetermined position;
obtaining a second image using the radiotherapy imaging system with the gantry in the predetermined position, the second image including the static component; and
determining changes in relative positions of the radiotherapy beam generator, the radiotherapy imaging system, and the static component based on differences in a position of the static component in the reference image and in the second image.

US Pat. No. 11,065,472

SYSTEM AND METHOD FOR CORRECTING POSITION ERRORS OF A MULTI-LEAF COLLIMATOR

SHANGHAI UNITED IMAGING H...


1. A method implemented on a computing device having at least one processor and at least one computer-readable storage medium for correcting position errors for a multi-leaf collimator (MLC), the MLC including a plurality of leaves to shape a radiation field, each of the plurality of leaves being associated with a driving component including a main encoder, the method comprising:determining a first position for each of the plurality of leaves, information associated with the first position including a first movement direction and a first angle, wherein a movement of the each of the plurality of leaves along the first movement direction is configured to move toward or away from a center of the radiation field;
obtaining a first reference offset value associated with the first position of the each of the plurality of leaves from a pre-determined offset table;
determining an offset value associated with the first position based on the first angle, the first movement direction, and the first reference offset value; and
determining a target position of the each of the plurality of leaves based on the offset value.

US Pat. No. 11,065,471

SYSTEMS AND METHODS FOR AUTOMATIC, CUSTOMIZED RADIATION TREATMENT PLAN GENERATION FOR CANCER

Duke University, Durham,...


1. A method comprising:at a processor and memory:receiving anatomy information of a patient;
receiving radiation beam characteristics of a radiation therapy system; and
generating a fluence map for the patient without an optimization step, based on the anatomy information and the radiation beam characteristics.


US Pat. No. 11,065,470

TISSUE SAMPLING AND CATHETER SELECTION CANCER TREATMENT METHODS

PROCEPT BioRobotics Corpo...


1. A method of treating a patient, the method comprising:placing the patient on a support;
removing a sample of a tissue from the patient using a water jet source while the patient is on the support;
placing, while the patient is on the support, a first catheter or a second catheter in the patient subsequent to removing the sample, the first catheter comprising a radioactive substance to treat a cancer of the patient subsequent to surgery, the second catheter without the radioactive substance for cancer treatment; and
receiving the sample using a device; and
determining using the device, while the patient is on the support, whether the patient has the cancer in order to select the first catheter or the second catheter for placement in the patient.

US Pat. No. 11,065,469

REGION DIVISION METHOD FOR LASER TREATMENT, AND LASER TREATMENT METHOD AND APPARATUS USING THE SAME


1. A region division method for laser treatment of dividing an area of a subject to be treated by laser irradiation into a plurality of treatment regions, the method comprising:constructing a three-dimensional image of subject;
using the three-dimensional image to obtain a normal vector for each of a plurality of points located on a surface of subject;
dividing the plurality of points on the surface of the object subject into one or more groups based on a similarity between the obtained normal vectors; and
generating a closed curve including at least some of the plurality of points grouped into a same group to set a treatment region.

US Pat. No. 11,065,467

SYSTEMS AND METHODS FOR FAST AND REVERSIBLE NERVE BLOCK

CASE WESTERN RESERVE UNIV...


1. A method for blocking conduction in a nerve, comprising:applying, by an optrode, a heat signal to the nerve to provide a heat-based nerve block that blocks conduction in the nerve; and
applying, by an electrode, an electrical signal to the nerve to provide an electrical nerve block to block the conduction in the nerve;
wherein a timing of the heat signal and another timing of the electrical signal are defined by a control device linked to the optrode and the electrode such that the heat signal and the electrical signal are applied simultaneously for a first period of 1 second or less so that the heat signal blocks an onset response in the nerve generated by the electrical signal, and after the first period of 1 second or less, the heat signal is stopped and the electrical signal is applied alone over a second period of at least one minute after the onset response.

US Pat. No. 11,065,466

SHOCK DETERMINATION BASED ON PRIOR SHOCKS

ZOLL Medical Corporation,...


1. An external defibrillator system for managing care of a person receiving emergency cardiac assistance, the external defibrillator system comprising:one or more capacitors for delivering a defibrillating shock to the person;
one or more electronic ports for receiving signals from sensors for obtaining indications of an electrocardiogram (ECG) for the person;
a patient treatment module comprising one or more computer processors; and
one or more computer readable media comprising instructions that, when executed by the one or more computer processors, cause the patient treatment module to carry out operations comprising:retrieving information about an indication of success associated with a prior defibrillating shock delivered during a session of the emergency cardiac assistance;
determining, based on the information about the indication of success associated with the prior defibrillating shock, a metric indicative of a likelihood of success from delivering a future defibrillating shock to the person with the one or more capacitors during the session of the emergency cardiac assistance; and
causing the one or more capacitors to be charged based on the metric indicative of the likelihood of success from delivering the future defibrillating shock.


US Pat. No. 11,065,465

DEFIBRILLATOR COVER


1. A defibrillator and an adhesive cover combined with the defibrillator,the adhesive cover comprising a flexible plastic film and a pressure-sensitive adhesive on one side of the flexible plastic film; and
the defibrillator comprising:a case;
a handle at an upper surface of the case;
a display panel comprising a display screen at a front face corresponding to a front surface of the case;
a bezel surrounding a periphery of the display panel at the front face of the case, the display panel being recessed from the bezel forming a gap between the display panel and the bezel; and
a plurality of buttons at the front face of the case,

wherein the adhesive cover is adhered to and covers the display screen, the bezel, all of the buttons at the front face, and an area of the front face between at least some of the buttons and the display screen,
wherein a portion of the adhesive cover between the portions adhered to the display panel and the bezel is slanted with respect to the portions adhered to the display panel and the bezel, and
wherein the adhesive cover extends from the front surface of the case to an adjacent surface of the case that is a surface other than the front surface and is adhered to the adjacent surface of the case to prevent introduction of foreign material between the adhesive cover and the front surface of the case.

US Pat. No. 11,065,464

METHODS FOR WEARABLE SYSTEM

West Affum Holdings Corp....


1. A method for a Wearable Cardiac Defibrillator (WCD) system that is wearable by a patient who may be moving, the WCD system including a support structure that is worn by the patient, the WCD system further including first electrodes coupled to the support structure such that, while the support structure is worn by the patient, at least a certain one of the first electrodes is moveable with respect to the patient's body responsive to the patient's moving, the method comprising:transmitting a polling signal from a processor of the WCD system via a sensor interface to a first sensor module and to a second sensor module, wherein the first sensor module is configured to monitor a first parameter of the patient that is other than an electrocardiogram (ECG) of the patient, and the second sensor module is configured to monitor a second parameter of the patient that is other than the ECG of the patient;
determining from a response of the first sensor module and from a response of the second sensor module whether a certain severity threshold has been reached, wherein said determining includes determining whether or not a first signal is received as the response of the first sensor module or a second signal is received as the response of the second sensor module responsive to the polling signal, and wherein said determining is based on a content of the first signal when the first signal received as the response and a content of the second signal when the second signal received as the response such that the certain severity threshold is determined to be reached when both the first signal and the second signal indicate the certain severity threshold has been reached; and
biasing, responsive to determining that the certain severity threshold has been reached, the certain electrode towards the patient's body against the support structure, the certain electrode thereby becoming less moveable with respect to the patient's body than prior to biasing.

US Pat. No. 11,065,463

WEARABLE CARDIOVERTER DEFIBRILLATOR (WCD) SYSTEM HAVING WCD MODE AND ALSO AED MODE

West Affum Holdings Corp....


1. A wearable cardioverter defibrillator (WCD) system for an ambulatory patient who is overseen by an attendant other than the ambulatory patient, the WCD system comprising:a housing;
an energy storage module within the housing, the energy storage module configured to store an electrical charge;
a support structure configured to be worn by the patient;
a first electrode configured to be coupled to the housing, and configured to be coupled to the support structure for a WCD mode in which the patient is wearing the support structure so that the first electrode is maintained on a body of the patient when the support structure is worn by the patient, the first electrode further configured to be uncoupled from the support structure and to be attached to the body of the patient and coupled to the housing for an AED mode in which the patient is not wearing a portion of the support structure;
a sensor configured to sense a parameter of the patient and to render a patient input responsive to the sensed parameter;
a user interface that includes a shock input device configured to receive a shock input entered by the attendant; and
a processor configured to:enter the WCD mode wherein in the WCD mode the processor is configured to cause a shock to be delivered responsive to a first shock criterion being met and to enter the AED mode distinct from the WCD mode wherein in the AED mode the processor is configured to cause a shock to be delivered responsive to the shock input entered by the attendant, wherein the processor enters the WCD mode or the AED mode responsive to an input received at the user interface or a default mode is entered after a preset time duration,
determine, from the patient input, when the first shock criterion is met,
cause, responsive to the first shock criterion being met, at least some of the stored electrical charge to be discharged via the first electrode through the patient so as to deliver a first shock to the patient when the support structure is worn by the patient, and
cause, responsive to the shock input being received, at least some of the stored electrical charge to be discharged via the first electrode through the patient to deliver a second shock to the patient, the second shock distinct from the first shock.


US Pat. No. 11,065,462

WIRELESS RECHARGING SYSTEM AND METHOD FOR FLEXIBLE IMPLANTABLE SUBCUTANEOUS MEDICAL DEVICE

NewPace Ltd., Caesarea (...


1. A method for simultaneously recharging and communicating data wirelessly to a subcutaneous rechargeable implantable medical device (IMD) including an antenna, comprising:transmitting electromagnetic (EM) radiation simultaneously over a plurality of frequencies for receiving by the antenna for recharging the subcutaneous rechargeable IMD; and
modulating the EM radiation for communicating data to the subcutaneous rechargeable IMD,
wherein the IMD includes an elongated and flexible body, at least one lead for providing an electric shock and at least one transition unit for coupling the at least one lead to at least one end of the elongated and flexible body, and wherein the at least one antenna is positioned in the at least one transition unit.

US Pat. No. 11,065,461

IMPLANTABLE POWER ADAPTER

Bioness Inc., Valencia, ...


1. An apparatus, comprising:a housing configured to be coupled to an implantable electrical conductor for disposition in a body, the coupling of the housing to the implantable electrical conductor being such that a pick-up electrode of the implantable electrical conductor is disposed in the housing;
a sleeve disposed about a portion of the housing and a portion of the implantable electrical conductor and electrically insulating the pick-up electrode from a first energy outside the housing when the housing is coupled to the implantable electrical conductor and implanted in the body; and
a circuit at least partially disposed in the housing, the circuit including a first conductor and a second conductor, the first conductor being formed by at least a portion of the housing disposed outside of the sleeve, the second conductor being electrically connected to the pick-up electrode of the implantable electrical conductor when the housing is coupled to the implantable electrical conductor,
the circuit, when the housing is coupled to the implantable electrical conductor and implanted in the body, configured to:(i) receive, transcutaneously from an electrical pulse generating device and via the first conductor, the first energy;
(ii) convert the first energy to a second energy different from the first energy; and
(iii) transmit, to the pick-up electrode, the second energy such that the implantable electrical conductor can apply, via a stimulating electrode, the second energy to a region in the body.


US Pat. No. 11,065,460

BATTERY ASSEMBLY FOR MEDICAL DEVICE

Medtronic, Inc., Minneap...


1. A battery assembly for an implantable medical device, the assembly comprising:an electrode stack comprising a plurality of electrode plates, wherein the plurality of electrode plates comprises a first electrode plate including a first tab extending from the first electrode plate and a second electrode plate including a second tab extending from the second electrode plate;
an alignment pin extending through a first aperture in the first tab and a second aperture in the second tab; and
a weld on a side of the electrode stack extending from the first tab to the second tab, wherein the weld penetrates into the alignment pin.

US Pat. No. 11,065,459

IMPLANTABLE MEDICAL DEVICE WITH PRESSURE SENSOR

CARDIAC PACEMAKERS, INC.,...


1. A leadless cardiac pacemaker (LCP) for implantation in a ventricle of a heart, wherein the heart includes an atrium that contracts to supply blood to the ventricle, the LCP configured to sense cardiac activity and to deliver pacing therapy to the ventricle of the heart, the LCP comprising:a housing having a proximal end and a distal end;
a first electrode secured relative to the housing and exposed to the environment outside of the housing;
a second electrode secured relative to the housing and exposed to the environment outside of the housing;
a diaphragm that is exposed to the environment outside of the housing, the diaphragm is responsive to an external pressure applied to the diaphragm by the environment outside of the housing;
a piezoelectric membrane having a first pressure sensor electrode and a second pressure sensor electrode, the piezoelectric membrane is configured to generate an electrical voltage between the first pressure sensor electrode and the second pressure sensor electrode in response to a flexing of the diaphragm caused by a pressure change applied to the diaphragm;
circuitry in the housing operatively coupled to the first electrode and the second electrode of the LCP, and also operatively coupled to the first pressure sensor electrode and the second pressure sensor electrode, the circuitry is configured to deliver a pacing therapy to the ventricle of the heart via the first electrode and the second electrode;
wherein the diaphragm is configured to flex and cause the piezoelectric membrane to generate an electrical signal responsive to a change in pressure in the ventricle of the heart that is caused by a contraction of the atrium of the heart, and wherein the circuitry is configured to identify an atrial contraction of the heart based at least in part on the electrical signal produced by the piezoelectric membrane responsive to a change in pressure in the ventricle of the heart that is caused by a contraction of the atrium of the heart; and
wherein a timing of delivery of at least part of the pacing therapy delivered to the ventricle of the heart by the circuitry is based at least in part on the identified atrial contraction of the heart.

US Pat. No. 11,065,458

ELECTRONIC PACEMAKER


1. An electronic cardiac pacemaker for implantation in a body of a living being and for controlling a heartbeat of a heart of a living being, wherein the pacemaker comprises:an electrode portion comprising at least one electrode;
an electronics assembly connected with the electrode portion, configured toa. monitor the heartbeat of the heart to acquire body data, wherein the electronic assembly is able, through the body data, to determine whether the heartbeat needs to be controlled,
b. generate a voltage impulse, if required, and
c. emit the same via the electrode portion to the heart of the living being to control the heartbeat;

an energy storage to supply the electronics assembly with electrical energy which can be recharged with electrical energy after discharge, wherein the energy storage is an accumulator; and
a charging impulse generation portion electrically connected to the energy storage, which is configured to emit a charging impulse to the energy storage for the recharging of the energy storage;
wherein
the charging impulse generation portion comprises a magnetization portion with oriented magnetic domains which can be contactlessly influenced by an external magnetic field reversing with a reversing frequency, so that, when a certain field strength is respectively reached, a remagnetization wave, caused by the continuously reversing magnetic domains, is initiated in the magnetization portion which runs across the magnetization portion and leads to the generation of the charging impulse
wherein
said electronic assembly together with said energy storage and said charging impulse generation portion are completely surrounded by a housing formed of a material which is not repelled by the body of the living being, and said at least one electrode is formed on an outer surface of said housing,
the cardiac pacemaker is configured to be implanted, as intended, into the heart or attached to an external surface of the heart, and the electrode formed on the external surface is configured to be brought into contact with and/or anchored to the heart as intended, and
the accumulator is to be charged as intended by generating the external magnetic field.

US Pat. No. 11,065,457

METHOD FOR WAKING UP AN IMPLANTABLE MEDICAL DEVICE FROM A DORMANT STATE, IMPLANTABLE MEDICAL DEVICE, AND SYSTEM COMPRISING SUCH AN IMPLANTABLE MEDICAL DEVICE AND AN EXTERNAL DEVICE


1. A method for waking up an implantable medical device from a dormant state, the method comprising:sending a modulated wakeup signal via a wireless link from an external device;
demodulating the modulated wakeup signal by a demodulator circuitry of the implantable medical device so as to produce a demodulated wakeup signal, wherein the demodulator circuitry is permanently ready for operation, and the demodulator circuitry is a zero-power-consumption, amplitude shift keying demodulator circuitry; and
activating an awake state of the implantable medical device in response to the demodulated wakeup signal.

US Pat. No. 11,065,456

APPARATUS AND METHOD FOR IMPLANTING AN IMPLANTABLE DEVICE

Greatbatch Ltd., Clarenc...


1. An apparatus for subcutaneously inserting an implantable device within a patient, the implantable device including a housing and an antenna extending outwardly from the housing, the antenna including an antenna length, the apparatus comprising:a dilator portion including a dilator and a handle fixedly attached to the dilator, the dilator including a dilator length, the dilator portion being configured to separate tissue to create a subcutaneous pocket within the patient sized and shaped to accommodate the implantable device within the subcutaneous pocket; and
a sheath portion removably couplable with the dilator portion, the sheath portion including:a sheath sized and shaped to accommodate the dilator within a sheath lumen, the sheath including a proximal sheath end and a distal sheath end, the sheath configured to accommodate the antenna of the implantable device with the dilator removed from within the sheath; and
a sheath housing at the proximal sheath end, the sheath housing including a passage substantially aligned with the sheath lumen, the handle of the dilator portion including a portion complementary to the passage of the sheath housing, the portion of the handle of the dilator portion being sized and shaped to fit within the passage with the dilator disposed within the sheath, wherein the sheath includes a sheath length that is at least substantially as long as the antenna length, the sheath housing including an opening along a side of the sheath housing to allow access to the passage from the side of the sheath housing, the opening and the passage being configured to allow the housing of the implantable device to pass through the sheath housing without splitting the sheath housing, and wherein the sheath portion includes an intermediate sheath opening disposed at the proximal sheath end distally of a sheath housing distal end, wherein, with the dilator portion removed from the sheath portion, the passage of the sheath housing permits movement of the implantable device into the sheath portion to a position residing in the intermediate sheath opening with the antenna residing in the sheath lumen, the sheath being configured to separate to allow removal of the sheath from around the implantable device to remove the sheath from and leave the implantable device within the subcutaneous pocket within the patient.


US Pat. No. 11,065,455

RESONANCE TUNING MODULE FOR IMPLANTABLE DEVICES AND LEADS

MEDTRONIC, INC., Minneap...


1. An implantable medical system, comprising:a first medical device comprising:a housing,
electronics contained within the housing, and
a first medical device interface to provide an electrical path to or from the electronics within the housing;

a second medical device comprising a second medical device interface to provide an electrical path to or from the second medical device; and
a removable resonance circuit, operatively connected between the first medical device interface and the second medical device,wherein the removable resonance circuit comprises a control circuit configured to determine a value of a combined resonant frequency of the first medical device, the second medical device, and the removable resonance circuit after implantation, and
wherein the removable resonance circuit further comprises an adjustable impedance circuit configured to adjust an impedance provided by the removable resonance circuit to change the value of the combined resonant frequency of the first medical device, the second medical device and the removable resonance circuit to be substantially equal to a predetermined resonant frequency value.


US Pat. No. 11,065,454

METHODS AND SYSTEMS FOR REDUCING INTERFERENCE IN STIMULATION TREATMENT

DJO, LLC, Lewisville, TX...


1. A stimulation treatment system for reducing interference between a first stimulation program on the stimulation treatment system that is operating simultaneously with a second stimulation program on another stimulation treatment system where the first stimulation program and the second stimulation program do not use a central controller to time and coordinate the delivery of stimulation pulses, the first stimulation program comprising a succession of stimulation pulses delivered to a first body site and the second stimulation program comprising a succession of stimulation pulses delivered to a second body site, the system comprising:a first stimulation transducer device configured with the first stimulation program to generate stimulation pulses applied at the first body site;
a first processor having communication circuitry configured to communicate with the first stimulation transducer device;
wherein the first stimulation transducer device includes circuitry that generates stimulation pulses and detects stimulation signals indicative of a stimulation pulse, the first stimulation transducer device configured to:receive treatment information from the first processor;
monitor the first body site during a first detection period to detect the presence of a signal indicative of a stimulation pulse delivered to the user by a second stimulation transducer device configured with the second stimulation program and operating simultaneously with the first stimulation program, wherein the first stimulation transducer device is not in communication with the second stimulation transducer device to coordinate delivery of stimulation signals;
in response to not detecting the signal indicative of a stimulation pulse from the second stimulation transducer device at the first body site, deliver a stimulation pulse at the first body site in accordance with the received treatment information; and
in response to detecting the signal indicative of a stimulation pulse from the second stimulation transducer device, delay the delivery of stimulation treatment of the first stimulation transducer device for a first delay period and at the end of the first delay period, deliver a stimulation pulse at the first body site.


US Pat. No. 11,065,453

EXTRA-CARDIOVASCULAR CARDIAC PACING SYSTEM

Medtronic, Inc., Minneap...


1. A medical device comprising:a therapy delivery module comprising a capacitor array having a plurality of capacitors for producing a stimulation pulse; and
a stimulation control module coupled to the therapy delivery module and configured to:select a first capacitor configuration comprising a first combination of the plurality of capacitors;
start a pulse width timer defining a stimulation pulse width;
control the therapy delivery module to start delivery of the stimulation pulse by discharging the first capacitor configuration;
obtain a first sampled amplitude of the stimulation pulse during a first portion of the stimulation pulse width;
determine that the first sampled amplitude is less than or equal to a first amplitude threshold; and
control the therapy delivery module to select a second capacitor configuration comprising a second combination of the plurality of capacitors different than the first combination by adding one or more capacitors of the plurality of capacitors not included in the first capacitor configuration and discharge the second capacitor configuration during a second portion of the stimulation pulse width in response to the amplitude of the stimulation pulse being less than or equal to the first amplitude threshold.


US Pat. No. 11,065,452

VENTRICULAR TACHYCARDIA STORM ANALYSIS AND VENTRICULAR TACHYCARDIA STORM INTERVENTION METHOD AND SYSTEM

PACESETTER, INC., Sylmar...


1. A method for treating cardiac ventricular storm disorder in a patient under control of one or more processors within an implantable medical device (IMD), comprising:obtaining cardiac signals that comprise candidate episodes over a period of time;
updating an episode count and episode density clock based on the candidate episodes within the period of time;
determining whether the candidate episodes are indicative of a ventricular storm arrhythmia based on the episode count and episode density clock;
identifying a storm origin characteristic of interest preceding onset of the candidate episodes;
setting a pacing rate of a pacing therapy based on the storm origin characteristic of interest; and
directing the IMD to perform a storm intervention by delivering the pacing therapy at the pacing rate that is set based on the storm origin characteristic of interest.

US Pat. No. 11,065,451

PROSTHETIC AORTIC VALVE PACING SYSTEMS

E-VALVE SYSTEMS LTD., He...


1. A prosthetic aortic valve, which is configured to be delivered to a native aortic valve of a patient in a constrained delivery configuration within a delivery sheath, and which comprises:a frame;
a plurality of prosthetic leaflets coupled to the frame;
a cathode and an anode, which are mechanically coupled to the frame; and
a prosthetic-valve coil, which is coupled to the frame and is in non-wireless electrical communication with the cathode and the anode,
wherein when the prosthetic aortic valve is in an expanded fully-deployed configuration upon release from the delivery sheath, (a) a line defined between upstream-most and downstream-most points of mechanical coupling between the prosthetic-valve coil and the frame and (b) a central longitudinal axis defined by the frame form an angle of between 20 and 70 degrees.

US Pat. No. 11,065,450

NEUROMODULATION SYSTEM AND METHOD WITH FEEDBACK OPTIMIZED ELECTRICAL FIELD GENERATION

Soin Neuroscience, LLC, ...


1. A method of providing therapy to a patient, comprising:generating an electrical noise stimulation signal from an electrical signal generator;
receiving the electrical noise stimulation signal by an electrode;
applying an electric field in a target tissue of the patient by the electrode in response to the electrical noise stimulation signal, wherein the target tissue comprises a neural tissue, a non-neural tissue, or a combination thereof;
receiving a value of a physical parameter associated with the target tissue in response to application of the electric field in the target tissue; and
automatically optimizing the electric field in response to the value of the physical parameter to produce a therapeutic effect within the target tissue without the value of the physical parameter indicating potential damage to the target tissue by the electrical noise stimulation signal.

US Pat. No. 11,065,449

SYSTEMS AND METHODS FOR ENHANCING OR AFFECTING NEURAL STIMULATION EFFICIENCY AND/OR EFFICACY

Advanced Neuromodulation ...


1. An apparatus for treating a neural condition of a patient, comprising:a signal generator for generating electrical stimulation for application to neural tissue of the patient;
wireless communication circuitry for conducting wireless communications with an external programming device;
a header structure for connecting to one or more implantable stimulation leads for application of electrical pulses to neural tissue of the patient; and
a controller operatively coupled to the signal generator, the controller being configured to control the signal generator to direct an application of electrical stimulation to the patient in a manner such that the electrical stimulation has a burst frequency and an intra-burst frequency greater than the burst frequency, wherein the controller directs application of the electrical stimulation according to a duty cycle with stimulation-on periods where electrical stimulation is applied with intervening stimulation-off periods where electrical stimulation is temporarily halted between respective stimulation on-periods, and wherein the duty cycle stimulation-on periods and stimulation-off periods are controlled by a programmable duty cycle parameter set by communication with the external programming device;
wherein the apparatus is adapted for implantation in the patient.

US Pat. No. 11,065,448

SYSTEM AND METHOD FOR OCULAR MICROCURRENT STIMULATION THERAPY

i-Lumen Scientific, Inc.,...


1. A system comprising:a therapy appliance that includes:a first substrate containing a first plurality of electrodes configured to apply microcurrent stimulation therapy to a patient during one or more treatment sessions, wherein each of the one or more treatment sessions has a protocol, wherein the first substrate is configured to place one or more of the first plurality of electrodes on an outer surface of a patient's upper eyelid and one or more of the first plurality of electrodes on the patient's lower eyelid, wherein each one of the first plurality of electrodes is configured to be individually activated; and

a microcurrent-stimulation controller, wherein each one of the first plurality of electrodes is operatively coupled to the microcurrent-stimulation controller, wherein the microcurrent-stimulation controller is configured to control the microcurrent stimulation therapy applied to the patient, wherein the one or more treatment sessions includes a first treatment session and a second treatment session, wherein the microcurrent-stimulation controller is configured to adjust the protocol for the second treatment session of the one or more treatment sessions based at least in part on sensed electrical signals of a nerve obtained from the patient's eyelid skin and received by the microcurrent-stimulation controller during the first treatment session.

US Pat. No. 11,065,447

METHOD AND SYSTEM FOR OCULAR MICROCURRENT STIMULATION THERAPY

i-Lumen Scientific, Inc.,...


1. A system comprising:a first electrode substrate that includes:a first plurality of electrodes on the first electrode substrate that are configured to apply microcurrent stimulation therapy to a patient, wherein the first electrode substrate is configured to place one or more of the first plurality of electrodes on an outer surface of a patient's upper eyelid and one or more of the first plurality of electrodes on the patient's lower eyelid, wherein each one of the first plurality of electrodes is configured to be individually activated, and
at least one light emitter on the first electrode substrate;

a microcurrent-stimulation controller, wherein the microcurrent-stimulation controller is operatively coupled to each one of the first plurality of electrodes and the at least one light emitter, wherein the microcurrent-stimulation controller is configured to control the microcurrent stimulation therapy applied to the patient; and
sensors operatively coupled to the microcurrent-stimulation controller and configured to sense electrical signals of a nerve from the patient's eyelid skin that indicate patient discomfort, wherein the microcurrent stimulation therapy applied to the patient is limited based on the sensed nerve electrical signals from the patient's eyelid skin.

US Pat. No. 11,065,446

GLASSES-SHAPED COCHLEAR IMPLANT DEVICE

Todae Co., Ltd., Seoul (...


1. A cochlear implant device with a glasses shape, comprising:an auditory organ stimulator configured to be implanted in a user's head; and
an external device for wirelessly communicating with the auditory organ stimulator, the external device comprising:a glasses lens part;
glasses temples coupled to the glasses lens part;
a microphone disposed in one of the glasses temples and collecting a sound signal;
a signal processor embedded in one of the glasses temples and processing the sound signal collected by the microphone, and generates an electrical signal;
a battery disposed in the glasses temple and supplies power to the microphone and the signal processor; and
a transmission coil coupled to an end portion of one of the glasses temples,
wherein the transmission coil is configured to provide the electrical signal generated by the signal processor and the power supplied by the battery to the auditory organ stimulator,

wherein the auditory organ stimulator includes:a receiver coil configured to receive the electrical signal and the power from the transmission coil;
a pulse generator configured to demodulate the electrical signal provided by the receiver coil and generate an electrical pulse corresponding to the sound signal; and
an electrode configured to deliver the electrical pulse generated by the pulse generator to a cochlea and stimulate the cochlea,
wherein the receiver coil is integrated on a first flexible polymer substrate;
wherein the pulse generator is integrated on a second flexible polymer substrate; and
the first flexible polymer substrate and the second flexible polymer substrate are connected by a flexible hinge member extended therebetween along an extension axis,
the first flexible polymer substrate includes an upper surface and a lower surface and the second flexible polymer substrate includes an upper surface and a lower surface,
wherein the glasses temple to which the transmission coil is coupled is bendable, such that, when the auditory organ stimulator is implanted in the user's head, a position of the transmission coil relative to the receiver coil is adapted to change according to a bending degree of said glasses temple;
wherein the transmission coil provides the electrical signal and the power to the auditory organ stimulator only when the transmission coil and receiver coil are aligned, and the auditory organ stimulator does not include a magnet for alignment of the receiver coil with the transmission coil;
wherein the second flexible polymer substrate comprises a first side surface connecting to the electrode, the flexible hinge member is disposed between the first side surface and the first flexible polymer substrate;
wherein an extending direction of the electrode is parallel to the extension axis of the flexible hinge member;
wherein a gap is formed between the electrode and the flexible hinge member;
wherein the first flexible polymer substrate is disposed on the second flexible polymer substrate and the upper surface of the first flexible polymer substrate faces the upper surface of the second flexible polymer substrate by bending of the flexible hinge member; and
wherein the upper surface of the second flexible polymer substrate comprises a first portion on which a plurality of electric components is disposed and a second portion on which the first flexible polymer substrate is disposed and electronic component is not disposed.


US Pat. No. 11,065,445

TRANSCRANIAL STIMULATION WITH REAL-TIME MONITORING

Monash University, Clayt...


1. A method of performing closed-loop transcranial stimulation comprising:generating, by using a processor, a stimulation signal having a set of first oscillation parameters;
applying, by using two or more electrodes, the stimulation signal transcranially to a patient;
monitoring, by using the processor, the stimulation signal as applied to the patient to determine changes in voltage and/or impedance of the stimulation signal for taking into account an actual nature of the stimulation signal;
engaging the patient in a cognitive task;
receiving, by using the processor, a brain activity signal from the patient;
generating, by using the processor, a feedback signal based on the monitored stimulation signal as applied to the patient;
generating, by using the processor, a modified activity signal by subtracting the feedback signal from the brain activity signal, wherein the subtraction of the feedback signal from the brain activity signal removes an artefact from the brain activity signal that is based on the stimulation signal;
iteratively optimizing the stimulation signal for a fit with the modified activity signal and triggering the application of the stimulation signal upon alignment of a phase of the stimulation signal with a phase of the modified activity signal;
determining, by using the processor, one or more second oscillation parameters of the generated modified activity signal; and
receiving, by using the processor, an external input to control how the stimulation signal is adjusted based on the one or more second oscillation parameters and/or to control which of the one or more second oscillation parameters of the modified activity signal, generated by subtracting the feedback signal constructed in view of the monitoring of the stimulation signal, from the brain activity signal, are determined and/or when the one or more second oscillation parameters are determined, wherein the external input is based on a response of the task provided to patient.

US Pat. No. 11,065,444

MOBILE PHONE FOR STIMULATING THE TRIGEMINAL NERVE TO TREAT DISORDERS

ElectroCore, Inc., Baski...


1. A system comprising:an energy source that generates an electrical impulse;
a wireless transmitter coupled to the energy source, wherein the wireless transmitter wirelessly transmits the electrical impulse and a therapy regimen;
a mobile device that wirelessly receives the electrical impulse and the therapy regimen from the wireless transmitter;
a stimulator coupled to the mobile device, wherein the stimulator includes a housing with a contact surface that contacts an outer skin surface of a head of a patient, wherein the stimulator transmits the electrical impulse transcutaneously through the outer skin surface to a trigeminal nerve at a target region of the head, wherein the electrical impulse modulates the trigeminal nerve such that a medical condition of the patient is treated; and
wherein the therapy regimen includes continuously applying the electrical impulse for a time period from about 30 seconds to about 300 seconds as a single dose, wherein the therapy regimen includes applying a dose on a daily basis.

US Pat. No. 11,065,443

RESPIRATORY RECTIFICATION

Zoll Respicardia, Inc., ...


1. A method of treating breathing disorders comprising the steps of:stimulating a phrenic nerve or diaphragm at a stimulation frequency below an intrinsic breathing rate at an intensity sufficient to entrain respiration while leaving intrinsic drive to breathe intact;
sensing a signal representative of a length of the patient's respiration over a period of time;
creating a histogram of the sensed lengths of the patient's respiration;
determining a frequency distribution of the sensed lengths of the patient's respiration;
comparing the frequency distribution of the sensed respiration signal to a target frequency distribution; and
adjusting the intensity of the stimulation based on the comparison of frequency distributions until the stimulation is at an intensity sufficient to entrain respiration while leaving intrinsic drive to breathe intact.

US Pat. No. 11,065,442

IMPLANTABLE MEDICAL DEVICE WHICH MAY BE CONTROLLED FROM CENTRAL STATION


1. A system for determining the identity of a person in whom a pacing device is implanted, comprising:(A) A sensing device configured to acquire and process information representing a state of a person and to provide biologic identification information pertaining to the person, including:(1) at least one first sensing element, configured and arranged to input biologic identification information from a finger of a body of a person, and wherein said biologic identification information represents a pattern of a fingerprint;
(2) at least one second sensing element, configured and arranged to input physiologic parameter information from said finger, representing a physiologic parameter of said person;
(3) at least one first microprocessor, coupled to each of said at least one first sensing element and said at least one second sensing element operative to receive each of said biologic identification information and said physiologic parameter information, and to produce a sensing device output signal representing both of said physiologic and said biologic information; and
(4) a communications device, coupled to said at least one first microprocessor, configured to transmit said sensing device output signal;

wherein at least one of (i) said at least one first sensing element and at least one of (ii) said at least one second sensing element is arranged to acquire information from the same finger of said person; and
wherein said sensing device output signal represents identification and physiologic parameter information, each acquired from the same finger of said person; and
wherein said at least one first microprocessor is operative to cause said communications device to transmit said sensing device output signal;
(B) An implanted pacing device (“IPD”), located within said body, including:(1) a pacing output circuit, configured to produce pacing output signals for stimulating a chamber of a heart of said person;
(2) a pacing sensing circuit, configured to sense electrical signals of said heart;
(3) a pacing communications device, having a communications address, and configured to receive a pacing prompt signal;
(4) a least one pacing microprocessor, coupled to each of said pacing output circuit, said pacing sensing circuit, and said pacing communications device, operative to:(i) control an output of said pacing output circuit, and process information from said pacing sensing circuit; and
(ii) temporarily alter the output of said pacing output circuit in response to a command specified by said received pacing prompt signal; and

(5) a power supply, coupled to and supplying electrical power to each of said pacing output circuit, said pacing sensing circuit, said at least one pacing microprocessor and said pacing communications device;

wherein said pacing output circuit, said pacing sensing circuit and said at least one pacing microprocessor are operative to perform pacing and sensing of said heart; and
(C) A management station, including:(1) a second communications device, configured to receive said sensing device output signal; and to transmit said pacing prompt signal to said IPD;
(2) a memory device configured to store and provide (i) fingerprint pattern information pertaining to said person, (ii) alphanumeric identification information pertaining to said person, (iii) the communications address of said IPD pacing communications device, and (iv) information specifying a pacing prompt represented by said pacing prompt signal;
(3) at least one second microprocessor, coupled to each of said second communications device and to said memory device, operative:(i) to produce said pacing prompt configured for transmission to said IPD, wherein(a) said pacing prompt specifies a temporary alteration in a pacing output of said IPD, and
(b) said temporary alteration is configured to result in a temporary alteration in a value of the physiologic parameter detected by said sensing device; and

(ii) to cause said second communications device to transmit said pacing prompt represented by said pacing prompt signal;


and wherein:said at least one sensing device output signal, outputted by said sensing device and received by said management station reflects said temporary alteration;
said at least one second microprocessor is further operative to determine and indicate the results of a physiologic comparison between (a) the temporary alteration specified by the received sensing device output signal, and (b) the temporary alteration specified by the stored information related to the transmitted pacing prompt signal; and
said at least one second microprocessor is further operative to determine and indicate the results of the fingerprint pattern identification comparison between (a) the fingerprint information specified by the received sensing device output signal, and (b) the stored fingerprint pattern information;

wherebythe acquired physiologic parameter information of the person is linked to the biologic identification information of the person; and
based on comparisons of each of the physiologic and the biologic information, a determination is made, at the management station, of whether the recipient of a communication is the intended recipient.


US Pat. No. 11,065,441

ELECTRODE FIXATION IN INTERVENTIONAL MEDICAL SYSTEMS

Medtronic, Inc., Minneap...


1. An implantable medical device assembly comprising:a mounting structure having a length defined from a proximal end thereof to a distal end thereof, the mounting structure comprising at least one shoulder formed in a surface of the structure and aligned along a portion of the length of the mounting structure; and
a tissue-penetrating fixation tine corresponding to the shoulder, the tissue-penetrating fixation tine being elastically deformable from a first position configured to fix the implantable medical device to tissue at a stimulation site to a second position configured to allow delivery of the implantable medical device to the stimulation site, in the first position a portion of the tissue-penetrating fixation tine bends toward the proximal end of the mounting structure and out of the shoulder of the mounting structure, and in the second position the portion of the tissue-penetrating fixation tine bends toward the distal end of the mounting structure and extends along and within the shoulder of the mounting structure.

US Pat. No. 11,065,440

HEARING ASSISTANCE DEVICE COMPRISING AN IMPLANTABLE PART


1. A hearing assistance device comprising an implantable part for electrically stimulating an auditory nerve of a user,the implantable part comprising
a current source generator;
an electrode array configured to be located inside one of the cochlear scala or adjacent to the auditory nerve, or at the auditory brainstem;
a processor programmed todetermine, based on an acoustic input signal picked up by a microphone, a location of the auditory nerve to be stimulated and a spatial range of neurons along the length of the auditory nerve to be excited,
calculate a slope of stimulation based on a rate of depolarization associated with the neurons of the auditory nerve and a correlation between the neurons' distances from a stimulation electrode and reductions in slope seen by the neurons, said slope of stimulation being defined as one of:an amount of charge density over time to be delivered to a singular stimulation electrode in said electrode array to stimulate the determined location of the auditory nerve to be stimulated, and
an amount of current over time to be delivered to the singular stimulation electrode in said electrode array to stimulate the determined location of the auditory nerve to be stimulated, and

cause said current source generator to deliver to the singular stimulation electrode in said electrode array a time-varying waveform comprising a positive pulse having a rising edge and a falling edge, the positive pulse further having a monotonically increasing segment connecting the rising edge and the falling edge such that an entirety of the positive pulse has a positive slope, the height of the falling edge being larger than the height of the rising edge by an amount that causes the monotonically increasing segment to have the calculated slope of stimulation, thereby causing the singular stimulation electrode in said electrode array to stimulate the determined location of the audio nerve in such manner as to provide a focussed neural excitation based on temporal shaping of a stimulating waveform,
wherein said processor calculates the slope of stimulation so as not to exceed a discharge threshold for each neuron of the auditory nerve outside the spatial range thereby preventing a discharge that otherwise would occur to at least one neuron of the auditory nerve based on an amplitude of said pulse in order to improve spectral resolution in the sound perception of the user.


US Pat. No. 11,065,439

CONFORMING MODULAR NEURAL INTERFACE SYSTEM

Modular Bionics Inc., Be...


1. A neural interface system, comprising:a first neural interface device and a second neural interface device, each of the first neural interface device and second neural interface device comprising at least two rigid panels, each rigid panel operably connected to an adjacent rigid panel by at least one movable structure in between adjacent rigid panels and configured to substantially conform to tissue in a first configuration and a second configuration different from the first configuration, wherein each rigid panel of both the first neural interface device and the second neural interface device comprises magnetic zones and non-magnetic zones,
wherein the first neural interface device is configured to be wearable above a skin surface of a subject;
wherein the second neural interface device is configured to be implantable below the skin surface of the subject;
wherein the first neural interface device and the second neural interface device are configured to movably align with each other via the magnetic zones; and
wherein the at least one movable structure comprises a hinge.

US Pat. No. 11,065,438

SYSTEMS AND METHODS FOR TRANSSEPTAL DELIVERY OF PERCUTANEOUS VENTRICULAR ASSIST DEVICES AND OTHER NON-GUIDEWIRE BASED TRANSVASCULAR THERAPEUTIC DEVICES

SYNECOR LLC, Durham, NC ...


1. A method of delivering a percutaneous ventricular assist device (pVAD) to a target site in the heart, comprising the steps of:positioning a flexible member in a body of a patient to run between a femoral artery, through the heart via an aortic valve, left ventricle, mitral valve, left atrium, and right atrium into the venous vasculature, the flexible member having a first end extending outside the body from a venous vessel superior to the heart and a second end external to the patient at the femoral artery;
releasably connecting a distal end of a pVAD to the first end of the flexible member;
providing a left ventricle redirector (LVR) having a tubular lumen and a distal end actively steerable to form a curve;
at the femoral artery, positioning the LVR with the shaft of the flexible member extending through the lumen of the LVR;
advancing the LVR over the shaft of the flexible member to the left ventricle actively forming a curve in the distal end of the LVR;
pushing the pVAD in a distal direction from the venous vessel while pulling the second end of the flexible member from the femoral artery to advance the pVAD to the target site and, in the left ventricle, pushing the distal end of the pVAD into contact with the distal end of the LVR, and then, with the pVAD and LVR maintaining contact, withdrawing the LVR by pulling it from the femoral artery while continuing to advance the pVAD to the aortic valve.

US Pat. No. 11,065,437

CARDIAC SUPPORT SYSTEMS AND METHODS FOR CHRONIC USE

CORVION, INC., Webster, ...


1. A method for treating heart failure, the method comprising:generating an amount of blood flow with a rotary blood pump implanted in a patient;
coupling a transmitting coil assembly to a receiving coil assembly, implanted in the patient and contained within an implantable housing, using magnetic resonance coupling, such that the transmitting coil assembly electromagnetically transfers energy to the receiving coil assembly; and
storing, in a power module implanted in the patient and contained within the implantable housing, the energy transferred to the receiving coil assembly, the energy being utilized to operate the rotary blood pump.

US Pat. No. 11,065,436

COMMUNICATION METHODS AND ARCHITECTURE FOR HEART TREATMENT SYSTEMS

TC1 LLC, Saint Paul, MN ...


1. A method of assisting a heart of a patient, the method comprising:receiving, through a first lead having a first end coupled with an implantable cardiac rhythm management device and a second end opposite the first end coupled with a pump processor of an implantable blood pump, an electrical pace signal from the implantable cardiac rhythm management device, the implantable cardiac rhythm management device delivering the electrical pace signal to the pump processor of the implantable blood pump;
adjusting a pumping protocol of the implantable blood pump based on the received electrical pace signal with the pump processor.

US Pat. No. 11,065,435

BLOOD PUMP AND BLOOD PUMP ADJUSTING METHOD

SUN MEDICAL TECHNOLOGY RE...


1. A blood pump for causing blood to flow into a pump chamber, flow out from the pump chamber, and flow into the inside of a body of a user by a blood supply mechanism housed in the pump chamber, the blood pump comprising:the blood supply mechanism connected to one end of a shaft and capable of moving a liquid due to rotation thereof;
a motor having a stator and a rotor, having the shaft connected to the rotor, and imparting rotational energy to the blood supply mechanism by way of the shaft;
a base body having a pedestal portion which partitions the blood pump into a pump chamber side and a rotor side which is a side opposite to the pump chamber, wherein a through hole which allows the shaft to pass therethrough is formed in the base body at a position close to a center of the pedestal portion;
a casing fitted into the base body thus forming the pump chamber together with the base body;
a fixed side slide member having a first slide surface, wherein a first insertion hole which allows the shaft to pass therethrough is formed in the fixed side slide member, and the fixed side slide member is fixed to the base body at a position corresponding to the through hole; and
a rotary side slide member having a second slide surface, wherein a second insertion hole which allows the shaft to pass therethrough is formed in the rotary side slide member, the shaft is fitted into the second insertion hole in a state where the shaft is interposed between the fixed side slide member and the blood supply mechanism, and the second slide surface is slidable on the first slide surface in a contact manner with the first slide surface by rotating together with the blood supply mechanism and the shaft, wherein
the stator has a core around which a coil is wound,
the rotor has a permanent magnet disposed so as to opposedly face a peripheral wall of the core, wherein an N pole and an S pole are alternately arranged along a circumferential direction that the rotor rotates,
assuming a rotary axis of the rotor as a z axis, a direction along the z axis extending from the pump chamber side to the rotor side as a +z direction, and a direction opposite to the +z direction as a ?z direction,
the stator is fixed to the base body,
the rotor is movable relative to the stator along a direction parallel to the z axis,
a center of the core in the direction parallel to the z axis is located at a position shifted on a more +z direction side than a center of the permanent magnet in the direction parallel to the z axis, and
the blood pump further comprises a core position adjusting member having a screw portion on which threads are formed, the core position adjusting member being capable of moving the core in the direction parallel to the z axis while being engaging with any portion of the stator due to rotation of the screw portion.

US Pat. No. 11,065,434

BLOOD PUMP WITH IMPELLER RINSE OPERATION

HeartWare, Inc., Miami L...


1. A method of operating an implantable blood pump having a first stator, a second stator, and an impeller movably disposed between the first stator and the second stator, wherein the first stator is located upstream of the impeller, the method comprising:applying a first voltage waveform at a first time of operation of the blood pump to the first stator to generate a magnetic field to rotate the impeller;
applying a second voltage waveform during the first time to the second stator to rotate the impeller, the second voltage waveform being symmetric to the first voltage waveform, wherein the second voltage waveform has a transition portion that has a same polarity as a respective transition portion of the first voltage waveform;
wherein applying the first and second voltage waveforms includes producing a zero net axial force on the impeller, thereby maintaining a predetermined axial gap between the impeller and the first stator during the first time;
applying the first voltage waveform at a second time of operation of the blood pump to the first stator to generate a magnetic field to rotate the impeller, the second time being later than the first time of operation of the blood pump;
changing the second voltage waveform applied to the second stator and rotating the impeller during the second time of operation, so that the second voltage waveform becomes asymmetric to the first voltage waveform; and
wherein applying the first voltage waveform and the second voltage waveform includes temporarily increasing the predetermined axial gap when the first voltage waveform is at a maximum torque angle with respect to the second voltage waveform, thereby increasing a rinsing effect on a surface of the impeller during a portion of the second time of operation of the implantable blood pump.

US Pat. No. 11,065,433

APPARATUS AND METHODS OF DISPENSING FLUID INTRAVENOUSLY AND FLUSHING LINES OF INTRAVENOUS FLUID ADMINISTRATION SYSTEMS


1. An apparatus for dispensing fluid intravenously to a subject, comprising:a pressure-operated valve configured to operate in fluid communication with an upstream source of a first fluid;
a reservoir pump configured to, during an expansion operation of the reservoir pump, automatically refill itself with the first fluid from the upstream fluid source; and
a port connector configured to operate in fluid communication with the upstream source and with the pressure-operated valve;
wherein, during operation, the pressure-operated valve is configured to pass therethrough to tubing downstream of the pressure-operated valve, under a first pressure condition, the first fluid from the upstream fluid source; and
wherein, during a compression operation of the reservoir pump, the pressure-operated valve is configured to automatically shut a normally open check valve within the pressure-operated valve to automatically shut off fluid communication with the upstream fluid source and to pass therethrough to the tubing downstream of the pressure-operated valve, under a second pressure condition resulting from the compression operation of the reservoir pump, the first fluid from the reservoir pump, wherein the second pressure condition is a condition of higher pressure than a threshold pressure condition of the pressure-operated valve, and wherein the first pressure condition is a condition of lower pressure than the threshold pressure condition of the pressure-operated valve.

US Pat. No. 11,065,432

APPARATUS AND METHODS OF DISPENSING FLUID INTRAVENOUSLY AND FLUSHING LINES OF INTRAVENOUS FLUID ADMINISTRATION SYSTEMS


1. A reservoir pump for use in flushing fluid in an intravenous line toward a subject, the reservoir pump comprising:an inlet port configured to be operably coupled to upstream tubing and to operate in fluid communication with a source of an intravenous fluid via the upstream tubing;
an outlet port configured to be operably coupled to downstream tubing and to operate in fluid communication with a pressure-operated valve;
a housing defining a chamber, the chamber in fluid communication with the inlet port and the outlet port, the chamber having a filling volume;
a plunger assembly at least partially disposed within the housing, wherein the plunger assembly comprises a piston and a handle, said handle is biased in a retracted position by a spring, and said handle and said spring are external to the housing;
wherein the reservoir pump, during operation, is configured to:during compression of the spring of the plunger assembly, introduce intravenous fluid from the chamber into the downstream tubing at a pressure at or exceeding a threshold pressure of the pressure-operated valve and as a flushing fluid for another intravenous fluid in the downstream tubing or in tubing downstream of the pressure operated valve; and
during expansion of the spring of the plunger assembly, automatically refill the filling volume of the chamber with intravenous fluid via the inlet port.


US Pat. No. 11,065,431

CAPPING AND CLEANSING DEVICES FOR NEEDLEFREE VASCULAR ACCESS CONNECTORS

CleanSite Medical, Inc., ...


1. A capping and cleansing device for a threaded valve portion of a needlefree vascular access connector, the capping and cleansing device comprising:(a) an inner housing rotatably disposed in an outer housing, wherein the inner housing comprises a sidewall that bounds a central bore comprising oppositely disposed first and second openings, wherein the central bore is configured to allow the capping and cleansing device to be screwed onto and unscrewed from the threaded valve portion of the needlefree vascular access connector and into which a compressible cleansing matrix attached to the outer housing protrudes into the central bore to allow contact with a valve surface of the threaded valve portion of the needlefree vascular access connector when the capping and cleansing device is screwed onto the threaded valve portion of the needlefree vascular access connector;
(b) the outer housing, wherein the outer housing comprises a cavity in which the inner housing is rotatably disposed, wherein the outer housing is configured to (A) retain and (B) engage and disengage from the inner housing so as to allow the outer housing to (i) retain the inner housing and be rotated independently of the inner housing at least 360 degrees in both a clockwise direction and a counter-clockwise direction by a user when the outer housing is not engaging the inner housing and (ii) retain the inner housing and be rotated in unison with the inner housing by the user when the outer housing and the inner housing are engaged; and
(c) the compressible cleansing matrix attached to the outer housing and that protrudes into the cavity of the outer housing and into the central bore of the inner housing, wherein the compressible cleansing matrix rotates with the outer housing, wherein the compressible cleansing matrix is impregnated with a liquid disinfectant.

US Pat. No. 11,065,430

COUPLING DEVICES FOR TUBE SETS USED WITH SURGICAL GAS DELIVERY SYSTEMS

Surgiquest, Inc., Milfor...


1. A coupling system for connecting a dual lumen tube set to a trocar comprising:a) a trocar connector having two coaxial flow passages formed therein including an inner flow passage defined by an inner annular wall and an outer flow passage defined between the inner annular wall and an outer annular wall, wherein a plurality of circumferentially spaced apart posts project radially outwardly from the outer annular wall of the trocar connector;
b) a dual lumen tube set including a first tube having a first diameter and a second tube having a second diameter that is greater than the first diameter;
c) a coupling including a generally cylindrical body having a first end portion configured to mate with the two coaxial flow passages of the trocar connector and a second end portion configured for attachment to the first tube and the second tube of the dual lumen tube set, the first end portion of the body having an inner flow passage defined by an inner annular wall for establishing fluid communication with the inner flow passage of the trocar connector and an outer flow passage defined between the inner annular wall of the body and an outer annular wall of the body for establishing fluid communication with the outer flow passage of the trocar connector, the second end portion of the body including first and second parallel interior recesses, wherein a central axis of the first interior recess is spaced apart from and parallel to a central axis of the second interior recess, and wherein the first interior recess is dimensioned and configured to receive a distal end portion of the first tube of the dual lumen tube set and the second interior recess is dimensioned and configured to receive a distal end portion of the second tube of the dual lumen tube set; and
d) a shroud rotatably supported on the body of the coupling and including an internal ring having an inner annular surface with an internal thread for rotationally engaging the plurality of circumferentially spaced apart posts that project radially outwardly from the outer annular wall of the trocar connector upon axial rotation of the shroud relative to the body of the coupling, wherein the internal ring includes a plurality of circumferentially spaced apart radially inwardly extending arcuate tabs configured to snap fit into corresponding arcuate slots formed in an outer surface of the coupling to restrict rotational movement therebetween, wherein the internal ring further includes a plurality of axially extending circumferentially spaced apart flexible fingers which engage with a plurality of circumferentially spaced apart ramps in the shroud that ratchet together when torque is applied to the flexible fingers, and wherein the plurality of arcuate tabs are located between the internal thread and the plurality of flexible fingers.

US Pat. No. 11,065,429

METHOD OF PRODUCING MICRONEEDLE ARRAY UNIT

FUJIFILM Corporation, To...


1. A method of producing a microneedle array unit, comprising:an array preparing step of preparing a microneedle array which includes a sheet and a plurality of needles arranged on one surface of the sheet;
a container preparing step of preparing a container which includes an accommodating portion defining an opening and a space for accommodating the microneedle array, and a deformable portion disposed on a side opposite to the opening and integrated with the accommodating portion;
an accommodating step of accommodating the microneedle array in the accommodating portion of the container by allowing the other surface of the sheet of the microneedle array and the deformable portion of the container to oppose each other; and
a deforming step of deforming an outer peripheral surface of the accommodating portion inward to form at least one protrusion, which is configured between the one surface of the sheet of the microneedle array and the opening of the accommodating portion, to reduce an area of the opening of the accommodating portion.

US Pat. No. 11,065,428

MICRONEEDLE ARRAY WITH ACTIVE INGREDIENT

Allergan, Inc., Irvine, ...


1. A microneedle array comprising:a base layer;
a plurality of microneedles projecting from the base layer, each of the microneedles comprising:an elongate body having a proximal portion and a distal portion,
the distal portion comprising a first dissolvable polymer and an active ingredient incorporated within a matrix of the first dissolvable polymer,
the proximal portion being contiguous with and attached to the base layer,

wherein the proximal portion and the base layer comprise the first dissolvable polymer and substantially no active ingredient.

US Pat. No. 11,065,427

METHOD FOR MANUFACTURING TRANSDERMAL ABSORPTION SHEET

FUJIFILM Corporation, To...


1. A method for manufacturing a transdermal absorption sheet comprising:a first filling step of filling needle-shaped recessed portions of a mold having the needle-shaped recessed portions with a first polymer solution containing a drug or a cosmetic component in an aseptic environment;
a storage step of storing the mold filled with the first polymer solution in a drying container in an aseptic environment;
a carrying-out step of carrying the drying container in which the mold is stored out of the aseptic environment;
a drying step of drying the first polymer solution of the mold stored in the drying container outside an aseptic environment;
an electron beam irradiation step of irradiating a surface of the drying container in which the mold is stored with an electron beam from an electron beam source; and
a carrying-in step of carrying the drying container into an aseptic environment after the electron beam irradiation step,
wherein in the electron beam irradiation step, a shield that shields an electron beam is arranged at a position on a straight line connecting the electron beam source and the needle-shaped recessed portions.

US Pat. No. 11,065,426

IMPLANTABLE DEVICE WITH INTRAVESICAL TOLERABILITY AND METHODS OF TREATMENT

TARIS Biomedical LLC, Le...


1. A drug delivery device for deployment within the bladder of a human patient which is well tolerated by the patient, comprising:an elongated elastic body comprising a first end, an opposed second end, an annular portion disposed between the first end and the second end, and a drug reservoir lumen defined at least in part by the annular portion; and
a drug formulation loaded in the drug reservoir lumen, the drug formulation comprising a drug,
wherein the device has a retention shape having (i) dimensions that provide intravesical mobility and that prevent voiding of the device through the urethra, and (ii) dimensions, buoyancy, or both, that exclude the device from entering the orifices of the ureters, wherein the retention shape has a maximum dimension in any dimension of 6 cm or less when in an uncompressed state, and wherein the device exerts a maximum acting force less than 1 N when the device is compressed from the retention shape to a shape having a maximum dimension in any dimension of 3 cm.

US Pat. No. 11,065,425

CEREBROSPINAL FLUID PURIFICATION SYSTEM

Neurofluidics, Inc., St....


1. A method for ameliorating a symptom of multiple sclerosis in a patient, said method comprising:selecting a patient having a symptom of multiple sclerosis;
removing cerebrospinal fluid from a first location in a lumbar cerebrospinal fluid space of the patient;
removing a causative agent from the removed cerebrospinal fluid, thereby conditioning the cerebrospinal fluid; and
returning the conditioned cerebrospinal fluid to the patient at a second location in a cervical cerebrospinal fluid space, a thoracic cerebrospinal fluid space, or a ventricle of the patient, wherein the cerebrospinal fluid is returned to the patient at substantially the same flow rate at which it is removed;
wherein the removing and returning steps are performed concurrently using one or more catheters, each catheter comprising one or more lumens.

US Pat. No. 11,065,423

BALLOON CATHETER

ASAHI INTECC CO., LTD., ...


1. A catheter comprising:an outer shaft;
an inner shaft disposed within the outer shaft; and
a reinforcement member disposed between the outer shaft and the inner shaft, wherein:the inner shaft includes a proximal variant portion and a distal variant portion that extend circumferentially around the inner shaft, the distal variant portion being distal of the proximal variant portion,
an outer diameter of the proximal variant portion is larger than an outer diameter of the inner shaft between the proximal variant portion and the distal variant portion,
an outer diameter of the distal variant portion is larger than the outer diameter of the inner shaft between the proximal variant portion and the distal variant portion, and
the reinforcement member includes:a proximal portion extending through a space between the proximal variant portion and the outer shaft, and having a diameter smaller than a distance between an outer periphery of the proximal variant portion and an inner periphery of the outer shaft in a radial direction; and
a bulged portion arranged between an outer surface of the inner shaft and an inner surface of the outer shaft and in direct contact with the inner surface of the outer shaft, the bulged portion having a diameter larger than both (i) the distance between the outer periphery of the proximal variant portion and the inner periphery of the outer shaft in the radial direction and (ii) a distance between an outer periphery of the distal variant portion and the inner periphery of the outer shaft in the radial direction, and being configured to move in an axial direction between the proximal variant portion and the distal variant portion until contacting with at least the distal variant portion.



US Pat. No. 11,065,422

DEVICES, SYSTEMS, AND METHODS USEFUL TO ENGAGE TISSUE USING SUCTION AND TO PERFORM MEDICAL PROCEDURES DURING SUCTIONAL ENGAGEMENT

CVDevices, LLC, San Dieg...


11. The method of claim 9, wherein the tissue is located proximal to the two or more arms relative to the two or more arms, and wherein the step of positioning is performed to proximally retract the two or more arms toward the tissue so that the two or more arms contact the tissue.

US Pat. No. 11,065,421

CATHETER CURVATURE BRACES AND METHODS OF USING SAME

INTEGRA LIFESCIENCES SWIT...


7. A method for managing fluid within a patient, comprising:selecting a catheter with an elongated shaft having a distal end and a proximal end, the shaft defining at least one lumen extending substantially therethrough, the shaft further defining a plurality of fluid management openings along a distal portion of the shaft, the fluid management openings being in fluid communication with the lumen;
selecting a catheter curvature brace attachable to the distal portion of the shaft, the catheter curvature brace having an elongated frame with a distal end and a proximal end, the frame being formed with at least one pre-defined curve in a desired pre-defined relaxed curved configuration, at least two coupling elements connected to the frame, each coupling element configured to engage an outer surface of the catheter, and at least the frame being formed of an elastic, biocompatible material capable of being straightened by a force and then returning to the desired pre-defined relaxed curved configuration after the force is removed;
attaching the catheter curvature brace to the distal portion of the catheter to form a catheter assembly and bend the distal portion of the catheter to substantially conform to the desired pre-defined relaxed curved configuration;
placing a stylet within the catheter lumen to apply the force to straighten the catheter assembly;
inserting the catheter assembly within the patient to implant the distal portion in a targeted location; and
removing the stylet to allow the distal portion of the catheter to substantially conform to the desired pre-defined relaxed curved configuration.

US Pat. No. 11,065,419

CATHETER DELIVERY DEVICES, SYSTEMS, AND METHODS

Piper Access, LLC, Salt ...


1. A system comprising:a handle;
a needle fixedly secured to the handle, the needle comprising a distal tip configured to be inserted through a sidewall of a vessel of a patient;
a catheter defining a lumen through which the needle extends, the catheter comprising an engagement surface at a distal end thereof;
a stiffener positioned within the lumen of the catheter at an exterior of the needle, the stiffener comprising an engagement surface configured to press distally on the engagement surface of the catheter; and
a stiffener hub attached to the stiffener, the stiffener hub being movably coupled with the handle so as to translate relative thereto, the stiffener hub being configured to move distally relative to the handle from a retracted position to a deployed position so as to move the stiffener distally relative to the needle such that the engagement surface of the stiffener presses distally on the engagement surface of the catheter to thereby pull the catheter distally over the needle to a target depth within a lumen of the vessel,
wherein the handle is configured to retract both the needle and the stiffener proximally from the catheter as the handle is moved proximally relative to the catheter.

US Pat. No. 11,065,418

BLADDER STORAGE ANOMALY ASSESSMENT

SRS Medical Systems, LLC,...


1. A method of assessing bladder storage anomalies via utilization of an indwelling urinary drainage catheter, the method comprising:a. providing a urodynamic assessment assembly characterized by a pressure sensor for vesical pressure measurement during either of bladder filling or emptying events, a processor for receiving, processing and/or displaying select urodynamic patient parameters comprising monitored pressure data, and a catheter balloon adaptor for operably uniting said pressure sensor of said urodynamic assessment assembly to a balloon inflation valve of the indwelling urinary drainage catheter, said catheter balloon adaptor directly coupled to the balloon inflation valve;
b. operably linking said indwelling urinary drainage catheter with said urodynamic assessment assembly;
c. sensing vesical pressure via said vesical pressure sensor during a bladder emptying event, the bladder emptying event characterized by an application of variable resistance to fluid flow from the bladder via said indwelling urinary drainage catheter; and,
d. establishing vesical pressure and/or outlet resistance or flow rate relationships based upon sensed vesical pressure values.

US Pat. No. 11,065,417

METHOD FOR MANUFACTURING CATHETER AND CATHETER MANUFACTURED BY THIS MANUFACTURING METHOD

TERUMO KABUSHIKI KAISHA, ...


1. A catheter manufacturing method comprising:positioning a shaft in a cavity of a mold, the shaft being an elongated tubular body having a lumen formed therein and configured to be inserted into a living body, the mold comprising a first mold die and a second mold die, the first and second mold dies contacting one another to define a closed space which is the cavity between the first and second mold dies, the shaft extending from a proximal end to a distal end in an axial direction and having a transverse direction perpendicular to the axial direction, the shaft possessing an outer surface and a center at a midpoint of the shaft in the transverse direction;
injecting a molding material into the cavity from a gate positioned between the proximal end and the distal end of the shaft in the axial direction, the position being offset from the center of the shaft in the transverse direction; and
molding a hub onto the shaft by solidifying the injected molding material in the cavity onto the outer surface of the shaft.

US Pat. No. 11,065,416

THERAPEUTIC DEVICE


1. A therapeutic device comprises:an enclosure;
at least one oil-diffusing device;
at least one frequency-infusing device;
at least one frequency-tone generator;
a first plurality of ambience lights;
at least one vent;
a first controller;
a control panel;at least one first wireless communication module;
a magnetic levitation mechanism;
the at least one first wireless communication module, the at least one frequency-tone generator, the at least one oil-diffusing device, the at least one frequency-infusing device, and the first controller being mounted within the enclosure;
the control panel, the first plurality of ambience lights and the at least one vent being integrated into the enclosure;
the at least one frequency-infusing device being in fluid communication with the at least one oil-diffusing device;
the at least one oil-diffusing device being in fluid communication with the at least one vent;
the control panel, the at least one first wireless communication module, the at least one frequency-tone generator, the at least one oil-diffusing device, the at least one frequency-infusing device and the first plurality of ambience lights being electronically connected to the first controller;
the enclosure comprises a top separable portion and a bottom separable portion;
the top separable portion being attached onto the bottom separable portion;
the at least one oil-diffusing device comprises at least one reservoir, an ultrasonic vibrator, at least one exhaust and a muffler;
the at least one reservoir being removably situated within the bottom separable portion;
the ultrasonic vibrator being mounted to a base of the at least one reservoir;
the at least one reservoir and the ultrasonic vibrator being enclosed by the muffler;
the at least one exhaust being in fluid communication with the at least one reservoir;
wherein the at least one frequency-infusing device comprises a vibrating rod mounted through an opening of the at least one reservoir;
wherein the magnetic levitation mechanism comprises a current-inducing module mounted within the bottom separable portion and electronically connected to the first controller and a magnet mounted within the top separable portion; and
the magnet and the current-inducing module being magnetically coupled to each other.


US Pat. No. 11,065,415

GAS DELIVERY DEVICE AND SYSTEM FOR USE IN MAGNETIC RESONANCE IMAGING

Mallinckrodt Pharmaceutic...


1. A nitric oxide delivery system for providing inhaled nitric oxide (iNO) to a patient situated in an MRI suite, the nitric oxide delivery system comprising:a patient connector;
a source of nitric oxide gas;
a source of breathing gas;
a monitoring control circuit;
a delivery control circuit;
a signal processor comprising a corrective signal processing algorithm operable to remove distortion and delay caused by a length of an iNO delivery tube; and
an injector module fluidly connected to the source of nitric oxide gas, the source of breathing gas and the delivery control circuit, wherein the injector module is located inside an iso-gauss safety line.

US Pat. No. 11,065,414

COMPONENT FOR MEDICAL CIRCUIT


1. A medical comprising:a tube wall defining a passageway for transportation of gas and having a first end and a second end, the passageway providing for fluid communication between the first end and the second end,
wherein at least one of the first end and the second end comprises:
a cuff over-moulded about one or more first preformed components, one or more second preformed components, and at least a portion of the tube wall, wherein at least a portion of an interior surface of the cuff is in fluid communication with the passageway,
such that in use, the one or more first preformed components are in fluid communication with the passageway, the one or more first preformed components configured for fluid connection with one or more further components of a breathing circuit, and the one or more second preformed components are receivable of one or more auxiliary medical tube appliances,
wherein the one or more first preformed components and the one or more second preformed components are formed from a relatively rigid material, and
wherein the cuff is formed of a material relatively more pliable than that of the one or more first preformed components and the one or more second preformed components.

US Pat. No. 11,065,413

ORO-NASAL PATIENT INTERFACE

ResMed Pty Ltd, Bella Vi...


1. A patient interface to provide breathable gas to a patient, comprising:a cushion assembly, comprising:a nasal cushion having a concave shape between a first lateral side and a second lateral side to receive and seal against an inferior periphery of the patient's nose, the nasal cushion including a nasal opening configured to direct breathable gas to the patient's nares in use;
a nasal plenum chamber and the nasal cushion forming a nasal gas chamber;
an oral cushion configured to contact and seal against the patient's face surrounding the patient's mouth, the oral cushion including an oral opening configured to direct breathable gas to the patient's mouth in use; and
an oral plenum chamber and the oral cushion forming an oral gas chamber, the nasal gas chamber and the oral gas chamber being pneumatically connected within the cushion assembly,
wherein the nasal cushion, the nasal plenum chamber, the oral plenum chamber, and the oral cushion are formed from one piece of silicone;

an anti-asphyxiation valve;
a positioning and stabilizing structure including a pair of upper side straps, a pair of lower side straps, and a rear portion, the pair of upper side straps and the pair of lower side straps extending from the rear portion; and
a unitary plate member removably connected to the cushion assembly, the unitary plate member including a connection port configured to be connected to an air delivery tube, the connection port being configured to receive breathable gas from the air delivery tube and direct breathable gas into the cushion assembly for breathing by the patient during use, the unitary plate member including an upper portion and a lower portion, each of the upper side straps being removably connected to the upper portion of the unitary plate member, each of the lower side straps being removably connected to the lower portion of the unitary plate member, and the upper portion of the unitary plate member contacting the nasal plenum chamber to support the nasal cushion against the patient's face in use.

US Pat. No. 11,065,412

VALSALVA MASK


1. A mask assembly for use with a respiratory interface for providing respiratory gas to a user in use, including nose tabs providing additional lateral compressive forces against a user's nose for nose bridge support and to reduce air leakage, the mask assembly comprising:a mask base comprising a mask base wall made of a first material, the mask base wall having a distal portion defining a respiratory gases inlet, the mask base wall extending from the distal portion, around the respiratory gases inlet and proximally toward a user in use, to a proximal peripheral end of the mask base wall, the mask base wall having an inner mask base wall surface;
a seal member made of a second material that is more flexible than the first material, the seal member having a distal peripheral end, a sidewall portion, a face contacting wall portion, and a proximal end of the face contacting wall portion, the distal peripheral end being connected to the proximal peripheral end of the mask base wall, the sidewall portion extending from the distal peripheral end of the seal member proximally toward a user in use, to the face contacting wall portion of the seal member, the proximal end of the face contacting wall portion being disposed radially inwardly from the sidewall portion, the sidewall portion having a sidewall outer surface facing radially outwardly and the face contacting wall portion having a face contacting wall outer surface facing toward a user in use, wherein the sidewall portion and the face contacting wall portion have a sidewall inner surface and a face contacting wall inner surface, respectively, and wherein the sidewall portion, the face contacting wall portion, and the mask base wall define a mask assembly sidewall, and wherein the sidewall inner surface, the face contacting wall inner surface, and the inner mask base wall surface define an inwardly facing surface of the mask assembly, the mask assembly sidewall comprising a flexible silicone connector portion;
a tab integrally formed with the seal member and disposed on an inner side of the mask assembly, the tab having a proximal end portion and a distal end portion, the proximal end portion of the tab extending from the face contacting wall inner surface to the distal end portion of the tab which is sealed to the mask assembly sidewall with the flexible silicone connector portion, the flexible silicone connector portion being disposed at a first location that is disposed distally from the face contacting wall portion, the tab including first and second side edges extending from the proximal end portion to the distal end portion, the tab forming a first loop with the inwardly facing surface of the mask assembly and configured to press at least part of the face contacting wall outer surface laterally against a first side of a user's nose in use.

US Pat. No. 11,065,411

CUSTOMIZED SEALING MEMBER FROM BLANK

Koninklijke Philips N.V.,...


1. A method of manufacturing, from a seal blank, a customized sealing member for a customized mask of a pressure support system, the method comprising the steps of:generating surface geometry data of a face of a patient, the surface geometry data corresponding to and representing a surface geometry of the face of the patient, the surface geometry data having first data representing one or more localized regions corresponding to facial features of the patient;
generating customization data using the surface geometry data, the customization data representing one or more edge portions defining one or more regions to be removed from the seal blank to create one or more thru holes in the seal blank, wherein generating the customization data includes spacing the one or more edge portions from corresponding one or more of the localized regions based on predetermined directions and distances from the one or more localized regions; and
customizing the seal blank using the customization data such that the one or more regions to be removed from the seal blank are removed to create one or more thru holes in the seal blank to produce the customized sealing member, wherein the customized sealing member includes the one or more thru holes and does not include the one or more regions removed from the seal blank.

US Pat. No. 11,065,410

DENTAL APPLIANCE USING AIRWAY DIALATION FOR TREATING COVID RELATED BREATHING DISORDERS


1. A single piece, molded breathing appliance for supporting a nasal oxygen tube, comprising:an upper bite rim;
a lower bite rim;
an intermediary bridge connecting a portion of a lower surface of the upper bite rim to a portion of an upper surface of the lower bite rim;
a moldable material disposed within the upper bite rim and lower bite rim, said moldable material adapted to set after conforming to a patient's maxillary bite impression and mandibular bite impression, respectively;
an L-shaped member projecting outwardly and perpendicular to the upper bite rim, the L-shaped member comprising a flat horizontal spacer and flat vertical extension; and
a transverse tube clamp disposed on the vertical extension of the L-shaped member, wherein the transverse tube clamp comprises a diameter and a length, such that when the appliance is worn by the patient, the length extends horizontally from a first lateral side to a second lateral side of the patient and wherein the transverse tube is configured with a plurality of sets of opposed semi-cylindrical clamps adapted to cooperate to retain the nasal oxygen tube in proximity with the patient's nostrils.

US Pat. No. 11,065,409

GUM ELASTIC BOUGIE INTRODUCER WITH TACTILE DEPTH AND ORIENTATION INDICATOR


1. A bougie comprising:a flexible elongated distal portion; and
a flexible elongated main portion coupled to the distal portion, a longitudinal axis of the distal portion being at an angle relative to a longitudinal axis of the main portion, the main portion being longer than the distal portion,
the main portion including one or more pairs of concave finger grooves, each pair including a finger groove on a left side and on a right side of a ridge running along a majority of the main portion, the finger grooves and the ridge providing a tactile indication of an axial orientation of the bougie and the finger grooves providing a tactile indication of a depth of insertion of the bougie into a patient's trachea.

US Pat. No. 11,065,408

METHOD FOR DELIVERY OF BREATHING GAS TO A PATIENT AND SYSTEM FOR PERFORMING SAME


1. A system for delivering a flow of breathing gas to a patient, the system comprising:an ambient air dispenser and a supplemental gas supply cooperating to supply a breathing gas having a breathing gas flowrate set point and a fraction of inspired oxygen to the patient, each one of the ambient air dispenser and the supplemental gas supply including at least one actuator to respectively vary the ambient air flowrate supplied by the ambient air dispenser and the supplemental flowrate supplied by the supplemental gas supply;
an oxygen saturation sensor measuring an oxygen saturation level of the patient;
a respiratory rate sensor determining a respiratory rate of the patient; and
a control unit operatively connected to the oxygen saturation sensor, the respiratory rate sensor, the actuator of the ambient air dispenser and the actuator of the supplemental gas supply, the control unit automatically adjusting the ambient air flowrate and the supplemental gas flowrate according to the measured oxygen saturation level and the breathing gas flowrate set-point and automatically adjusting the breathing gas flowrate set-point according to the determined respiratory rate;
wherein the breathing gas flowrate set-point is adjusted solely when the fraction of inspired oxygen meets a predetermined fraction of inspired oxygen threshold, the breathing gas flowrate set-point remaining at an initial breathing gas flowrate set-point until the predetermined fraction of inspired oxygen threshold is met, the predetermined fraction of inspired oxygen threshold being a weaning threshold.

US Pat. No. 11,065,407

RESUSCITATION BAG

SOLENO THERAPEUTICS, INC....


1. An apparatus for respiratory resuscitation of an individual comprising:an actuator bag having (i) a non-compressed free state first size and compressible to a compressed state second size and (ii) an inside that is pneumatically sealed to not communicate with the outside of the bag;
one or more ventilation bags disposed within the inside of the actuator bag, each one or more ventilation bags having (i) a proximal single opening at a patient end in pneumatic communication with outside ambient air, (ii) other than the single opening a body sealed to the outside, and (iii) a non-compressed free-state first volume corresponding to the actuator bag free state;
a fluidically sealed space between the inside of the actuator bag and the outside of the ventilation bags;
and further wherein (a) compression of the actuator bag from its non-compressed free state first size to its compressed state second size increases its internal pressure in the fluidically sealed space without allowing any gas to escape out of the fluidically sealed space to compress the one or more ventilation bags to it's compressed-state second volume to displace gas in the bag to deliver a volume of breath to the individual through only the ventilation bags' single opening at the patient end, and (b) discontinuation of the compression force on the actuator bag allows the actuator bag to naturally expand to its resting state, causing the fluidically sealed space to return to its free state thereby causing the ventilation bags to expand to the free state volume, thereby refilling the ventilation bags with gas entering through the single opening at the patient end with a gas volume available for a next breath delivery.

US Pat. No. 11,065,406

INTERFACE COMPRISING A ROLLING NASAL BRIDGE PORTION


13. A mask assembly comprising:a first upper portion configured to be positioned in proximity to a face of a user in use;
a lower portion being positioned below the first upper portion;
a second upper portion positioned distally from the first upper portion;
wherein the first upper portion comprises a proximal portion having a first side profile length and a distal portion having a second side profile length; and
wherein the first upper portion is configured to be movable relative to the second upper portion and the lower portion such that during the relative movement the first side profile length decreases and the second side profile length increases when at least part of the first upper portion is moved toward the second upper portion.

US Pat. No. 11,065,405

ELECTRONIC CIGARETTE, AND METHOD OF CLEANING AN ELECTRONIC CIGARETTE

JT International S.A.


1. An electronic cigarette, comprising:a liquid storage;
a heating element;
a liquid delivery member configured to deliver liquid from the liquid storage to the heating element;
a battery; and
an electric circuit configured to electrically connect the heating element to the battery for the heating element to produce heat, and further configured to electrically disconnect the battery from the heating element,
wherein the heating element is a ceramic heating element comprising a current conducting heating member on and/or in a body of ceramic material,
wherein the body of ceramic material is configured to heat the liquid delivered by the liquid delivery member to vaporize the liquid when the ceramic heating element produces heat, and
wherein the electronic cigarette further comprises a cartomizer part and a battery holding part, the electronic cigarette being configured to be brought in an assembled state in which the cartomizer part and the battery holding part are assembled, and further being configured to be brought in a disassembled state in which the cartomizer part and the battery holding part are separated from one another,
wherein the cartomizer part comprises the liquid storage and the liquid delivery member; and
wherein the battery holding part comprises the battery, the ceramic heating element, and the electric circuit.

US Pat. No. 11,065,404

ELECTRONIC CIGARETTE

FONTEM HOLDINGS 1 B.V., ...


1. A vaporizing device, comprising:a battery assembly including a battery, an LED and an electronic circuit board in a battery assembly housing, the battery and the LED electrically connected to the electronic circuit board;
a sensor in the battery assembly housing electrically connected to the electronic circuit board;
a plastic or rubber separator in the battery assembly housing adjacent to the sensor, the separator having a through hole providing an air passage through the separator; a liquid supply assembly including an outlet; an aerosol passage leading from an air inlet to the outlet; a heating wire oriented perpendicular to a longitudinal axis of the device, the heating wire in a cavity; and a porous component for absorbing liquid in the liquid supply assembly and for moving the liquid towards the heating wire.

US Pat. No. 11,065,403

BLISTER STRIP ADVANCE MECHANISM

MICRODOSE THERAPEUTX, INC...


29. A blister strip advance mechanism comprising:a drive means;
an indexing gear train configured to be driven by said drive means, said indexing gear train comprising:a worm gear carried on an output shaft of the drive means and arranged to rotate therewith;
a first spur gear meshing with said worm gear;
a first sector gear carried on said first spur gear and arranged to rotate therewith;
a second spur gear meshing with said first sector gear;
a second sector gear carried on said second spur gear and arranged to rotate therewith; and
a third sector gear meshing with said second sector gear;

a hub carried on the third sector gear and arranged to rotate therewith, said hub comprising a recess shaped to engage a first blister of a blister strip, said hub being rotatable by the indexing gear train to engage the first blister in said recess and move the engaged blister strip such that a second blister of the blister strip is moved to a dosing position, wherein the second blister is configured to be emptied when the second blister is in the dosing position; and
a spooling gear comprising a third spur gear meshing with the first sector gear, the spooling gear carrying a spool arranged to rotate therewith, wherein an end of a backing strip of the blister strip is configured to be affixed to the spool,
wherein said spooling gear is configured to be rotated by the indexing gear train substantially concurrently with the hub such that backing is peeled off the second blister as the second blister is moved into the dosing position, arrival of the second blister at the dosing position being substantially coincident with completion of peeling of backing from the second blister.

US Pat. No. 11,065,402

AROMATHERAPY VAPORIZATION DEVICE

GSEH Holistic, Inc., Van...


1. A vaporization device comprising:a) a housing extending axially between a first housing end and a second housing end;
b) a fluid pathway extending through the housing between the first housing end and the second housing end;
c) an inhalation aperture fluidly coupled to the fluid pathway, the inhalation aperture positioned at the second housing end;
d) a heating element that is heatable to at least one predetermined vaporization temperature, wherein the heating element comprises a protruding portion, wherein the protruding portion protrudes from the first housing end thereby enabling the protruding portion to contact phyto material external to the housing, wherein in use the predetermined vaporization temperature is selected to vaporize phyto material proximate the protruding portion of the heating element whereby a phyto material vapor is emitted;
e) an energy storage member disposed within the housing and electrically coupled to the heating element; and
f) a control circuit disposed within the housing and electrically coupled to the energy storage member, the control circuit having a user-activated switch operable to control a flow of electric current from the energy storage member to the heating element,
wherein, in response to a user inhalation at the inhalation aperture, a pressure gradient is created across the fluid pathway that draws ambient air from the external environment into the fluid pathway and the ambient air mixes with the phyto material vapor, and the mixed phyto material vapor and air are drawn through the fluid pathway to the inhalation aperture.

US Pat. No. 11,065,400

AEROSOL FORMING DEVICE FOR USE IN INHALATION THERAPY

ALEXZA PHARMACEUTICALS, I...


1. A device for delivering apomorphine containing aerosols including: a housing; and, an airway including a gas/vapor mixing area, wherein the airway includes a subassembly, and wherein the subassembly includes a metallic substrate, and wherein a composition comprising apomorphine is coated on the substrate.

US Pat. No. 11,065,399

NEBULIZER VIBRATING APERTURE PLATE DRIVE FREQUENCY CONTROL AND MONITORING

STAMFORD DEVICES LIMITED,...


1. A nebulizer, comprising:a vibrating aperture plate mounted within the nebulizer and driven by an actuator; and
an aperture plate drive circuit coupled to the actuator and having a controller, wherein the controller is configured to:perform a short scan measuring drive current to the aperture plate; and
initiate a full scan of the drive current if the short scan measures a change in the drive current outside a predetermined tolerance.


US Pat. No. 11,065,398

AEROSOL GENERATING APPARATUS

MICROBASE TECHNOLOGY CORP...


1. An aerosol generating apparatus, comprising:a dosage liquid container having a first end and a second end, an opening at the second end, and a perforated membrane covering the opening defining a membrane surface through which liquid can permeate;
an adaptor configured to releasably couple with the second end of the container, the adaptor including a receiving portion, wherein the receiving portion includes at least one jack;
a driving element including a substrate adjacent a piezoelectric element, wherein the substrate includes an aperture and a projection, and wherein at least a portion of the driving element is configured to be supported by the at least one jack of the receiving portion of the adaptor, and wherein the substrate includes at least one corresponding mating structure to mate with the structure of the at least one jack; and
an attachment assembly configured for coupling the container and the adaptor, the attachment assembly including a first attachment element on the container configured to be attached with a second attachment element on the adaptor, such that when the first and second attachment elements are attached, a portion of the driving element presses against the membrane surface such that the aperture of the substrate aligns with the membrane surface and the projection of the substrate presses against the membrane surface, and at least a portion of the driving element is supported by the receiving portion of the adaptor, and such that when the first and second attachment elements are detached, the container is detached from the adaptor and the driving element is released from pressing against the membrane surface of the container.

US Pat. No. 11,065,397

INHALATION DEVICE, INHALATION DEVICE SET, AND NOZZLE PLATE THEREFOR

Aptar Radolfzell GMBH, R...


1. An inhalation device for inhaling a liquid in nebulized form, comprising:a housing configured in part as a rotationally symmetrical body with a center axis defining a main axis of extent of the housing, the rotationally symmetrical body enclosing a liquid reservoir in which a liquid is stored in pressurized form by application of a propellant gas or compressed air, or by a pretensioned spring mechanism, before being discharged;
an applicator head comprising:a nebulization chamber; and
an applicator piece connected to the nebulization chamber, the applicator piece being configured as a mouthpiece to be received in a mouth of a patient, as an inhalation mask to sealingly cover a mouth, a nose or a mouth and nose of a patient, or as an adapter piece for fitting a mouthpiece or an inhalation mask;

a discharge channel connecting the liquid reservoir to the nebulization chamber of the applicator head; and
an outlet valve disposed to open and close the discharge channel, wherein a rotational movement of the housing about the main axis of extent with respect to the applicator piece switches the outlet valve to open the discharge channel and discharge the liquid from the inhalation device while the outlet valve is open, the applicator piece being oriented laterally relative to the main axis of extent of the housing such that the applicator piece allows the patient to generate a force adjacent a mouth area which permits the rotational movement of the housing with respect to the applicator piece.

US Pat. No. 11,065,396

METHOD OF PRODUCING NEEDLE CANNULA WITH REDUCED END PORTION BY ELECTROCHEMICAL ETCHING


1. A method for producing a needle cannula comprising:(i.) providing a needle cannula tube, wherein the needle cannula tube comprises an end portion comprising:an outer surface, and
a steel alloy comprising:carbon (C) in 0.07 to 0.15% by mass,
silicon (Si) in 0.50 to 1.00% by mass,
manganese (Mn) in 5.0 to 7.5% by mass,
phosphorus (P) in 0 to 0.030% by mass,
sulfur (S) in less than or equal to 0.015% by mass,
chromium (Cr) in 17.5 to 19.5% by mass,
nickel (Ni) in 6.5 to 8.5% by mass, and
nitrogen (N) in 0.20 to 0.30% by mass,


(ii.) providing an electrolyte, and
(iii.) bringing the end portion into contact with the electrolyte,
(iv.) applying a potential between the needle cannula tube and a cathode, and thereby establishing an electrochemical reaction to remove material from the outer surface of the end portion, thereby providing a needle cannula with a tapered end portion.

US Pat. No. 11,065,395

CONTACT TRIGGER RELEASE NEEDLE GUARD WITH ELASTIC SPRING

Safety Syringes, Inc., F...


1. A needle guard comprising:a lock collar couplable to a portion of a syringe;
a device shield; and
a flexible member interconnecting the lock collar and the device shield, wherein the device shield is movable relative to the lock collar from a first configuration, in which the device shield is free to retract proximally to expose a syringe sharp, to a second configuration, in which the device shield may move distally under the bias of the flexible member,
wherein the device shield is caused to disengage from the first configuration as the device shield moves proximally, and
wherein the device shield includes an angled cutout and the lock collar comprises a protrusion, and wherein in the first configuration, the protrusion is aligned longitudinally with a first end of the angled cutout.

US Pat. No. 11,065,394

SYRINGE WITH RETRACTABLE NEEDLE

GUANGDONG INTMED MEDICAL ...


1. Syringe with a retractable needle comprisinga barrel (2) having a nozzle (19) integrated in a male Luer adapter element;
a piston (3) slidably arranged in the barrel (2) and coupled to a sealing element (16), said sealing element (16) having a central channel (20);
a needle assembly comprising a needle (4), a needle holder (6) and a female Luer adapter element (7);
a spring assembly arranged in the piston (3) comprising a spring sleeve (12), a spring (13) mounted on the spring sleeve (12), a spring tensioning element (14) located on the spring sleeve (12) and held in position by the piston wall, and a plunger (15) mounted within the spring sleeve (12); and
a piston cap (10);
said piston (3) being coupled to the sealing element (16) by means of the spring tensioning element (14);
said spring sleeve (12) being held in position within the piston (3) by a ring element (18) protruding from the inner wall of the piston (3) and supporting the proximal end of the spring sleeve (12), the spring sleeve (12) extending into the channel (20) of the sealing element (16) to the distal end thereof;
said spring sleeve (12) comprising at its distal end a circular protrusion (21) on the inside designed to engage a circular recess (22) at the proximal end of the needle holder (6);
wherein the spring sleeve (12) comprises an outer flange (17) supporting the proximal end of the spring (13) and comprises a widened section (46a) adjacent to the outer flange (17) for securing the proximal end of the spring (13);
wherein upon exertion of pressure to the piston (3) in its advanced position results in the engagement of the spring sleeve (12) and the needle holder and the release of the spring (13) sleeve thus actuating the spring and retracting the needle holder (6) and the needle (4), wherein the piston (3) comprises a holding ring (11) on its inner surface in the proximal part of the piston;
wherein the holding ring is designed to engage with the outer flange (17) of the spring sleeve (12) where, after actuation of the spring (13) the reaction mechanism stays locked; and
wherein the spring element (13) is a compression spring comprising closed ring elements at the ends where spring windings form parallel double rings (46) that run perpendicular to the centerline of the spring (13) and are seated on and held by the widened section.

US Pat. No. 11,065,393

DEVICE FOR THE DOSED ADMINISTRATION OF A FLUID PRODUCT, ADAPTED FOR THE REPLACEMENT OF A CONTAINER

Ypsomed AG, Burgdorf (CH...


1. A device for administering a fluid product, said device including:a) a first casing part comprising a reservoir for the product;
b) a second casing part connected to the first casing part;
c) a piston rod for exerting a delivery movement in an advancing direction from the second casing part;
d) a drive member, which can be operated for moving the piston rod, wherein the drive member is sleeve-shaped and comprises a thread, and wherein the second casing part forms a linear guide for the drive member such that movement of the drive member is linearly guided relative to the second casing part in and counter to the advancing direction; and
e) a coupler comprising a coupler input member adapted to couple the drive member to the piston rod in a coupler engagement, wherein the coupler input member is adapted to transfer a drive force of the drive member onto the piston rod, wherein the coupler input member is sleeve-shaped and comprises a thread complementary to the thread of the drive member, and wherein the coupler input member is in a threaded engagement with the drive member such that a drive movement of the drive member causes a rotational movement of the coupler input member, and
f) wherein the coupler input member is coupled to the piston rod such that a rotational movement of the coupler input member causes the delivery movement of the piston rod.

US Pat. No. 11,065,392

APPARATUSES AND METHODS FOR INJECTING MEDICAMENTS

Action Medical Technologi...


1. An injector comprising:an outer tubular sleeve defining a longitudinal axis;
a cam disposed within the outer tubular sleeve;
an inner sleeve disposed partially within the outer tubular sleeve and a first end of the inner sleeve is configured to engage with the cam; and
a syringe comprising a barrel, a needle mounted to an end of the barrel, a plunger, and a seal slidably mounted in the barrel, the plunger being engaged with the outer tubular sleeve in a fixed spatial relationship such that the plunger and outer tubular sleeve translate as a unit throughout operation of the injector,
wherein the outer tubular sleeve is disposed and configured for axial translation relative to the inner sleeve from a first configuration,
wherein the inner sleeve is configured to extend from the outer tubular sleeve a first distance to a second configuration in which the inner sleeve extends from the outer tubular sleeve a second distance that is less than the first distance, and
wherein the inner sleeve is further configured to extend from the outer tubular sleeve to a third configuration in which the inner sleeve extends from the outer tubular sleeve a third distance that is greater than the second distance and the cam rotates from a first position to a second position thereby restricting the inner sleeve from axially translating with respect to the outer tubular sleeve.

US Pat. No. 11,065,391

AUTOMATIC INJECTION DEVICE WITH VARIABLE DOSING

Min Wei, Carmel, IN (US)...


1. A medication injection device comprising:a medication container to contain medication, having a proximal end and a distal end;
a connector provided with a blocking feature;
a push rod having a plurality of teeth disposed along the length thereof, wherein the medication is drawn into the medication container when the push rod moves proximally and the medication is dispensed out of the medication container when the push rod moves distally;
a spring biasing against the push rod to move proximally; and
a means for preventing the push rod from moving distally by enabling engagement between the blocking feature on the connector and one of the plurality of teeth on the push rod while allowing the push rod to move distally by disabling engagement between the blocking feature on the connector and one of the plurality of teeth on the push rod.

US Pat. No. 11,065,390

AUTOMATIC DELIVERY DEVICE WITH END OF INJECTION INDICATION DEVICE

SHL MEDICAL AG, Zug (CH)...


1. A drive mechanism for a delivery device, the drive mechanism comprising,a rotator comprising an outer surface and an inner surface, the rotator configured to rotate from a first position to a second position;
a needle cover comprising an inner surface that engages the outer surface of the rotator;
a plunger rod spring positioned within a cavity defined by the rotator;
an end of injection indication device comprising a proximal end and a rod positioned at least partially within the plunger rod spring, where the end of injection indication device directly provides a signal to a user of the drive mechanism that an injection has been completed; and
a rotatable plunger rod comprising an outer surface that directly engages with the inner surface of the rotator when the rotator moves from the first position to the second position causing the rotatable plunger rod to rotate with the rotator.

US Pat. No. 11,065,389

ASSEMBLY FOR A DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...


1. An assembly for a drug delivery device, the assembly comprising:a housing;
a piston rod axially movable relative to the housing; and
a guide member movable with respect to the piston rod to switch the assembly from a first state to a second state, the second state being different from the first state,
wherein the assembly is configured such that,in the first state, the guide member is in a first axial position relative to the piston rod in which a portion of the piston rod is configured to engage a portion of the guide member to prevent proximal movement of the piston rod with respect to the housing, and
in the second state, the guide member is in a second axial position relative to the piston rod in which the portion of the piston rod and the portion of the guide member are arranged to allow proximal movement of the piston rod with respect to the housing, the second axial position being different from the first axial position,

wherein the assembly comprises a spring element, and
wherein, in the first state of the assembly, the spring element tends to move an entirety of the guide member from the first axial position to the second axial position relative to the piston rod.

US Pat. No. 11,065,388

MEDICAMENT PACKAGING

Owen Mumford Limited, Ox...


1. A cartridge for packaging a medicament, the cartridge being suitable for use with multiple different types of dosing devices and comprising:a generally tubular body having an interior cavity;
a closure member disposed at a distal end of the body and comprising a sealing element;
a piston member disposed in the cavity to contain the medicament between the piston member and the sealing element;
a coupling element disposed at the distal end of the body for coupling the cartridge to a dosing device or to an adaptor for a dosing device; and
a seal arrangement comprising a passage for receiving a sealing element release member of the dosing device or adaptor,the passage comprising a sealing surface arranged to form a seal around the release member;

wherein the coupling element is arranged for engagement with an engagement part of the dosing device or adaptor to clip the cartridge to the dosing device or adaptor upon insertion of the cartridge to the dosing device or adaptor;
and wherein the seal arrangement is disposed distally with respect to the sealing element and is arranged to form a seal around the release member when the cartridge is coupled to the dosing device or adaptor.

US Pat. No. 11,065,387

ACTIVATION MECHANISM FOR A MEDICAMENT DELIVERY DEVICE AND A MEDICAMENT DELIVERY DEVICE USING THE ACTIVATION MECHANISM

SHL MEDICAL AG, Zug (CH)...


1. An activation mechanism for a medicament delivery device, where the activation mechanism comprises:a housing elongated along a generally longitudinal axis, the housing having a proximal end and a distal end;
a spring-biased drive member, longitudinally movable relative to the housing;
a track axially fixed relative to the housing;
a locking unit, engaged with the track and movable only in an axial direction relative to the housing, from a locked position, in engagement with said spring-biased drive member, preventing longitudinal movement of said spring-biased drive member, to an unlocked position, disengaged from said spring-biased drive member, allowing longitudinal movement of said spring-biased drive member;
a first activation member movable relative to the housing between a first initial position and a first activation position;
a second activation member movable relative to the housing between a second initial position and a second activation position;
wherein the locking unit comprises a key member, movable relative to the locking unit from a neutral position to a cooperating position, and wherein the first activation member and the second activation member are configured to move the locking unit, by interaction with the key member, from the locked position to the unlocked position when the first activation member and the second activation member are moved to the first activation position and to the second activation position, respectively, and wherein actuation of the first activation member moves the first activation member from the first initial position to the first activation position, and wherein combined actuation of the second activation member moves the second activation member from the second initial position to the second activation position, such that the first activation member and the second activation member cooperate in interacting with the key member to move the key member to the cooperating position and to move the locking unit from the locked position to the unlocked position.

US Pat. No. 11,065,386

AUTOMATIC MEDICATION INJECTION DEVICE WITH AUDIBLE INDICATION OF INJECTING PROGRESS

Eli Lilly and Company, I...


9. An automatic medication injection device for delivering a single dose comprising:a user grippable housing having a length extending in an axial direction between a proximal end and a distal end;
a container of medication including an outlet that is disposed proximally of said housing proximal end at least during injection;
a drive mechanism within said housing which when triggered automatically advances to force medication from the outlet for a single injection;
a plurality of sound elements within said housing;
at least one actuating element within said housing;
at least one of said at least one actuating element and said plurality of sound elements configured to travel within said housing when said drive mechanism advances to force medication from the outlet so that said plurality of sound elements and said at least one actuating element move relative to each other to have said at least one actuating element engage said plurality of sound elements to generate audible notices during the injection;
wherein each of said plurality of sound elements other than a most distal sound element has a spacing in the axial direction from a proximally adjacent one of said sound elements; and
wherein said spacings are selected to provide a pattern of shortening time intervals between said audible notices throughout at least a portion of time that said drive mechanism advances to force medication from the outlet,
wherein the pattern of shortening time intervals comprises a first time interval between said audible notices at the start of the injection that is different than a second time interval between said audible notices at the end of the injection to indicate a nearing end of the injection.

US Pat. No. 11,065,385

FLUID BOLUS DETECTION

Edwards Lifesciences Corp...


1. A monitor for tracking a fluid bolus, the monitor comprising:a display;
a memory; and
a processor connected to the display and to the memory, the processor configured to execute instructions that cause the monitor to:receive flow signals indicative of flow-related data from a flow probe that is communicatively coupled to the monitor, the flow probe configured to measure fluid flow in a conduit between one or more fluid sources and a patient;
send a control signal to a flow controller that causes the flow controller to initiate a fluid bolus from one of the one or more fluid sources, the flow controller spatially separated from the flow probe;
automatically detect initiation of the fluid bolus responsive to the received flow-related data from the flow probe indicating that a flow rate has exceeded a first threshold flow rate value;
display a prompt on the display indicating that the fluid bolus has started, the prompt including real-time flow-related data received from the flow probe;
automatically detect termination of the fluid bolus responsive to the received flow-related data from the flow probe indicating that the flow rate has fallen below a second threshold flow rate value;
determine a total volume of fluid delivered between the initiation of the fluid bolus and the termination of the fluid bolus;
responsive to the determined total volume of fluid being within a line flush volume range, display a prompt on the display indicating that the fluid bolus is categorized as a line flush; and
responsive to the determined total volume of fluid exceeding a fluid bolus volume threshold, display a prompt on the display indicating the total volume of fluid delivered and that the fluid bolus is categorized as a fluid bolus.


US Pat. No. 11,065,384

ADMINISTRATION SET DETECTION AND AUTHENTICATION USING CAM PROFILES

Curlin Medical Inc., Elm...


1. An apparatus comprising:an infusion pump including a pumping mechanism, an actuating member, and a sensor; and
an administration set including tubing for conveying an infusion liquid and a free-flow prevention device operable to selectively stop and permit flow of the infusion liquid through the tubing;
wherein the free-flow prevention device includes a carrier and a plunger movable relative to the carrier between an open position permitting flow of the infusion liquid through the tubing and a closed position stopping flow of the infusion liquid through the tubing, the plunger being biased toward the closed position and having a cam surface defining a profile along a direction of movement of the plunger;
wherein a segment of the tubing is loadable into the infusion pump for engagement by the pumping mechanism;
wherein the free-flow prevention device is loadable into the infusion pump and is operated by the actuating member, the actuating member being movable from a non-pumping position to a pumping position thereby moving the plunger from the closed position to the open position;
wherein the sensor is arranged to sense movement of the plunger, and the sensor generates a profile signal in the time domain representative of the cam surface profile.

US Pat. No. 11,065,383

CONNECTOR AND TRANSFUSION SET

TERUMO KABUSHIKI KAISHA, ...


1. A connector comprising:a housing defining an insertion section configured for a male connector to be inserted therein from outside and a flow path communicating with the insertion section; and
an elastic valve body having a slit and blocking the insertion section;
wherein the housing includes a tip receiving section formed on an inner wall defining the flow path, the tip receiving section configured for receiving a tip of the male connector inserted through the slit of the elastic valve body;
wherein the tip receiving section is formed on only a part of the inner wall in a cross section that is perpendicular to an insertion direction of the male connector such that the tip receiving section extends along less than an entire circumference of the inner wall defining the flow path;
wherein the tip receiving section comprises a plurality of projections projecting toward the flow path in a direction perpendicular to the insertion direction, each of the plurality of projections including a first side and a second side, each of the plurality of projections extending from a base of the projection to an apex of the projection in the direction perpendicular to the insertion direction and toward the flow path;
each of the projections gradually and continuously narrowing from the base of the projection to the apex of the projection; and
wherein the inner wall includes the plurality of projections and at least one circular arc section continuous between the first side of one of the plurality of projections and the first side of another of the plurality of projections in the cross section.

US Pat. No. 11,065,382

APPARATUS TO INJECT FLUIDS INTO BONE MARROW AND OTHER TARGET SITES

TELEFLEX LIFE SCIENCES LI...


1. An apparatus operable to provide access to bone marrow,the apparatus comprising:
a driver including a housing and a drive shaft, the housing having a first end and a second end, and the drive shaft extending from the first end of the housing;
a plunger operating and cartridge drive mechanism configured to releasably retain a portion of a cartridge assembly having a plunger assembly;
a plunger operating assembly disposed within a longitudinal bore of the plunger operating and cartridge drive mechanism, the plunger operating assembly including a plunger barrel having a chamber configured to receive a portion of the plunger assembly of the cartridge assembly; and
a drive housing having a first end, a second end, and a generally hollow cylindrical configuration extending from the first end toward the second end, wherein the drive housing is operable to transmit rotational forces from the drive shaft to the cartridge assembly releasably engaged with the plunger operating and cartridge drive mechanism.

US Pat. No. 11,065,381

INFUSION PUMP DEVICE AND METHOD FOR USE THEREOF

E3D A.C.A.L., Merom Haga...


1. A patch pump comprising:a medicament reservoir having an inner surface defining an elongate piston engagement pathway;
an electric motor having a rotary drive element;
a piston replaceably axially fixed to said electric motor, said piston having an outer surface arranged for sealing engagement with said inner surface of said medicament reservoir, said piston also comprising a rotary to longitudinal drive converter receiving a rotary drive input from said rotary drive element of said electric motor and providing a longitudinal drive to said medicament reservoir, thereby driving said medicament reservoir in longitudinal motion relative to said piston in which said elongate piston engagement pathway defined by said inner surface of said medicament reservoir is displaced axially and in sealing engagement with said outer surface of said piston.

US Pat. No. 11,065,380

METHOD FOR RELIABLE INTERMODULE CONNECTION IN AN INFUSION SYSTEM

Carefusion 303, Inc., Sa...


1. A modular pump system, comprising:a program module that controls and removably connects to a first modular pump device and a second modular pump device via a plurality of connector contacts;
a microprocessor coupled to the program module, the microprocessor configured to:
repeatedly obtain an electrical current measurement for each of the plurality of connector contacts of the program module over a prolonged period of time, the connector contacts associated with at least one powered line,wherein the connector contacts include a first connector contact that connects the program module to the first modular pump device and a second connector contact that connects the program module to the second modular pump device, and
wherein the first connector contact transmits an electrical signal or communication signal between the first modular pump device and the program module, and
wherein the second connector contact transmits an electrical signal or communication signal between the second modular pump device and the program module;

compare a first plurality of obtained electrical current measurements of at least the first connector contact with a second plurality of obtained electrical current measurements of at least the second connector contact;
determine that the first plurality of obtained electrical current measurements differ from the second plurality of obtained electrical current measurements over the prolonged period of time; and
based at least in part on the determination, inhibit operation of at least one of the first modular pump device and the second modular pump device.

US Pat. No. 11,065,379

METHOD AND SYSTEM FOR CONTROLLED HYPERTHERMIA

VERYHERMIA ACQUISTION, IN...


1. A method for inducing hyperthermia to treat a condition in a patient, said method comprising:a. Withdrawing only a portion of patient's blood from the patient using one of more cannulae and returning the withdrawn blood to the patient to establish an arterio-venous or veno-venous extracorporeal flow circuit for tighter control of blood chemistry;
b. heating blood passing through the extracorporeal circuit using a modular heater cooler at a rate of between 0.05° C./min to 0.15° C./min to raise the patient's body core temperature to a target body core temperature;
c. controlling the rate of heating and blood flow to within defined limits through the use of four or five pumps, thus controlling the blood flow based on the patient's body size;
d. maintaining the target body core temperature for a treatment period in the range from between 1.1 to 1.9 and 2.1 to 3.0 hours;
e. temperature correcting the blood gases at the elevated core temperature, wherein the target body core temperature is a weighted average of indirect cerebral, esophageal, bladder, rectal and nasopharynx temperature;
f. treating the blood with a hemodiaultrafiltration process, which combines a dialysis and plasma-pheresis process to introduce preselected salts selected to treat the metabolic condition;
g. detoxifying the blood by continuously passing it through a sorbent column; and
h. after the treatment period has ended, cooling the blood using a modular heater cooler until the body temperature has returned to 38° C. or below.

US Pat. No. 11,065,377

APPARATUS AND METHOD FOR CANNULATION OF VASCULAR ACCESS GRAFT

InnAVasc Medical, Inc., ...


1. A guiding apparatus for guiding cannulation with a dialysis needle of an arteriovenous dialysis access graft subcutaneously implanted in a body of a subject, the arteriovenous dialysis graft including a flexible conduit defining a longitudinal flow passageway and having a first end portion configured to connect to a first blood vessel of the subject and a second end portion configured to connect to a second blood vessel of the subject such that blood flows through the longitudinal flow passageway of the flexible conduit from the first end portion to the second end portion, and a cannulation chamber defining a cannulation port, the flexible conduit extending through the cannulation chamber for receiving the needle inserted through the cannulation port, the guiding apparatus comprising:an elongated body member having a first end, a second end, a longitudinal axis extending between the first end and the second end, and an inner surface, the body member comprisinga planar base portion terminating in longitudinal edges substantially parallel to the longitudinal axis of the body member, a distance between the longitudinal edges of the base portion being substantially equal to a lateral dimension of the cannulation chamber, and
legs extending from the longitudinal edges of the base portion in a direction transverse to the the base portion, the legs terminating in longitudinal edges, the base portion and legs defining an open longitudinal channel for receiving the cannulation chamber,


wherein the body member is adapted to be secured adjacent the cannulation chamber such that the legs operatively engage the cannulation chamber for aligning the inner surface of the base portion with the cannulation port for guiding location of a needle insertion through the body member and into the cannulation chamber.

US Pat. No. 11,065,376

PLASMAPHERESIS CENTRIFUGE BOWL

HAEMONETICS CORPORATION, ...


1. A core for a plasmapheresis bowl comprising:a cylindrical body defining the core and an interior of the core;
a ledge located within the interior of the core between a proximal end and a distal end of the cylindrical body, the ledge extending radially inward from an inner diameter of the core and having a top surface that defines, at least partially, a collection chamber within the plasmapheresis bowl; and
a plurality of ribs located on and spaced about a proximal portion of the cylindrical body, the plurality of ribs extending above the proximal end of the cylindrical body, thereby creating flow paths between each of the plurality of ribs, the flow paths allowing fluid to enter the interior of the cylindrical body and the collection chamber.

US Pat. No. 11,065,375

BLOOD OXYGENATOR

UNIVERSITY OF MARYLAND, B...


1. A blood oxygenator, comprising:a housing comprising a blood inlet and a blood outlet;
a fiber bundle in an interior of the housing;
a spiral volute located at an inlet end of the housing and in fluid communication with said blood inlet,
said spiral volute decreasing in width from a first end of said spiral volute to a second end of said spiral volute, and
an annular space between an outer surface of the fiber bundle and an interior surface of the housing, wherein the annular space tapers conically inwardly in a direction away from the inlet end and receives blood from the spiral volute, and wherein the spiral volute and the annular space are configured to uniformly distribute blood to the outer surface of said fiber bundle.

US Pat. No. 11,065,374

RENAL FAILURE THERAPY SYSTEM AND METHOD OF CLEANING USING CITRIC ACID

GAMBRO LUNDIA AB, Lund (...


1. A renal failure therapy system comprising:a dialysis fluid circuit including a dialysis fluid pump;
a source of physiological cleaning, disinfecting, and/or decalcifying substance in fluid communication with the dialysis fluid circuit;
a source of purified water in fluid communication with the dialysis fluid circuit; and
a logic implementer in operable communication with the dialysis fluid pump, wherein the logic implementer is programmed such that the system is configured to:cause the physiological cleaning, disinfecting, and/or decalcifying substance to be added from its source to purified water from the purified water source to form a mixture,
circulate the mixture within the dialysis fluid circuit using the dialysis fluid pump to at least one of clean, disinfect, or decalcify at least a portion of the dialysis fluid circuit without a subsequent rinse after circulating and moving directly to a drain sequence,
cause a portion of the mixture to be drained in the drain sequence, wherein draining a portion of the mixture from the dialysis fluid circuit includes trapping air in the dialysis fluid circuit, and

cause a filling procedure for a second treatment to begin with a portion of the mixture remaining in the dialysis fluid circuit, wherein the filling procedure reduces the remaining mixture to a lower level and removes a portion of the remaining mixture to drain.

US Pat. No. 11,065,373

WATER PREPARATION SYSTEM FOR DIALYSIS TREATMENTS

Fresenius Medical Care De...


1. A water treatment system for dialysis treatments, which comprises:a first heat exchange circuit, a second heat exchange circuit, a heat exchanger, and a buffer tank,
the buffer tank being in thermal communication with both the first heat exchange circuit and the second heat exchange circuit and being configured exclusively for storing thermal energy,
the second heat exchange circuit being separate from the first heat exchange circuit and configured to feed the buffer tank with thermal energy from, and exchange heat with, a thermal energy source, and the heat exchanger being separate from the buffer tank;
at least one tap;
a reverse osmosis system; and
a permeate circuit hydraulically separated from the buffer tank such that it is not possible to tap permeate from the buffer tank,
wherein the first heat exchange circuit is configured to transfer thermal energy from the buffer tank to the heat exchanger, the heat exchanger is configured to transfer heat in a controlled manner from the first heat exchange circuit to permeate in the permeate circuit, the permeate circuit is configured to introduce raw water, reflux from the at least one tap, or both, into the reverse osmosis system to produce permeate from said raw water, from said reflux, or from both, prior to passing said permeate into the heat exchanger, and the heat exchanger is integrated into the permeate circuit,
wherein the heat exchanger comprises a primary circuit inlet, a primary circuit outlet, a secondary circuit inlet, and a secondary circuit outlet, and
wherein the heat exchanger is disposed in between the reverse osmosis system and the at least one tap such that the water treatment system is configured to flow permeate from the reverse osmosis system to the secondary circuit inlet of the heat exchanger, through the heat exchanger, and out of the secondary circuit outlet of the heat exchanger to deliver permeate heated by the heat exchanger to the at least one tap.

US Pat. No. 11,065,372

NEEDLE SYSTEM RESTRICTOR

Gyrus Acmi, Inc., Westbo...


1. A needle system comprising:a handle;
a needle slider partially positioned in the handle, the needle slider having an aspiration port at a proximal end of the needle slider and an internal lumen extending therethrough;
a needle connected to and extending away from the needle slider; and
a restrictor disposed in the aspiration port of the needle slider and extending distally into the internal lumen of the needle slider, the restrictor being configured to inhibit passage of a sample through the aspiration port, wherein the restrictor comprises:a hollow body with a proximal end having a proximal opening and a distal end having a distal opening; and
a rim extending from the proximal end of the body having a radial flange portion and a circumferential lip portion, wherein the rim of the restrictor is positioned around an outer diameter of the aspiration port of the needle slider.


US Pat. No. 11,065,371

FLOW RESTRICTOR FOR SURGICAL DEVICE


1. A flow restrictor suitable for inclusion in an aspiration flow of an ocular surgical device, comprising:a conical valve head suitable for insertion into a valve stage, wherein the conical valve head at least substantially impedes the aspiration flow when the conical valve head is at least partially inserted into the valve stage;
a flexible spider membrane having a plurality of valve passages that open and close with a flexation of the flexible spider membrane, wherein the flexible spider membrane is connective with the conical valve head and forces the insertion of the conical valve head into the valve stage proportionally to the aspiration flow;
a circular receiving plate for receiving the aspiration flow, wherein the circular receiving plate imparts the proportional insertion to the flexible spider membrane; and
a plurality of ribs, integral to at least one of the conical valve head and the valve stage, that provides a minimum for the aspiration flow when the conical valve head is fully inserted into the valve stage.

US Pat. No. 11,065,370

DEVICE FOR DRAINAGE, IN PARTICULAR FOR THE DRAINAGE OF A CHRONIC SUBDURAL HEMATOMA

Primed Halberstadt Medizi...


1. A device for drainage comprising:a tubular reservoir comprising a tubular pliable wall and a rigid cover and a rigid bottom closing respective ends of the tubular pliable wall of uniform diameter and thereby constituting rigid walls of the reservoir, and
at least one spring situated within the reservoir and configured to apply a force which urges the cover and the bottom apart, wherein the tubular reservoir is configured so that the cover is movable toward the bottom in order to compress the spring into a start position and at least one of the springs is configured to bear against the tubular pliable wall to retain the uniform diameter of the tubular pliable wall by preventing collapse of the tubular pliable wall when the reservoir is being compressed, and

at least one magnet configured to apply an additional force on the reservoir in such a way that a resulting force pressing the cover and the bottom apart is substantially constant throughout deflection of the at least one spring from the start position to an end position defined by axial length of the reservoir,wherein the device for drainage is configured to produce a negative pressure not exceeding 30 mmHg.

US Pat. No. 11,065,369

BIOABSORBABLE POLYMERIC COMPOSITION FOR A MEDICAL DEVICE

ORBUSNEICH MEDICAL PTE. L...


1. A bioabsorbable composition comprising a crystalline polymer composition, the polymer composition comprising: a poly (L-lactide) moiety, and/or a poly (D-lactide) moiety, and/or poly L-lactide-co-PEG moiety, and/or poly D-lactide-co-PEG moiety, linked or admixed with poly (L-lactide-co-Tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-?-caprolactone) or poly (D-lactide-co-?-caprolactone) in the form of block copolymers or blocky random copolymers.

US Pat. No. 11,065,367

HIGHLY HYDROPHOBIC ANTIFOULING COATINGS FOR IMPLANTABLE MEDICAL DEVICES

INTERNATIONAL BUSINESS MA...


1. A compound, the compound comprising:a polythioether polymer comprising the substructure:





wherein n is greater than 1.

US Pat. No. 11,065,366

METHOD FOR PRODUCING A FIBRIN-BASED BIOARTIFICIAL, PRIMARILY ACELLULAR CONSTRUCT, AND THE CONSTRUCT ITSELF

Medizinische Hochschule H...


1. Method for producing a fibrin-based bioartificial and acellular construct, comprising the following steps:provision of a fibrinogen-containing and cell-free composition;
provision of a thrombin-containing and cell-free composition;
application of the fibrinogen-containing cell-free and the thrombin-containing cell-free compositions to a surface;
pressurisation of the mixture of compositions applied to the surface at least until the fibrin formation is essentially completed; and
removal of the fibrin-based acellular bioartificial construct from the surface, wherein application of the compositions takes place in a rotating hollow body and pressurization takes place by rotation of the hollow body and wherein during the rotation, liquid is discharged via holes present in the hollow body and through a semipermeable membrane arranged on an outside surface of the hollow body.

US Pat. No. 11,065,361

WATER-CONTAINING HYDROGELS FOR DRESSING WOUNDS

Paul Hartmann AG, Heiden...


1. A wound dressing comprising a backing layer and a layer comprising an aqueous hydrogel for the treatment of wounds obtainable by reacting an a) amine-terminated prepolymer containing polyalkylene oxide units with an b) isocyanate-terminated prepolymer containing polyalkylene oxide units, the reaction taking place in the presence of a polyhydric alcohol, except propylene glycol, and in the presence of water and, based on the total mass of all reactants,the sum total of the masses of amine-terminated prepolymer and isocyanate-terminated prepolymer being 10-30% by weight of the total mass of all reactants and
the mass of the polyhydric alcohol, except propylene glycol, being 5-35% by weight of the total mass of all reactants and
the mass of the water used being at least 40% by weight of the total mass of all reactants, and
the molar ratio of reactive isocyanate end groups to reactive amine end groups being 1.0 to 2.0.

US Pat. No. 11,065,359

DEODORIZATION MODULE AND STORAGE DEVICE INCLUDING DEODORIZATION MODULE

Seoul Viosys Co., Ltd., ...


1. A deodorization module comprising:a housing including a main body having an open top and a planar cover covering the open top of the main body;
a suction hole formed through a bottom of the housing to allow air to be sucked into the housing therethrough;
a fan disposed at the suction hole to suck in air;
a discharge hole allowing the air sucked in by the fan to be discharged from the housing therethrough;
a photocatalyst bar disposed between the fan and the discharge hole;
a light source module comprising a light source substrate and an ultraviolet (UV) light source and emitting UV light toward the photocatalyst bar; and
a cover guide formed on a lower surface of the cover, the cover guide having a wedge shape that is continuously reduced in a thickness direction toward the discharge hole, wherein the thickness direction is transverse to the planar cover and the cover guide is located above the fan when the cover is coupled to the main body,
wherein the photocatalyst bar is disposed such that all of the air sucked in by the fan passes through the photocatalyst bar,
wherein an upper surface of the light source module is spaced apart from an upper inner surface of the housing and a lower surface of the light source module is spaced apart from a lower inner surface of the housing, and
wherein the main body receives the suction hole, the fan, the discharge hole, the photocatalyst bar, and the light source module; and
wherein the cover is detachably coupled to the main body.

US Pat. No. 11,065,358

AIR-BLADE, SILENCER AND SEPARATOR APPARATUS AND METHOD


1. A method of atomizing liquid in a flow of air, the method comprising:providing a source of the liquid and a source of the air, the air pressurized to urge a flow characterized by thickness, width, and length, generally mutually orthogonal at any point in the flow, wherein a cross-sectional area is characterized by the width and length, and a distance traveled is characterized by the length;
providing an atomizer dispersing into the flow a portion of the liquid as droplets entrained therein;
providing a first drift chamber segregating the droplets by receiving the flow and changing a direction thereof prior to the flow exiting therefrom;
providing a tower, having an inlet formed by a curved drip edge, and a tower wall, defining thereinside a channel protruding upward from the first drift chamber into a second drift chamber, formed as a bowl having a bowl wall surrounding and spaced from the tower, to receive and contain the flow, the channel having first and second ends defining a first aspect ratio of length to thickness thereof greater than one, and a second aspect ratio of length t o width thereof, at least one of the first and second aspect ratios selected to form a boundary layer in the channel segregating the droplets; and
providing the second drift chamber connected to receive the flow from the second end, opposite the first drift chamber at the first end, imposing at least two changes of direction of the flow prior to exit therefrom
wherein the tower is shaped to protrude straight along the length of the flow therethrough and is curved along the width, thereby forming the flow into an air blade, within the wall enclosing the entire flow of air, the droplets contained therewithin, passing as a blade of air, having a thickness less than a width thereof and less than a length of the flow therethrough, to maintain the boundary layer of the blade removing comparatively larger droplets from comparatively smaller droplets between the first drift chamber and the second drift chamber.

US Pat. No. 11,065,356

MAGNETIC SEPARATION USING NANOPARTICLES

Massachusetts Institute o...


1. A nanoparticle configured to bind to a bacterial contaminant, the nanoparticle comprising:a core comprising a magnetic material; and
a plurality of ligands attached to the nanoparticle, wherein the ligands comprise bis(dipicolylamine) coordinated with a zinc ion (bis-Zn-DPA) and wherein the bis-Zn-DPA comprises a hydroxyphenyl, wherein the bis-Zn-DPA can bind to the bacterial contaminant.

US Pat. No. 11,065,354

POST-STEAM STERILIZATION MOISTURE-INDICATING ARTICLES

3M Innovative Properties ...


1. A moisture-indicating article comprising:a moisture-permeable material;
a moisture-impermeable layer peripherally bonded to the moisture-permeable material;
a moisture-indicating layer disposed between the moisture-permeable material and the moisture-impermeable layer; and
a color-enhancing layer located proximate the moisture-indicating layer such that a visual comparison between the color-enhancing layer and the moisture-indicating layer can be made;
wherein the moisture-indicating layer comprises a colorimetric reversible steam-sterilization-compatible moisture-indicating medium comprising a solid metal oxide support, a bis-glyoxime-transition metal complex bound to the solid metal oxide support, and a silyl-containing compound bound to the solid metal oxide support through a silanol bond with at least one hydroxyl group on the surface of the solid metal oxide support.

US Pat. No. 11,065,353

UNIVERSAL STERILIZING TOOL

1WORLDVISTA MEDICAL, INC....


1. A sterilizing device configured to couple onto a male luer end of a syringe, the male luer end having a threaded male luer shroud and a tapered male luer slip; the sterilizing device comprising:an elongated integrated housing comprising a first housing portion having a first cavity accessible through a first opening in the first housing portion from a first axial direction and a second housing portion having a second cavity accessible through a second opening in the second housing portion from a second axial direction opposite the first axial direction;
a partition separating the first cavity from the second cavity;
an article carrying an antipathogenic agent disposed within the first cavity, the article configured to structurally engage and disinfect an end-site of a medical device inserted through the first opening and into the first cavity;
a frangible lid or seal covering the first opening; and
a form-fit connector disposed within the second cavity, the form-fit connector configured to secure to the male luer end of the syringe, the form-fit connector further having an inner cavity different from the second cavity and accessible through an access opening in the form-fit connector from the second axial direction configured to frictionally engage the tapered male luer slip of the syringe.

US Pat. No. 11,065,352

INDUCTIVE HEATING SYSTEMS AND METHODS OF CONTROLLING THE SAME TO REDUCE BIOLOGICAL CARRYOVER

Abbott Laboratories, Abb...


1. A system comprising:an induction heater including a tank circuit, the tank circuit including a work coil and a sense coil, the sense coil to detect a magnetic field generated by the work coil and output a signal in response to the detection; and
a controller to drive the tank circuit to selectively oscillate between a fixed frequency and a resonant frequency for the tank circuit to inductively heat a work piece disposed proximate to the tank circuit, the controller to drive the tank circuit to oscillate at the resonant frequency in response to the signal output by the sense coil.

US Pat. No. 11,065,350

HSP90-TARGETED INFLAMMATION AND INFECTION IMAGING AND THERAPY

Memorial Sloan Kettering ...


1. A method for treatment of brain inflammation comprising administering to a subject in need thereof a compound having the formula:




or a pharmaceutically acceptable salt thereof;
wherein the brain inflammation is not caused by cancer.

US Pat. No. 11,065,349

18F LABELED BODIPY DYE AND ITS DERIVATIVES FOR PET IMAGING OF HEART PERFUSION AND OTHERS


1. A cardiac imaging agent comprising:a dual mode imaging tracer capable of acting both as a fluorescent tracer and a positron emission tomography tracer, wherein said dual mode imaging tracer comprises a fluorescent core with a boron-flouride element embedded therein, and wherein the tracer has one of the following general formulae:




wherein
RL is selected from an aliphatic group being a C1-C10 straight or branched chain alkyl or cycloalkyl, an aromatic group being a monocyclic or condensed ring aromatic hydrocarbon, or a PEG linker;
X is C, and Y and Z are independently selected from C, N, and O;
A, R1-R2 and R7-R9 are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, nitro, substituted and unsubstituted animo, alkyl, cycloalkyl, carboxy, carboxylic acids and esters thereof, cyano, haloalkyl, aryl, including phenyl and aminophenyl, and heteroaryl.

US Pat. No. 11,065,345

METHODS FOR ASSEMBLING SCAVENGING PARTICLES

NaNotics, LLC, Mill Vall...


1. A scavenging construct comprising:a first particle;
a second particle coupled to the first particle;
a capture environment;
a first region of protected surface; and
a first agent immobilized on the first region of protected surface, wherein the first agent can bind a first molecule on the surface of an exosome; and further wherein:
the capture environment is a volume between the surface of the first particle and the second particle;
the capture environment has a characteristic dimension from 30 nm to 1 ?m; and
the first region of protected surface is a surface of the first particle adjacent to the capture environment.

US Pat. No. 11,065,343

COMPOUND BEARING BETA-GALACTOSIDE-INTRODUCED SELF-IMMOLATIVE LINKER

IntoCell Inc., Daejeon (...


1. A compound comprising a ?-galactoside-introduced self-immolative linker represented by Chemical Formula 1 below:



in Chemical Formula 1,
R is hydrogen or a hydroxy protection group;
X is —C(?O)—, —NH—, —O—, or —S—;
T is an active agent;
Q is B?—U1-(CH2CH2X3)p4—(CH2)p3—Wa4-Q2-Wa3—W1?;
n is an integer of 0 or 1;
Y is hydrogen, haloC1-C8alkyl, halogen, cyano or nitro;
z is an integer of 1 to 3, and Y may be the same or different from each other, if z is an integer of not less than 2;
z1 is an integer of 0 or 1;
W1 is ?Wa2—(CH2)a1—Wb1-Q1?;
W2 is ?Wa4-Q2-Wa3?;
Wa1 and Wa2 are each independently —NH—, —C(?O)—, or —CH2—;
Wa3 and Wa4 are each independently —NH—, —C(?O)—, —CH2—, —C(?O)NH—, —NHC(?O)—, or triazolylene;
Wb1 is an amide bond or triazolylene;
L is an amino acid, peptide, or amide bond as a linker connecting Wa2 and Z;
Z is a single bond, —Wa5—(CH2)a2—Wb2—(CH2)a3—Wa6—, or —Wa7—(CH2)a4—CR?R?—X?—;
R? is C1-C8alkyl or B—Wa8-Q3-Wc1—(CH2)a5—;
R? is B—Wa8-Q3-Wc1—(CH2)a5—;
Q1 and Q3 are each independently —(CH2)a6—(X1CH2CH2)b1—(CH2)a7—;
X1 and X3 are each independently —O—, —S—, —NH—, or —CH2—;
X? is —NHC(?O)—(CH2)a8—Wa9— or —C(?O) NH—(CH2)a8—Wa9—;
Wa5, Wa6, Wa7, Wa8, and Wa9 are each independently —NH—, —C(?O)—, or —CH2—;
Wb2 is an amide bond or triazolylene;
Wc1 is —NHC(?O)— or —C(?O)NH—;
Q2 is a saturated or unsaturated alkylene, which is linear or branched with a carbon number of 1 to 50, satisfying any one of (i) to (iii) below;
(i) at least one —CH2— in the alkylene is substituted with one or more heteroatoms selected from —NH—, —C(?O), —O—, and —S—,
(ii) at least one arylene or heteroarylene is included in the alkylene,
(iii) the alkylene is further substituted with one or more selected from the group consisting of C1-C20alkyl, C6-C20arylC1-C8alkyl, —(CH2)s1COOR3, —(CH2)s1COR3, —(CH2)s2CONR4R5, and —(CH2)s2NR4R5;
arylene or heteroarylene of (ii) above may be further substituted with nitro;
R3, R4, and R5 are each independently hydrogen or C1-C15 alkyl;
X2 is —O—, —S—, —NH—, or —CH2—;
U1 is bound to B? in the position of asterisk (*) with a linking group selected from the following structures:




R is C1-C10 alkyl, C6-20 aryl or C2-C20 heteroaryl;
B and B? are each independently a ligand or a protein having properties selectively targeting a particular organ with a drug, a tissue or a cell, that is, properties binding to a receptor;
a1, a2, a3, a4, a5, a6, a8, b1, p1, p2, p3 and p4 are each independently an integer of 1 to 10;
a7, y, s1, s2 and s4 are each independently an integer of 0 to 10; and
R1 and R2 are each independently hydrogen, C1-C8alkyl or C3-C8cycloalkyl.

US Pat. No. 11,065,342

LONG ACTING MULTI-SPECIFIC MOLECULES AND RELATED METHODS

SHENZHEN ENDURING BIOTECH...


1. A compound of the Formula Ib:



wherein:
P is a non-immunogenic polymer wherein the polymer is PEG, and the total molecular weight of PEG ranges from 10,000 to 60,000;
B is H, a terminal capping group or void, said capping group selected from C1-50 alkyl and aryl, wherein one or more carbons of said alkyl may be replaced with a heteroatom;
T is lysine;
each of L1 and L2 is independently a bifunctional linker, wherein one of (L1)a and (L2)b comprises a linkage formed from azide and alkyne and the other of the (L1)a and (L2)b comprises a linkage formed from maleimide and thiol, wherein at least one of the (L1)a and (L2)b comprises —(CH2)mO(CH2CH2O)n—, wherein m is an integer selected from 0 to 25 and n is an integer selected from 1 to 25;
a and b are each an integer selected from 1-10;
A1 and A2 are two different antibodies or antigen-binding portions thereof; and
y is 1.

US Pat. No. 11,065,340

POLYOXAZOLINE ANTIBODY DRUG CONJUGATES

Serina Therapeutics, Inc....


1. A polymer conjugate, the polymer conjugate comprising a polyoxazoline polymer, a single chain antibody linked to the polyoxazoline polymer, an optional purification moiety and a plurality of agents linked to the polyoxazoline polymer via a releasable linkage, wherein the single chain antibody and the polyoxazoline polymer are present in a 1:1 ratio, the polymer conjugate having the structure:



wherein
a is ran which indicates a random copolymer or block which indicates a block copolymer;
R1 is H;
o is an integer from 0 to 50;
m is an integer from 0 to 50;
n is an integer from 0 to 1000;
b is an integer from 1 to 30;
scAb is a single chain antibody;
Se is a selenocysteine residue;
Agent is selected from the group consisting of monomethyl auristatin E, monomethyl auristatin F, desmethyl-auristatin F, daunorubicine, doxorubicin, epirubicin, idarubicin, valrubicin, mitoxantrone, calicheamicin, N-acetyl-? calicheamicin 1,2-dimethyl hydrazine dichloride, DM1, DM4, ansomitocin, abbeymycin, chicamycin, DC-81, mazethramycin, neothramycins A and B, porothramycin prothracarcin, sibanomicin, sibiromycin, tomamycin, SJG-136, SG 2285, DRG-16, ELB-21, colchicine, deacetylcholchicine, dolstatin 10, dolstatin 15, dolstatin 16, tubulysin A, tubulysin B, tubulysin D, tubulysin M, maytansinol, duocarmycin A, duocarmycin B1, duocarmycin B2, duocarmycin C1, duocarmycin C2, duocarmycin D, duocarmycin SA, CC-1065, adozelesin, bizelesin, carzelesin, nemorubicin, cryptophycin 1, cryptophycin 8, cryptophycin 24, cryptophycin 52, cryptophycin 55, cryptophycin 296, cryptophycin 309, epithilone A, epithilone B, epithilone C, epithilone D, epithilone E, epithilone F, BMS 247550, BMS 310705, safracin A and safracin B; and
the number of agents and optional purification moieties linked to the conjugate is less than or equal to the sum of o and m,
provided that both o and m are not each 0 and the total of n, o and m is at least 30.

US Pat. No. 11,065,339

FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS

Trustees of Tufts College...


1. A pharmaceutical preparation comprising a therapeutically effective amount of a fibroblast activation protein (FAP)-activated proteasome inhibitor represented by formula III:



wherein:
—R1(C?O)—represents an acyl N-terminal blocking group;
R2 represents H, lower alkyl, or a mono- or di-hydroxy-substituted lower alkyl;
R3 represents lower alkyl;
R4 is absent;
R5 represents a hydrophobic amino acid sidechain;
R6 represents alkyl, cycloalkyl, aryl, heterocycle or —(CH2)n—R7;
R7 represents aryl, aralkyl, cycloalkyl, alkoxy, alkylthio, —OH or —SH;
R11 represents H or lower alkyl;
W represents




Y1 and Y2 are independently OH, or a group capable of being hydrolyzed to a hydroxyl group; or Y1 and Y2 taken together with the B to which they are attached form a ring having from 5 to 8 atoms in the ring structure; and
n is an integer in the range of 1 to 8.

US Pat. No. 11,065,336

CONJUGATES FOR TARGETING AND CLEARING AGGREGATES

MEDIMMUNE LIMITED, Cambr...


1. A conjugate comprising a peptide having the amino acid sequence of AQVNSCLLLPNLLGCGDDK (SEQ ID NO: 3) fused to a targeting moiety that targets molecular aggregates having the formula of Compound I:




US Pat. No. 11,065,335

METHODS OF TREATING LEUKEMIA USING COMPOSITIONS CONTAINING BIS(BENZYLTHIO)OCTANOIC ACID AND ION PAIRS THEREOF

Rafael Pharmaceuticals, I...


1. A method of treating leukemia in a human patient in need thereof, comprising the step of intravenously administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of 6,8-bis(benzylthio)octanoic acid or an ion pair thereof, and a pharmaceutically acceptable diluent for solubilizing 6,8-bis(benzylthio)octanoic acid or an ion pair thereof, wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 2,500 mg/m2.

US Pat. No. 11,065,334

BORON-10 CONTAINING BIOCOMPATIBLE NANOSTRUCTURES

UChicago Argonne, LLC, C...


1. A method, comprising:providing a plurality of nanostructures comprising a base material comprising Fe2O3;
exposing the plurality of nanostructures to a first material comprising trimethylaluminum (Al(CH3)3) (TMA) at a first deposition temperature in the range of 100° C. to 300° C.;
exposing the plurality of nanostructures to a second material at a second deposition temperature in the range of 100° C. to 300° C.; and
exposing the plurality of nanostructures to a Boron-10 (10B) containing material comprising trimethyl borate (TMB) at a third deposition temperature in the range of 100° C. to 300° C. so as to form 10B-metal oxide composite nanostructures comprising an atomic percent concentration of oxygen in the range of 50 atomic % to 60 atomic % and an atomic percentage of aluminum in the range of 25 atomic % to 40 atomic %.

US Pat. No. 11,065,326

LIVE-ATTENUATED VACCINE HAVING MUTATIONS IN VIRAL POLYMERASE FOR THE TREATMENT AND PREVENTION OF CANINE INFLUENZA VIRUS

University of Rochester, ...


1. An immunological composition comprising a live-attenuated canine influenza virus (LACIV), wherein the LACIV comprises one or more mutations selected from the group consisting of: (a) a mutation in segment 1 of the viral genome encoding a mutant PB2 comprising a N265S point mutation; (b) a mutation in segment 2 of the viral genome encoding a mutant PB1 comprising a K391E point mutation; (c) a mutation in segment 2 of the viral genome encoding a mutant PB1 comprising a E581G point mutation; (d) and a mutation in segment 2 of the viral genome encoding a mutant PB1 comprising A661T point mutation; further wherein all segments of the viral genome are of canine influenza virus origin; wherein said mutant PB2 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 3, and wherein said mutant PB1 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 4.

US Pat. No. 11,065,325

VACCINE COMPOSITION FOR NAIVE SUBJECTS

Eurocine Vaccines AB, So...


1. A method of immunizing a pediatric subject to reduce influenza virus shedding comprising:selecting a pediatric subject in need of a composition that reduces influenza virus shedding; and
administering intranasally to said pediatric subject from newborn to 12 years of age a composition comprising:one or more non-live influenza virus antigen(s) selected from the group consisting of split virus, subunit influenza antigen, and recombinant antigens, and
an adjuvant comprising mono-olein and oleic acid;

wherein the mono-olein and oleic acid are in a 1:1 ratio, and wherein the combined concentration of the mono-olein and oleic acid is up to 3% (w/v).

US Pat. No. 11,065,312

VACCINATION BY MEANS OF RECOMBINANT YEAST BY PRODUCING A PROTECTIVE HUMORAL IMMUNE RESPONSE AGAINST DEFINED ANTIGENS

VEROVACCiNES Gmbh, Halle...


1. A recombinant yeast of the species Kluyveromyces lactis, said recombinant yeast comprising a genomically integrated expression cassette comprising lactose inducible LAC4 promoter from Kluyveromyces lactis, a foreign gene or a part of a foreign gene, a transcription terminator and GAL80 promoter from K lactis (KIGAL80-P) which drives transcription of a LAC4 coding sequence,
wherein the foreign gene or the part of the foreign gene is flanked by the lactose inducible LAC4 promoter and the transcription terminator, which transcription terminator is followed downstream by the KIGAL80-P;
and wherein the foreign gene is expressed as a foreign protein, and wherein subcutaneous administration of the recombinant yeast creates a protective humoral immune response.

US Pat. No. 11,065,306

METHODS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN

Alexion Pharmaceuticals, ...


1. A method of treating hypophosphatasia (HPP) in a child from about 5 to about 12 years of age, wherein the method comprises administering a soluble alkaline phosphatase (sALP) to the child at a dosage providing about 1 mg/kg/week to about 10 mg/kg/week for a treatment period comprising at least five years, wherein the sALP comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1, and wherein the method comprises:a) performing a Bruininks-Oseretsky Test of Motor Proficiency 2nd Edition (BOT-2) test, wherein the child has an average BOT-2 strength score of less than about 10 and administration of the sALP results in an average increase in the BOT-2 strength score to about 10 to about 20 after a period of at least five years;
b) performing a BOT-2 test, wherein the child has an average BOT-2 running speed and agility score of less than 5 and administration of the sALP results in an average increase in the BOT-2 running speed and agility score to about 5 to about 20 after a period of at least five years;
c) performing a Childhood Health Assessment Questionnaire (CHAQ), wherein the child has an average CHAQ disability index and/or discomfort score of greater than about 0.8 and administration of the sALP results in an average decrease in the CHAQ disability index score and/or discomfort score to about 0 to equal to or less than about 0.5 after a period of at least five years;
d) performing a Pediatric Outcomes Data Collection Instrument (PODCI), wherein the child has an average PODCI transfer and mobility, sports and physical functioning, and/or pain score of less than about 40 and administration of the sALP results in an average increase in the PODCI score to about 40 to about 50 after a period of at least five years; and
e) performing a Six Minute Walk Test (6MWT), wherein administration of the sALP for a treatment period of at least five years results in an average increase in a 6MWT distance of the child of about 20 m or greater or to greater than about 80% of a predicted 6MWT distance relative to the 6MWT distance of the child prior to administration of the sALP.

US Pat. No. 11,065,304

PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE

Mederis Diabetes, LLC, S...

wherein:Z is selected from the group consisting of OH, N—R4-His, and —NH—R3, whereinR3 is selected from the group consisting of H, substituted or unsubstituted C1-C12 alkyl, and a PEG chain of less than 10 Da;
R4 is a C2-C10 acyl group;

aa1 is selected from the group consisting of His, N—R4-His, pGlu-His, and N—R3-His;
aa2 is selected from the group consisting of Ser, D-Ser, Ala, Gly, Pro, MePro, Aib, Ac4c, and Ac5c;
aa3 is selected from the group consisting of Gln and Cit;
aa4 is selected from the group consisting of Gly and D-Ala;
aa5 is selected from the group consisting of Thr and Ser;
aa6 is selected from the group consisting of Phe, Trp, 2FPhe, MePhe, 2FMePhe, and Nal2;
aa7 is selected from the group consisting of Thr and Ser;
aa8 is selected from the group consisting of Ser and Asp;
aa9 is selected from the group consisting of Asp and Glu;
aa10 is selected from the group consisting of Tyr, Feu, Met, Nal2, Bip, Bip2EtMeO, and U;
aa11 is absent or selected from the group consisting of Ser, Asn, Bip, and U;
aa12 is absent or selected from the group consisting of Lys, Glu, Ser, Arg, and U;
aa13 is absent or selected from the group consisting of Tyr, Gln, Cit, and U;
aa14 is absent or selected from the group consisting of Leu, Met, Nle, and U;
aa15 is absent or selected from the group consisting of Asp, Glu, and U;
aa16 is absent or selected from the group consisting of Ser, Gly, Glu, Ala, Aib, Ac5c, Lys, Arg, and U;
aa17 is absent or selected from the group consisting of Arg, hArg, Gln, Glu, Cit, Aib, Ac4c, Ac5c, Lys, and U;
aa18 is absent or selected from the group consisting of Arg, hArg, Ala, Aib, Ac4c, Ac5c, and U;
aa19 is absent or selected from the group consisting of Ala, Val, Aib, Ac4c, Ac5c, and U;
aa20 is absent or selected from the group consisting of Gln, Lys, Arg, Cit, Glu, Aib, Ac4c, Ac5c, and U;
aa21 is absent or selected from the group consisting of Asp, Glu, Leu, Aib, Ac4c, Ac5c, and U;
aa22 is absent or selected from the group consisting of Phe, Trp, Nal2, Aib, Ac4c, Ac5c, and U;
aa23 is absent or selected from the group consisting of Val, lle, Aib, Ac4c, Ac5c, and U;
aa24 is absent or selected from the group consisting of Gln, Ala, Glu, Cit, and U;
aa25 is absent or selected from the group consisting of Trp, Nal2, and U;
aa26 is absent or selected from the group consisting of Leu and U;
aa27 is Leu;
aa28 is Gln;
aa29 is absent or selected from the group consisting of Thr, Gly, Aib, Ac4c, Ac5c, and U;
aa30 is absent or selected from the group consisting of Lys, Aib, Ac4c, Ac5c, Arg, and U;
aa31 is absent or selected from the group consisting of Arg, Aib, Ac4c, Ac5c, and U;
aa32 is absent or selected from the group consisting of Asn, Aib, Ac4c, Ac5c, and U;
aa33 is absent or selected from the group consisting of Arg, Aib, Ac4c, Ac5c, and U;
aa34 is absent or selected from the group consisting of Asn, Aib, Ac4c, Ac5c, and U;
aa35 is absent or selected from the group consisting of Asn, Aib, Ac4c, Ac5c, and U;
aa36 is absent or selected from the group consisting of Ala, lle, Aib, Ac4c, Ac5C, and U;
aa37 is absent or U;
U is a natural or unnatural amino acid comprising a functional group used for covalent attachment to the surfactant X;

wherein any two of aa1-aa37 are optionally cyclized through their side chains to form a lactam linkage; and
provided that one, or at least one, of aa10-aa26 or aa29-aa37 is the linker amino acid U covalently attached to X.

US Pat. No. 11,065,282

CORAL COMPOSITE EXTRACT, COMPOSITION INCLUDING THE SAME AND METHOD OF PRODUCING THE SAME

National Sun Yat-Sen Univ...


1. A coral composite extract obtained from a Briareum violaceum coral starting material by (i) a crude extraction step and (ii) a column chromatography step, wherein the crude extraction step comprises a solvent extraction treatment combined with an ultrasonic treatment, wherein the coral composite extract comprises at least two briarane-type diterpenoid compounds that are excavatolide B (EXC-B) and excavatolide Z (EXC-Z), and wherein the at least two briarane-type diterpenoid compounds are the two that are present in the highest amounts in the coral composite extract.

US Pat. No. 11,065,272

OXYGEN REACTIVE POLYMERS FOR TREATMENT OF TRAUMATIC BRAIN INJURY

University of Washington,...


1. A method for treating traumatic brain injury, comprising administering a therapeutically effective amount of an oxygen reactive copolymer to a subject in need thereof, wherein the oxygen reactive copolymerhas the formula




wherein
n is an integer from 1 to 12,
m is an integer from 0 to 12, and
p is an integer from 6 to 40; and
*represents the remainder of the copolymer.

US Pat. No. 11,065,271

MATERNAL VITAMIN B12 ADMINISTRATION FOR THE PREVENTION OF INCREASED ADIPOSITY, OVERWEIGHT OR OBESITY IN THE OFFSPRING ESPECIALLY OFFSPRING OVERWEIGHT AND/OR OBESE MOTHERS

Societe des Produits Nest...


1. A maternal food composition comprising a protein source, a carbohydrate source, a lipid source, lecithin, bulking agents, probiotic bacteria, and 0.18-18.2 ?g vitamin B12/100 g dry weight of the maternal food composition.

US Pat. No. 11,065,264

METAL-OLSALAZINE COORDINATION POLYMERS FOR MEDICAL APPLICATIONS

THE REGENTS OF THE UNIVER...


1. A pharmaceutical material, comprising:(a) a metalorganic coordination polymer M2(olz), where M=Mg, Ca, Fe, Co, Ni, K, Na and Zn, and olz=olsalazine;
(b) wherein disassembly of the material under physiological conditions releases olsalazine.

US Pat. No. 11,065,261

BOTANICAL EXTRACTS AND COMPOUNDS FROM SCHINUS PLANTS AND METHODS OF USE

Emory University, Atlant...


1. A pharmaceutical formulation consisting of(a) therapeutically effective amounts of: a compound having Formula (I) or a salt thereof




and, optionally, an antibiotic other than (I); and
(b) an amount of a pharmaceutically acceptable excipient.

US Pat. No. 11,065,259

METHODS OF TREATING PRURITUS

Duke University, Durham,...


1. A method of treating pruritus in skin of a subject in need thereof, comprising administering to said subject an active agent in a treatment effective amount to treat pruritus in said skin of said subject,wherein said administering comprises topically administering to said skin of said subject a composition comprising said active agent in an amount of 0.01% to 1% by weight of said composition, and
wherein said active agent is a compound of Formula A1:




wherein:each R is independently a C1-12 alkyl;
each A is independently selected from the group consisting of hydrogen, halogen, —NO2, and —CHO;
M is manganese, and
Z— is a counterion;

or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,065,258

CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES


1. A method of treating a subject with Diamond Blackfan Anemia (DBA), comprising administering a therapeutically effective amount of a phenothiazine compound or a pharmaceutically acceptable salt thereof to the subject to decrease p53 or p21 in at least one of CD34+ cells, erythroid cells or erythroid differentiated cells in the subject, wherein the phenothiazine compound is selected from the group consisting of:




or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,065,257

SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS


1. A compound of general formula (I)



wherein
R1 and R4 are independently selected from the group consisting of hydrogen and (C1-C4)alkyl;
R2 and R3 are independently selected from the group consisting of hydrogen and (C1-C4)alkyl; or R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, tetrahydrofuranyl, or tetrahydropyranyl ring;
n=0, 1 or 2; and when n is 0, R4 does not exist;
Q is selected from the group consisting of —O—C(O)—R5 and —O—C(O)—(C1-C6)alkyl-R5;
R5 is selected from the group consisting of heteroaryl and heterocycloalkyl, wherein said heteroaryl and heterocycloalkyl are optionally substituted with one or more substituents independently selected from R6;
R6 consists of halogen, cyano, hydroxyl, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)-alkyloxy, —S(O)2Rx, —S(O)2NRaRb, —ORx, —C(O)NRaRb, —C(O)ORa, —C(O)Ra, cycloalkyl, aryl and heteroaryl;
Rx is (C1-C4)alkyl;
Ra and Rb are independently selected from the group consisting of hydrogen, (C1-C4)alkyl, phenyl-(C1-C4)alkyl, or
Ra and Rb together with the nitrogen to which they are attached form a 4-6 membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one or more (C1-C4)alkyl;
or a pharmaceutically acceptable salt, hydrate or solvate thereof.

US Pat. No. 11,065,256

ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES

WisTa Laboratories Ltd., ...


1. A method of therapeutic treatment of a neurodegenerative disorder of protein aggregation in a subject,which method comprises orally administering once per day to said subject a methylthioninium (MT)-containing compound,
wherein said administration provides a total daily dose of between 0.5 and 20 mg of MT to the subject per day,
wherein the MT compound is a compound of the following formula (“LMTX”):




wherein each of HnA and HnB (where present) are protic acids which may be the same or different,
and wherein p=1 or 2; q=0 or 1; n=1 or 2; (p+q)×n=2,
and wherein said neurodegenerative disorder is selected from the list consisting of:
Alzheimer's disease;
Pick's disease, progressive supranuclear palsy, frontotemporal dementia, FTD with parkinsonism linked to chromosome 17, frontotemporal lobar degeneration syndromes;
disinhibition-dementia-parkinsonism-amyotrophy complex, pallido-ponto-nigral degeneration, Guam-ALS syndrome, pallido nigro luysian degeneration, cortico-basal degeneration, dementia with argyrophilic grains, dementia pugilistica or chronic traumatic encephalopathy, Down's syndrome, subacute sclerosing panencephalitis, Niemann-Pick disease, type C, Sanfilippo syndrome type B, or a myotonic dystrophy DM1 or DM2;
Huntington's disease, spinal bulbar muscular atrophy, dentatorubropallidoluysian atrophy or spinocerebellar ataxias;
A TDP-43 proteinopathy which is FTLD-TDP;
Parkinson's disease, dementia with Lewy bodies and multiple system atrophy;
Hereditary cerebral angiopathy;
Amyotrophic lateral sclerosis; and
familial encephalopathy with neuronal inclusion bodies.

US Pat. No. 11,065,254

ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS

The United States Governm...


1. A method for treating or preventing an AIDS-related neurological disorder, comprising administering to a patient in need thereof an effective amount of a compound of Formula A:



wherein:

or the pharmaceutically acceptable salt thereof; whereinR1 is a group of the formula





wherein y is 0, 1 or 2;R4 is selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkylsulfonyl, (C2-C6)alkenyl, (C2-C6)alkynyl wherein the alkyl, alkenyl and alkynyl groups are optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C1-C4)alkoxy, (C1-C6)acyloxy, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, cyano, nitro, (C2-C6)alkenyl, (C2-C6)alkynyl or (C1-C6)acylamino; or
R4 is (C3-C10)cycloalkyl wherein the cycloalkyl group is optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C1-C6)acyloxy, (C1-C6)acylamino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, cyano, cyano(C1-C6)alkyl, trifluoromethyl(C1-C6)alkyl, nitro, nitro(C1-C6)alkyl or (C1-C6)acylamino;
R5 is (C2-C9)heterocycloalkyl wherein the heterocycloalkyl groups must be substituted by one to five carboxy, cyano, amino, deuterium, hydroxy, (C1-C6)alkyl, (C1-C6)alkoxy, halo, (C1-C6)acyl, (C1-C6)alkylamino, amino(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH, (C1-C6)alkylamino-CO—, (C2-C6)alkenyl, (C2-C6) alkynyl, (C1-C6)alkylamino, amino(C1-C6)alkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)acyloxy(C1-C6)alkyl, nitro, cyano(C1-C6)alkyl, halo(C1-C6)alkyl, nitro(C1-C6)alkyl, trifluoromethyl, trifluoromethyl(C1-C6)alkyl, (C1-C6)acylamino, (C1-C6)acylamino(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)acylamino, amino(C1-C6)acyl, amino(C1-C6)acyl(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)acyl, ((C1-C6)alkyl)2amino(C1-C6)acyl, R15R16N—CO—O—, R15R16N—CO—(C1-C6)alkyl, (C1-C6)alkyl-S(O)m, R15R16NS(O)m, R15R16NS(O)m(C1-C6)alkyl, R15S(O)mR16N, R15S(O)mR16(C1-C6)alkyl wherein m is 0, 1 or 2 and R15 and R16 are each independently selected from hydrogen or (C1-C6)alkyl; or a group of the formula




wherein a is 0, 1, 2, 3 or 4;
b, c, e, f and g are each independently 0 or 1;
d is 0, 1, 2, or 3;
X is S(O)n wherein n is 0, 1 or 2; oxygen, carbonyl or —C(?N-cyano)-;
Y is S(O)n wherein n is 0, 1 or 2; or carbonyl; and
Z is carbonyl, C(O)O—, C(O)NR— or S(O)n wherein n is 0, 1 or 2;
R6, R7, R8, R9, R10 and R11 are each independently selected from the group consisting of hydrogen or (C1-C6)alkyl optionally substituted by deuterium, hydroxy, amino, trifluoromethyl, (C1-C6)acyloxy, (C1-C6)acylamino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, cyano, cyano(C1-C6)alkyl, trifluoromethyl(C1-C6)alkyl, nitro, nitro(C1-C6)alkyl or (C1-C6)acylamino;
R12 is carboxy, cyano, amino, oxo, deuterium, hydroxy, trifluoromethyl, (C1-C6)alkyl, trifluoromethyl(C1-C6)alkyl, (C1-C6)alkoxy, halo, (C1-C6)acyl, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, amino(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH, (C1-C6)alkylamino-CO—, (C2-C6)alkenyl, (C2-C6) alkynyl, (C1-C6)alkylamino, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)acyloxy(C1-C6)alkyl, nitro, cyano(C1-C6)alkyl, halo(C1-C6)alkyl, nitro(C1-C6)alkyl, trifluoromethyl, trifluoromethyl(C1-C6)alkyl, (C1-C6)acylamino, (C1-C6)acylamino(C1-C6)alkyl, (C1-C6)alkoxy(C1-C6)acylamino, amino(C1-C6)acyl, amino(C1-C6)acyl(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)acyl, ((C1-C6)alkyl)2amino(C1-C6)acyl, R15R16N—CO—O—, R15R16N—CO—(C1-C6)alkyl, R15C(O)NH, R15OC(O)NH, R15NHC(O)NH, (C1-C6)alkyl-S(O)m, (C1-C6)alkyl-S(O)m—(C1-C6)alkyl, R15R16NS(O)m, R15R16NS(O)m(C1-C6)alkyl, R15S(O)mR16N, R15S(O)mR16N(C1-C6)alkyl wherein m is 0, 1 or 2 and R15 and R16 are each independently selected from hydrogen or (C1-C6)alkyl;
R2 and R3 are each independently selected from the group consisting of hydrogen, deuterium, amino, halo, hydroxy, nitro, carboxy, (C2-C6)alkenyl, (C2-C6)alkynyl, trifluoromethyl, trifluoromethoxy, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C10)cycloalkyl wherein the alkyl, alkoxy or cycloalkyl groups are optionally substituted by one to three groups selected from halo, hydroxy, carboxy, amino (C1-C6)alkylthio, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C5-C9)heteroaryl, (C2-C9)heterocycloalkyl, (C3-C9)cycloalkyl or (C6-C10)aryl; or R2 and R3 are each independently (C3-C10)cycloalkyl, (C3-C10)cycloalkoxy, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C6-C10)arylamino, (C1-C6)alkylthio, (C6-C10)arylthio, (C1-C6)alkylsulfinyl, (C6-C10)arylsulfinyl, (C1-C6)alkylsulfonyl, (C6-C10)arylsulfonyl, (C1-C6)acyl, (C1-C6)alkoxy-CO—NH—, (C1-C6)alkylamino-CO—, (C5-C9)heteroaryl, (C2-C9)heterocycloalkyl or (C6-C10)aryl wherein the heteroaryl, heterocycloalkyl and aryl groups are optionally substituted by one to three halo, (C1-C6)alkyl, (C1-C6)alkyl-CO—NH—, (C1-C6)alkoxy-CO—NH—, (C1-C6)alkyl-CO—NH—(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH—(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH—(C1-C6)alkoxy, carboxy, carboxy(C1-C6)alkyl, carboxy(C1-C6)alkoxy, benzyloxycarbonyl(C1-C6)alkoxy, (C1-C6)alkoxycarbonyl(C1-C6)alkoxy, (C6-C10)aryl, amino, amino(C1-C6)alkyl, (C1-C6)alkoxycarbonylamino, (C6-C10)aryl(C1-C6)alkoxycarbonylamino, (C1-C6)alkylamino, ((C1-C6)alkyl)2amino, (C1-C6)alkylamino(C1-C6)alkyl, ((C1-C6)alkyl)2amino(C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, carboxy, carboxy(C1-C6)alkyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkoxycarbonyl(C1-C6)alkyl, (C1-C6)alkoxy-CO—NH—, (C1-C6)alkyl-CO—NH—, cyano, (C5-C9)heterocycloalkyl, amino-CO—NH—, (C1-C6)alkylamino-CO—NH—, ((C1-C6)alkyl)2amino-CO—NH—, (C6-C10)arylamino-CO—NH—, (C5-C9)heteroarylamino-CO—NH—, (C1-C6)alkylamino-CO—NH—(C1-C6)alkyl, ((C1-C6)alkyl)2amino-CO—NH—(C1-C6)alkyl, (C6-C10)arylamino-CO—NH—(C1-C6)alkyl, (C5-C9)heteroarylamino-CO—NH—(C1-C6)alkyl, (C1-C6)alkylsulfonyl, (C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C6-C10)arylsulfonyl, (C6-C10)arylsulfonylamino, (C6-C10)arylsulfonylamino(C1-C6)alkyl, (C1-C6)alkylsulfonylamino, (C1-C6)alkylsulfonylamino(C1-C6)alkyl, (C5-C9)heteroaryl or (C2-C9)heterocycloalkyl;
or of Formula B:





including pharmaceutically acceptable salt forms or prodrugs thereof, wherein:A1 and A2 are independently selected from C and N;
T, U, and V are independently selected from O, S, N, CR5, and NR6;
wherein the 5-membered ring formed by A1, A2, U, T, and V is aromatic;
X is N or CR4;
Y is C1-8 alkylene, C2-8 alkenylene, C2-8 alkynylene, (CR11R12)p—(C3-10 cycloalkylene)-(CR11R12)q, (CR11R12)p-(arylene)-(CR11R12)q, (CR11R12)\p—(C1-10 heterocycloalkylene)-(CR11R12)q, (CR11R12)p-(heteroarylene)-(CR11R12)q, (CR11R12)pO(CR11R12)q, (CR11R12)pS(CR11R12)q, (CR11R12)pC(O)(CR11R12)q, (CR11R12)pC(O)NRc(CR11R12)q, (CR11R12)pC(O)O(CR11R12)q, (CR11R12)pOC(O)(CR11R12)q, (CR11R12)pOC(O)NRc(CR11R12)q, (CR11R12)pNRc(CR11R12)q, (CR11R12)pNRcC(O)NRd(CR11R12)q, (CR11R12)pS(O)(CR11R12)q, (CR11R12)pS(O)NRc(CR11R12)q, (CR11R12)pS(O)2(CR11R12)q, or (CR11R12)pS(O)2NRc(CR11R12)q, wherein said C1-8 alkylene, C2-8 alkenylene, C2-8 alkynylene, cycloalkylene, arylene, heterocycloalkylene, or heteroarylene, is optionally substituted with 1, 2, or 3 substituents independently selected from -D1-D2-D3-D4;
Z is H, halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, halosulfanyl, C1-4 hydroxyalkyl, C1-4 cyanoalkyl, ?C—Ri, ?N—Ri, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(?NRi)NRcRd, NRcC(?NRi)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(?NOH)Rb, C(?NO(C1-6alkyl)Rb, and S(O)2NRcRd, wherein said C1-8 alkyl, C2-8 alkenyl, or C2-8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, halosulfanyl, C1-4 hydroxyalkyl, C1-4 cyanoalkyl, Cy1, CN, N2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(?NRi)NRcRd, NRcC(?NRi)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(?NOH)Rb, C(?NO(C1-6 alkyl))Rb, and S(O)2NRcRd;
wherein when Z is H, n is 1;
or the —(Y)n—Z moiety is taken together with i) A2 to which the moiety is attached, ii) R5 or R6 of either T or V, and iii) the C or N atom to which the R5 or R6 of either T or V is attached to form a 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring fused to the 5-membered ring formed by A1 A2, U, T, and V, wherein said 4- to 20-membered aryl, cycloalkyl, heteroaryl, or heterocycloalkyl ring is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from —(W)m-Q;
W is C1-8 alkylenyl, C2-8 alkenylenyl, C2-8 alkynylenyl, O, S, C(O), C(O)NRc?, C(O)O, OC(O), OC(O)NRc?, NRc?, NRc?C(O)NRd?, S(O), S(O)NRc?, S(O)2, or S(O)2NRc?;
Q is H, halo, CN, NO2, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, halosulfanyl, C1-4 hydroxyalkyl, C1-4 cyanoalkyl, Cy2, CN, NO2, ORa?, SRa?, C(O)Rb?, C(O)NRc?Rd?, C(O)ORa?, OC(O)Rb?, OC(O)NRc?Rd?, NRc?Rd?, NRc?C(O)Rb?, NRc?C(O)NRc?Rd?, NRc?C(O)ORa?, S(O)Rb?, S(O)NRc?Rd?, S(O)2Rb?, NRc?S(O)2Rb?, and S(O)2NRc?Rd?;
Cy1 and Cy2 are independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, halosulfanyl, C1-4 hydroxyalkyl, C1-4 cyanoalkyl, CN, NO2, ORa?, SRa?, C(O)Rb?, C(O)NRc?Rd?, C(O)ORa?, OC(O)Rb?, OC(O)NRc?Rd?, NRc?Rd?, NRc?C(O)Rb?, NRc?C(O)ORa?, NRc?S(O)Rb?, NRc?S(O)2Rb?, S(O)Rb?, S(O)NRc?Rd?, S(O)2Rb?, and S(O)2NRc?Rd?;
R1, R2, R3, and R4 are independently selected from H, halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NRcC(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, and S(O)2NR9R10;
R5 is H, halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, halosulfanyl, CN, NO2, OR7, SR7, C(O)R8, C(O)NR9R10, C(O)OR7, OC(O)R8, OC(O)NR9R10, NR9R10, NR9C(O)R8, NR9C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, NR9S(O)2R8, or S(O)2NR9R10;
R6 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, OR7, C(O)R8, C(O)NR9R10, C(O)OR7, S(O)R8, S(O)NR9R10, S(O)2R8, or S(O)2NR9R10;
R7 is H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R8 is H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl;
R9 and R10 are independently selected from H, C1-10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkylcarbonyl, arylcarbonyl, C1-6 alkylsulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl;
or R9 and R10 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group;
R11 and R12 are independently selected from H and -E1-E2-E3-E4;
D1 and E1 are independently absent or independently selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, C1-6 alkyl, C1-6 haloalkyl, C2-8 alkoxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, C1-6 alkylamino, and C2-8 dialkylamino;
D2 and E2 are independently absent or independently selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, (C1-6 alkylene)r-O—(C1-6 alkylene)s, (C1-6 alkylene)r-S—(C1-6 alkylene)s, (C1-6 alkylene)r-NRc—(C1-6 alkylene)s, (C1-6 alkylene)r-CO—(C1-6 alkylene)s, (C1-6 alkylene)r-COO—(C1-6 alkylene)s, (C1-6 alkylene)r-CONRc—(C1-6 alkylene)s, (C1-6 alkylene)r-SO—(C1-6 alkylene)s, (C1-6 alkylene)r-SO2—(C1-6 alkylene)s, (C1-6 alkylene)r-SONRc—(C1-6 alkylene)s, and (C1-6 alkylene)r-NRcCONRf—(C1-6 alkylene)s, wherein each of the C1-6 alkylene, C2-6 alkenylene, and C2-6 alkynylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, C1-6 alkyl, C1-6 haloalkyl, C2-8 alkoxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, C1-6 alkylamino, and C2-8 dialkylamino;
D3 and E3 are independently absent or independently selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene, wherein each of the C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, arylene, cycloalkylene, heteroarylene, and heterocycloalkylene is optionally substituted by 1, 2 or 3 substituents independently selected from halo, CN, NO2, N3, SCN, OH, C1-6 alkyl, C1-6 haloalkyl, C2-8 alkoxyalkyl, C1-6 alkoxy, C1-6 haloalkoxy, amino, C1-6 alkylamino, and C2-8 dialkylamino;
D4 and E4 are independently selected from H, halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, halosulfanyl, C1-4 hydroxyalkyl, C1-4 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRa, C(O)ORa, OC(O)RbOC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(?NRi)NRcRd, NRcC(?NRi)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(?NOH)Rb, C(?NO(C1-6 alkyl)Rb, and S(O)2NRcRd, wherein said C1-8 alkyl, C2-8 alkenyl, or C2-8 alkynyl, is optionally substituted with 1, 2, 3, 4, 5, or 6 substituents independently selected from halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, halosulfanyl, C1-4 hydroxyalkyl, C1-4 cyanoalkyl, Cy1, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)NRcRd, NRcC(O)ORa, C(?NRi)NRcRd, NRcC(?NRi)NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, NRcS(O)2Rb, C(?NOH)Rb, C(?NO(C1-6 alkyl))Rb, and S(O)2NRcRd;
Ra is H, Cy1, —(C1-6 alkyl)-Cy1, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb is H, Cy1, —(C1-6 alkyl)-Cy1, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Ra? and Ra? are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rb? and Rb? are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc and Rd are independently selected from H, Cy1, —(C1-6 alkyl)-Cy1, C1-10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, wherein said C1-10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, or C2-6 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, —(C1-6 alkyl)-Cy1, OH, CN, amino, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkyl, and halosulfanyl;
or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, —(C1-6 alkyl)-Cy1, OH, CN, amino, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkyl, and halosulfanyl;
Rc? and Rd? are independently selected from H, C1-10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said C1-10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
or Rc? and Rd? together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Rc? and Rd? are independently selected from H, C1-10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl and heterocycloalkylalkyl, wherein said C1-10 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 haloalkyl, halosulfanyl, C1-6 haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
or Rc? and Rd? together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkyl, halosulfanyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl;
Ri is H, CN, NO2, or C1-6 alkyl;
Re and Rf are independently selected from H and C1-6 alkyl;
Ri is H, CN, or NO2;
m is 0 or 1;
n is 0 or 1;
p is 0, 1, 2, 3, 4, 5, or 6;
q is 0, 1, 2, 3, 4, 5 or 6;
r is 0 or 1; and
s is 0 or 1.

US Pat. No. 11,065,251

PAK1 INHIBITORS AND USES THEREOF

ALBERT EINSTEIN COLLEGE O...


1. A method of treating acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in a subject, the method comprising administering to the subject a compound of Formula I, II, III or IV in an amount effective to inhibit p21 protein (Cdc42/Rac)-activated kinase (PAK1) in a subject, wherein Formula I has the structure:



wherein R1, R2, R3 and R4 of Formula I are independently H, halogen, —OH, —NH2, C1-C6 alkyl, —OCH3, —COCH3, 5- or 6-membered cyclic or heterocyclic, 5- or 6-membered aryl or heteroaryl, wherein the heteroaryl or heterocyclic contains one or more of the same or different heteroatom, or optionally substituted phenyl or benzyl, wherein the phenyl or benzyl is optionally substituted with one or more of halogen, —OH, —NH2, —CH3, or —OCH3;
wherein R5, R6, R7, R8 and R9 of Formula I are independently H, halogen, —OH, —NH2, —NHCH3, —N(CH3)2, C1-C6 alkyl, —OCH3, —SH, —OCH3, —SCH3, 5- or 6-membered cyclic or heterocyclic, or 5- or 6-membered aryl or heteroaryl, wherein the heteroaryl or heterocyclic contains one or more of the same or different heteroatom, or optionally substituted phenyl or benzyl, wherein the phenyl or benzyl is optionally substituted with one or more of halogen, —OH, —NH2, —CH3, or —OCH3;
wherein A is a heteroaryl or heterocyclic containing one or more of the same or different heteroatom, or





where ( ) represents the point of attachment to the molecular scaffold;wherein R10, R11, R12, R13 and R14 of Formula I are independently H, halogen, —OH, —NH2, C1-C6 alkyl, —OCH3, —COCH3, 5- or 6-membered cyclic or heterocyclic, or 5- or 6-membered aryl or heteroaryl, wherein the heteroaryl or heterocyclic contains one or more of the same or different heteroatom, and/or R10 and R11, or R11 and R12, or R12 and R13, or R13 and R14 of Formula I together form a 5- or 6-membered hetrocyclic or heteroaryl containing one or more of the same or different heteroatom;
or a pharmaceutically acceptable salt thereof;
wherein Formula II has the structure:




wherein R1, R2, R3, R4, R5 and R6 of Formula II are independently H, halogen, —OH, —NH2, —NHCH3, —N(CH3)2, C1-C6 alkyl, —OCH3, —COCH3, —SH, or —SCH3,
or a pharmaceutically acceptable salt thereof;
wherein Formula III has the structure:




wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 of Formula III are independently H, halogen, —OH, —NH2, —NHCH3, —N(CH3)2, C1-C6 alkyl, —OCH3, —COCH3, —SH, or —SCH3,
or a pharmaceutically acceptable salt thereof; and
wherein Formula IV has the structure:




wherein A1 and A2 of Formula IV are independently




where ( ) represents the point of attachment to the molecular scaffold;
wherein X1, X2, X3, X4, X5 and X7 of Formula IV are independently CH or N;
wherein X6 of Formula IV is CH, N or




wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 of Formula IV are independently H, halogen, —OH, —NH2, —NHCH3, —N(CH3)2, C1-C6 alkyl, —OCH3, —COCH3, —SH, or —SCH3;
wherein A3 of Formula IV is O or N, and when A3 is N, R6 is a C2 alkyl that bonds to the N of A3;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,065,250

SOLID DOSAGE FORMS OF PALBOCICLIB

Pfizer Inc., New York, N...


1. A tablet consisting of about 20 wt % of palbociclib, about 10 wt % of succinic acid, about 50 wt % to about 75 wt % of microcrystalline cellulose, about 5 wt % to about 10 wt % of crospovidone, about 0.5 wt % to about 6 wt % of magnesium stearate, and about 0.5 wt % to about 2 wt % of silicon dioxide.

US Pat. No. 11,065,249

DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOR

Pfizer Inc., New York, N...


1. A compound of Formula (I)



wherein
R1 is H or fluoro;
R2, R3, R4 and R5 are each independently selected from H, and (C1-C3)fluoroalkyl and
R6, R7, R8, and R9 are each independently selected from H, fluoro, and (C1-C3)fluoroalkyl; and
wherein 1 or 2 of R2, R3, R4, R5, R6, R7, R8, and R9 are other than H;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 11,065,243

INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION

Sonic Master Limited, To...


1. A method for modulating DUX4 activity in a subject in need thereof comprising administering to the subject in need thereof a composition comprising a compound, or a pharmaceutically acceptable salt thereof, having the structure of Formula (I):



wherein the compound comprises: 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridine-4-yloxy)phenyl)urea;
wherein E1 is phenyl;
wherein A is pyrazolyl N-substituted with A1-6 quinoline;




A ring is substituted at any substitutable position with one A1 moiety, wherein A1 is selected from:




wherein the symbol (**) is a point of attachment to the A ring of formula I;
X2 is a direct bond wherein E1 is directly linked to the NR3 group of formula I;
X3 is —O—;
Z3 is H;
Z6 is —C(O)N(R3)2, specifically —C(O)NHCH3
R3 is independently and individually selected from the group consisting of H, C1-C6alkyl specifically CH3.

US Pat. No. 11,065,240

DRUG COMBINATIONS TO TREAT MULTIPLE MYELOMA

Exelixis, Inc., Alameda,...


US Pat. No. 11,065,239

USE OF EZH2 INHIBITOR COMBINED WITH BTK INHIBITOR IN PREPARING DRUG FOR TREATING TUMOR

Jiangsu Hengrui Medicine ...


1. A method for treating a tumor in a subject in need thereof, the method comprising administering to the subject a combination of an EZH2 inhibitor and a BTK inhibitor, wherein the EZH2 inhibitor is a compound of formula (I):




or a pharmaceutically acceptable salt thereof or a stereoisomer thereof,wherein,
ring A is selected from the group consisting of heterocyclyl and cycloalkyl;
each R1 is identical or different and each is independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, nitro, hydroxy, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, —OR6, —C(O)R6, —C(O)OR6, —S(O)mR6, —S(O)mNR7R8 and —(CH2)xRa, wherein the alkyl, haloalkyl, heterocyclyl, aryl and heteroaryl are each independently and optionally substituted by one or more substituents selected from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
Ra is selected from the group consisting of halogen, cycloalkyl, heterocyclyl and —NR7R8, wherein the cycloalkyl and heterocyclyl are each independently and optionally substituted by one or more substituents selected from the group consisting of alkyl, haloalkyl, halogen, amino, nitro, cyano, hydroxy, alkoxy, haloalkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R2 is hydrogen or alkyl, wherein the alkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, cyano, cycloalkyl and heterocyclyl;
R3 is selected from the group consisting of hydrogen, alkyl, halogen, cyano, alkoxy and haloalkyl;
each R4 is identical or different and each is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxy, amino, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —OR6, —C(O)R6, —C(O)OR6, —S(O)mR6, —S(O)mNR7R8 and —NR7R8;
each R5 is identical or different and each is independently selected from the group consisting of hydrogen, alkyl, oxo, halogen, haloalkyl, hydroxy, amino, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —OR6, —C(O)R6, —C(O)OR6, —S(O)mR6, —S(O)mNR7R8 and —NR7R8;
R6 is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, hydroxyalkyl, hydroxy, amino, cycloalkyl, heterocyclyl, aryl and heteroaryl;
R7 and R8 are identical or different and each is independently selected from the group consisting of hydrogen, alkyl, alkoxy, hydroxyalkyl, hydroxy, amino, alkoxycarbonyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, amino, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently and optionally substituted by one or more substituents selected from the group consisting of alkyl, halogen, hydroxy, amino, alkoxycarbonyl, nitro, cyano, alkoxy, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
m is 0, 1 or 2;
n is 0, 1, 2 or 3;
p is 0, 1, 2, 3, 4 or 5;
q is 0, 1 or 2; and
x is 0, 1, 2 or 3.

US Pat. No. 11,065,237

SOLID FORMS OF {[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO}ACETIC ACID, COMPOSITIONS, AND USES THEREOF

Akebia Therapeutics, Inc....


1. A crystalline Compound (I):



which has an X-ray powder diffraction pattern comprising peaks at approximately 18.1, 20.3, 22.9, 24.0, and 26.3±0.2°2?;
wherein the crystalline Compound (I) is anhydrous and unsolvated; and
comprises less than 10% by weight of any other amorphous or crystalline forms of Compound (I).

US Pat. No. 11,065,235

SUBSTITUTED METHANOPYRIDO [2, 1-A] ISOINDOLONES AS MACHR MODULATORS FOR TREATING VARIOUS ASSOCIATED PATHOPHYSIOLOGICAL CONDITIONS AND PROCESS FOR PREPARATION THEREOF

Centre for Biomedical Res...


1. A substituted methanopyrido [2,1-a]isoindoline selected from the group consisting of (a), (b), (c), (d), (e), (f), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:(a) a compound of Formula I





wherein:
R1 is selected from phenylsulfonyl or p-toluenesulfonyl; and
n=1, 2, or 3;

(b) (6S,6aR,11S,12aR)-13-oxo-6-(phenyl sulfonyl)-1,2,3,5,6,6a,11,12a-octahydro-6,11-methanoisoindolo[2,1-a]quinolin-4-yl trifluoromethanesulfonate (RG-12) or its enantiomer:




(c) (6S,6aR,11S,12aR)-13-oxo-6-tosyl-1,2,3,5,6,6a,11,12a-octahydro-6,11-methanoisoindolo[2,1-a]quinolin-4-yl trifluoromethanesulfonate (RG-13) or its enantiomer:




(d) (4aS,6R,6aR,11S,12aR)-methyl 4-oxo-6-(phenylsulfonyl)-1,2,3,4,4a,5,6,6a,11,12a-decahydroisoindolo[2,1-a]quinoline-11-carboxylate (RG-04) or its enantiomer:




(e) (4aS,6R,6aR,11S,12aR)-ethyl 4-oxo-6-(phenylsulfonyl)-1,2,3,4,4a,5,6,6a,11,12a-decahydroisoindolo[2,1-a]quinoline-11-carboxylate (RG-05) or its enantiomer:





and(f) trifluoroacetate (TFA) salt of (4aS,6S,6aR,11S,12aR)-6-(phenylsulfonyl)-1,2,3,4a,5,6,6a,12a-octahydro-6,11-methanoisoindolo[2,1-a]quinoline-4,13(11H)-dione (RG-02) or its enantiomer:





US Pat. No. 11,065,234

ESTROGEN RECEPTOR MODULATORS

Recurium IP Holdings, LLC...


1. A method of treating breast cancer, comprisingidentifying a subject that is in need of treatment for a breast cancer that is estrogen receptor alpha dependent and/or estrogen receptor alpha mediated; and
administering to said subject an effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt thereof having the structure:




wherein:
A1 is an optionally substituted aryl;
R1 is an optionally substituted cycloalkyl;
R2 and R3 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl and an optionally substituted C1-6 haloalkyl; or R2 and R3 together with the carbon to which R2 and R3 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;
R4 and R5 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl and an optionally substituted C1-6 haloalkyl; or R4 and R5 together with the carbon to which R4 and R5 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;
R6, R7, R8 and R9 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted haloalkyl, an optionally substituted mono-substituted amine, and an optionally substituted di-substituted amine;
R10 is hydrogen, deuterium, halogen, an optionally substituted alkyl, or an optionally substituted cycloalkyl;
R11 is hydrogen or an optionally substituted C1-6 alkyl; and
R12 is hydrogen or C1-3 alkyl.

US Pat. No. 11,065,233

ESTROGEN RECEPTOR MODULATORS

Recurium IP Holdings, LLC...


1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:



wherein:
A1 is an optionally substituted aryl;
R1 is an optionally substituted cycloalkyl;
R2 and R3 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl and an optionally substituted C1-6 haloalkyl; or R2 and R3 together with the carbon to which R2 and R3 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;
R4 and R5 are each independently selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl and an optionally substituted C1-6 haloalkyl; or R4 and R5 together with the carbon to which R4 and R5 are attached form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl or an optionally substituted heterocyclyl;
R6, R7, R8 and R9 are each independently selected from the group consisting of hydrogen, halogen, hydroxy, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted haloalkyl, an optionally substituted mono-substituted amine, and an optionally substituted di-substituted amine;
R10 is hydrogen, deuterium, halogen, an optionally substituted alkyl, or an optionally substituted cycloalkyl;
R11 is hydrogen or an optionally substituted C1-6 alkyl; and
R12 is hydrogen or C1-3 alkyl.

US Pat. No. 11,065,231

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR- ASSOCIATED KINASE 4 POLYPEPTIDES

ARVINAS OPERATIONS, INC.,...


1. A bifunctional compound having the chemical structure:PTM-L-ULM,
or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, or polymorph thereof,

wherein:(a) the L is a chemical linker group that covalently couples the ULM to the PTM;
(b) the ULM is a cereblon E3 ubiquitin ligase binding moiety (CLM) that has a chemical structure represented by





wherein:W is selected from the group consisting of CH2, CHR, C?O, SO2, NH, and N-alkyl;
each X is independently selected from the group consisting of absent, O, and S;
Y is selected from the group consisting of CH2, —C?CR?, NH, N-alkyl, N-aryl, N-hetaryl, N-cycloalkyl, N-heterocyclyl, O, and S;
Z is selected from the group consisting of absent, O, and S;
G and G? are independently selected from the group consisting of H, optionally substituted linear or branched alkyl, OH, R?OCOOR, R?OCONRR?, CH2-heterocyclyl optionally substituted with R?, and benzyl optionally substituted with R?;
Q1, Q2, Q3, and Q4 represent a carbon C substituted with a group independently selected from H, R, N or N-oxide;
A is independently selected from the group H, optionally substituted linear or branched alkyl, cycloalkyl, Cl and F;
n is an integer from 1 to 4, wherein one Ra is modified to be covalently joined to the PTM or the chemical linker group;
R comprises —CONR?R?, —OR?, —NR?R?, —SR?, —SO2R?, —SO2NR?R?, —CR?R?—, —CR?NR?R?—, (—CR?O)n?R?, -aryl, -hetaryl, optionally substituted linear or branched -alkyl, -cycloalkyl, -heterocyclyl, —P(O)(OR?)R?, —P(O)R?R?, —OP(O)(OR?)R?, —OP(O)R?R?, —Cl, —F, —Br, —I, —CF3, —CN, —NR?SO2NR?R?, —NR?CONR?R?, —CONR?COR?, —NR?C(?N—CN)NR?R?, —C(?N—CN)NR?R?, —NR?C(?N—CN)R?, -alkyl-aryl, —NR?C(?C—NO2)NR?R?, —SO2NR?COR?, —NO2, —CO2R?, —C(C?N—OR?)R?, —CR??CR?R?, —CCR?, —S(C?O)(C?N—R?)R?, —SF5and —OCF3;
R? and R? are independently selected from the group consisting of a bond, H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclic, —C(?O)R, heterocyclyl, each of which is optionally substituted;
represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific; and
n? is an integer from 1-10;
(c) the PTM is a small molecule comprising an Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4) targeting moiety represented by PTM-Va or PTM-Vb:





wherein:X1 and X3 of PTM-Va or PTM-Vb independently are CH or N; X2 of PTM-Va is CR2 or N; provided one and not more than one of X1, X2 or X3 is N;
Y of PTM-Va or PTM-Vb is —CH2—, NH, or O;
Ring Z of PTM-Va or PTM-Vb is aryl, heteroaryl, or heterocyclyl;
A of PTM-Va is O, S, or NH;
A of PTM-Vb is —CH or —CCH3;
R1 of PTM-Va or PTM-Vb at each occurrence, is independently hydrogen, cyano, halo, hydroxy, —NO2, —NR5R6, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocyclyl or optionally substituted heteroaryl, wherein the substituent, in each occurrence, is independently selected from alkyl, alkoxy, haloalkyl, cyano, aminoalkyl, halo, hydroxyl, hydroxyalkyl, —NR7R8, or COOR9;
R2 of PTM-Va or PTM-Vb is hydrogen, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heterocyclyl; wherein the substituent is alkyl, amino, halo or hydroxyl;
R3 of PTM-V, at each occurrence, is independently selected from hydrogen, carboxy, cyano, hydroxy, hydroxyalkyl, alkyl, aryl, heteroaryl, —SO2R7, hydroxyl or oxo;
R4 of PTM-Va or PTM-Vb at each occurrence is independently selected from hydrogen, halogen, alkyl, aryl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, Y1-arylalkyl or —Y1-cycloalkyl; wherein cycloalkyl, aryl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and arylalkyl can be optionally substituted with hydroxy, alkyl, haloalkyl, cyano or halo;
Y1 of PTM-Va or PTM-Vb is selected from direct bond, O, —C(O)— or NR9;
R5 and R6 of PTM-Va or PTM-Vb are independently selected from hydrogen, hydroxyalkyl, aminoalkyl, acyl, optionally substituted alkyl, optionally substituted heterocyclyl, optionally substituted aryl; wherein the optional substituent, in each occurrence, is independently selected from halo, haloalkyl or —COOR9;
R7 and R8 of PTM-Va or PTM-Vb are independently hydrogen, alkyl, acyl, heterocyclyl, —COR9 or —COOR9;
R9 of PTM-V or PTM-Vb at each occurrence is independently selected from hydrogen or alkyl;
R9a of PTM-Vb is selected from hydrogen, halo, optionally substituted alkoxy, optionally substituted alkyl, hydroxyalkyl, or haloalkyl;
“m”, “n” and “q” of PTM-Va or PTM-Vb are independently selected from 0, 1, 2, or 3;
“p” of PTM-Va or PTM-Vb is 0 or 1; and
Y, R1, R2, R3, R4, R5, R6, R7, R8, R9, or R9a is modified to be covalently joined to the chemical linker group.